1

CURRICULUM VITAE W. Timothy Garvey, M.D. HOME ADDRESS: 3824 Rock Creek Trail Mountain Brook, AL 35223 OFFICE ADDRESS: Department of Nutrition Sciences, Webb 232 University of Alabama at Birmingham 1675 University Boulevard Birmingham, AL 35294-3360 Tel. (205) 996-7433 FAX (205) 934-7049 E-mail: garveyt@uab.edu CITIZENSHIP: U.S.A. MARITAL STATUS: Married to Mary Elizabeth Garvey Children: Alexandra Elizabeth Garvey, born 11/25/90 William John Garvey, born 6/6/93 Olivia Maria Garvey, born 6/6/93 EDUCATION: Dates Institution Attended Field of Study Washington University, St. Louis 1970-1974 B.A.: Biology Missouri magna cum laude St. Louis University School of 1974-1978 M.D. Medicine, St. Louis, Missouri cum laude POSTGRADUATE TRAINING:

Intern in Internal Medicine, Barnes Hospital, Washington University School of Medicine Junior Resident in Internal Medicine, Barnes Hospital, Washington University School of Medicine Senior Resident in Internal Medicine, Barnes Hospital, Washington University School of Medicine Clinical and Research Fellow, Division of Endocrinology and Metabolism, University of Colorado Health

Sciences Center, 1982-1983 Clinical and Research Fellow, Division of Endocrinology and Metabolism, University of California, San Diego

School of Medicine, 1983-1984

PROFESSIONAL EXPERIENCE: 1984 - 1985 Instructor in Medicine, Division of Endocrinology and Metabolism, University of California, San Diego School of Medicine, La Jolla, California. 1985 - 1989 Assistant Professor of Medicine, Division of Endocrinology and Metabolism. University of California, San Diego School of Medicine, La Jolla, California.

2

1989 - 1993 Associate Professor of Medicine, Division of Endocrinology and Metabolism, Indiana University School of Medicine. Staff Physician, Indianapolis Veterans Affairs Medical Center, Indianapolis, Indiana. 1992 - 1993 Associate Professor of Physiology and Biophysics, Indiana University School of Medicine, Indianapolis, Indiana. 1993 - 1994 Professor of Medicine, Division of Endocrinology and Metabolism, Indiana University School of Medicine. Staff Physician, Indianapolis Veterans Affairs Medical Center, Indianapolis, Indiana. Professor of Physiology and Biophysics, Department of Physiology and Biophysics, Indiana University School of Medicine. 1994 Chief, Section of Endocrinology, Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana.

1994-2003 Director, Division of Endocrinology, Diabetes, and Medical Genetics, Professor of Medicine, Medical University of South Carolina. Staff Physician, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina. Associate Director, General Clinical Research Center, Medical University of South Carolina. 2003-present Adjunct Professor of Medicine, Medical University of South Carolina 2003-2018 Chair, Department of Nutrition Sciences Professor of Nutrition Sciences University of Alabama at Birmingham Staff Physician and GRECC Investigator, Birmingham Veterans Affairs Medical Center Birmingham, Alabama 2018-present Professor, Department of Nutrition Sciences University of Alabama at Birmingham GRECC Investigator, Birmingham Veterans Affairs Medical Center Birmingham, Alabama HOSPITAL AND OTHER APPOINTMENTS: Staff Physician, Internal Medicine and Endocrinology, University of California, San Diego Medical Center, University Hospital, San Diego, California, 1985 - 1989. Staff Physician, Internal Medicine and Endocrinology, Indiana University Hospital, Indianapolis, Indiana, 1989 - 1994.

3

Staff Physician, Medical Service, Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, 1989 - 1994. Staff Physician, Internal Medicine and Endocrinology Wishard Memorial Hospital, Indianapolis, Indiana, 1990 - 1994. Staff Physician, Internal Medicine and Endocrinology, Medical University Hospital, Charleston, South Carolina, 1994 - 2003. Staff Physician, Medical Service, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina, 1994 – 2003. Staff Physician, University Hospital, University of Alabama at Birmingham, Birmingham AL, 2003-present. Staff Physician, Birmingham Veterans Affairs Medical Center, Birmingham, AL, 2003-2018. BOARD CERTIFICATION: Diplomate, National Board of Medical Examiners, 1979 Diplomate, American Board of Internal Medicine, 1982 Diplomate, Specialty Board in Endocrinology and Metabolism, 1983 Master, American Board of Obesity Medicine, 2017 PROFESSIONAL SOCIETIES: American Society for Clinical Investigation Association of American Physicians American Diabetes Association American Federation for Clinical Research International Diabetes Federation American Association for Advancement of Science Endocrine Society The Obesity Society FASEB American Association of Clinical Endocrinologists LICENSURE: Alabama State Medical License No. 00025460 (active) South Carolina State Medical License No. 17736 (inactive) Indiana State Medical License No. 01037373 - Renewal No. H308074 (inactive) California State Medical License No. G051948 (inactive) Colorado State Medical License No. 23942 (inactive) Missouri State Medical License No. R74A77 (inactive) DEA No. AG3040944 AWARDS AND HONORS: 2017 Joseph F. Volker Award, UAB School of Health Professions 2017 Master, American Board of Obesity Medicine 2014 FACE designation from the American Association of Clinical Endocrinologists, 2014

4

2011 UAB Excellence in Mentoring Award 2009 Excellence in Scholarship Award, UAB School of Health Professions 2006 Charles E. Butterworth, Jr.,M.D. Professorship at UAB 2002 Member, Association of American Physicians 2000 Pfizer Visiting Professor at the University of Mississippi 1994 Member, American Society for Clinical Investigation

Research Award of the Indiana Affiliate of the American Diabetes Association 1988-1993 National Institute of Health, FIRST Award

Research and Development Award, American Diabetes Association Pfizer Scholars Award, Pfizer Pharmaceuticals Pfizer Postdoctoral Fellowship Award in Diabetes Mellitus

1978 Graduate cum laude, St. Louis University School of Medicine Wendell Griffith Prize in Biochemistry, St. Louis University School of Medicine Alpha Sigma Nu Jesuit Honor Society

1977 Alpha Omega Alpha Honor Medical Society (elected junior year of medical school) Winner of AOA Student Research Forum, St. Louis University School of Medicine

1974 Graduate magna cum laude, Washington University UNIVERSITY SERVICE: A] INDIANA UNIVERSITY SCHOOL OF MEDICINE University Associate Professor and Professor of Medicine, and Physiology and Biophysics, (1989-1994) Attending Physician in Internal Medicine and in Endocrinology& Metabolism at Indiana University

Hospital and Wishard Memorial Hospital (1989-1994) Elected Member, Indiana University SOM Biomedical Research Committee (1991-1994) Member of the Faculty of the University Graduate School (1993-1994) Co-Director, Diabetes Research and Training Center (1991-1994) Co-Director, Human Biology Core, Diabetes Research and Training Center (1992-1994) Member, Pilot and Feasibility Project Review Committee, Diabetes Research and Training Center

(1989-1994) Member, Research Advisory Committee, Diabetes Research and Training Center (1989-1994) Search and Screen Committee for faculty recruitment in the Department of Physiology and Biophysics

(1992) Co-author, two chapters in the Coursebook for Introduction to Medicine used by sophomore medical

student class, “Diabetes Mellitus” and “Hypoglycemia” (1990-1994) VA Medical Center Chief, Section of Endocrinology and Metabolism, Indianapolis VA Medical Center (1994) Staff Physician (1989-1994) Member, Research and Development Committee, Indianapolis VA Medical Center (1989-1992) Radionuclide Radiation safety Committee, Indianapolis VA Medical Center (1989-1994) Chair, Space and Equipment Subcommittee, VA Medical Center (1990-1994) Quality Medical Assurance Program for the Section of Endocrinology at the VA Medical Center

(1989-1994) Supervisor of Diabetes Nurse Educator, Norma Hall, RN, at the VA Medical Center, 1989-1994.

5

B] MEDICAL UNIVERSITY OF SOUTH CAROLINA Academic Director, Division of Endocrinology, Diabetes, and Medical Genetics (1994-2003) Professor of Medicine, and Attending Physician in Internal Medicine and Endocrinology &

Metabolism at the Medical University Hospital and the Charleston Memorial Hospital (1994- 2003)

Staff Physician, Charleston VA Medical Center (1994-2003) Member, Graduate School Faculty (1997-2003) Adjunct Professor of Medicine (2003 – present) University Chair, MUSC Conflict of Interest Review Committee (1997-1998) Elected Member, Faculty Senate (2002-2003) Member, Committee to Advise the President on the Impact of Hospital Authority Status on Research

Activities (1999-2000) University-wide Strategic Planning Initiatives: in 1995 University Strategic Plan as a member of the

Research and Research Training working group; in 1998 in conjunction with Deloitte&Touche Consulting Group for the ‘MUSC Clinical Enterprise’; in 2002-2003 as a member of the Research Infrastructure Committee.

Search Committees Chair, Search Committee for program Director of the General Clinical Research Center (2001) Chair, Search Committee for faculty in statistical genetics in the Department of Biometry and

Epidemiology (1995-1996) Member, Search Committee for the Executive Director of the MUSC Foundation for Research

Development (1996) Member, Search Committee for Chair of the Department of Physiology and Program in Neurosciences

(1997) Member, Search Committee for the Vice President of Finance and Administration (2000) Member, Search Committee for Vascular Wall Biologists faculty member in the Department of

Microbiology (2000) Member, Search Committee for faculty members in the Department of Biology and Epidemiology (1997-1998) Research Member, Executive Committee of the University Research Council (1995-1998) Research Strategic Planning Subcommittee at the VA Medical Center (1995-1996) Member, Dean’s Research Advisory Committee (1996-2003) Member, College of Medicine Research Task Force (2001-2002) Associate Director, MUSC General Clinical Research Center (1994-2003) Member, GCRC Advisory Committee (1994-2003) Member, GCRC Executive Committee (1994-2003) Member, College of Medicine Clinical Investigation Task Force (1998-2000) Advisory Committee for AHRQ P01 HS10871, “The EXCEED Initiative for Understanding and Eliminating Health Disparities in Blacks in South Carolina”, PI: Barbara Tilley (2001-2003) Member, Pediatrics Research Institute Advisory Committee (2001-2003) Member, Research & Development Committee of the Charleston VA Medical Center (1996-1999) Research Judge, Student Research Day, 1995, 1996, 1997, 1998, 1999, 2000, 2001. Chair, MUSC Post-Doctoral Fellowship Awards Committee (1996-1997) Member, VA Research Space Subcommittee (1997-2002)

6

Member, Provost’s Committee to Examine Impact of Hospital Authority Status on Research, 1999-2000. Mentor in the SC COBRE for Cardiovascular Disease P20 RR16434, PI: Roger Markwald (2001-2003) Mentor in the South Carolina Center of Biomedical Excellence (COBRE) for Oral Health P20 RR17696,

PI: Steve London (2002-2003) Director of the Pilot Project Core Facility, EXPORT Center on Metabolic Syndrome and Minority Health

P60 MD000267, PI: Sabra Slaughter (2002-2003) Director of the MUSC/HBCU Partners in Wellness: Collaboration with the Historically Black Colleges and

Universities in South Carolina (1998-2003) Director of the Sea Islands Family Project/Project Sugar (1995-present) Faculty member on training grants: NIH T35 DK07431 Short-Term Research Training in Health

Professional Schools (PI: R. Crouch); NIH T32 GM08716 Training Program for Medical Scientists (PI: P. Halushka); NIH T32 HL07260 Training to Improve Cardiovascular Drug Therapy (PI: J. Hildebrandt); NIH K30 HL04536 Clinical Research Curriculum Award (PI: L. Key); NIH T35 HL07923 Summer Research Program for Minority Medical Students (PI: D. Menick); NIH T32 DK07752 Training Grant in Glomerular Function and Disease (PI: J. Raymond); NIH T35 HL07769 Short-Term Training for Minority Students (PI: Wright); and the VA REAP in Glomerular Diseases (PI: J. Raymond).

Department of Medicine Member, Medicine Clinical Council (1998-2001) Member, Diabetes Patient Care Committee, Charleston VA Medical Center (1999-2002) Member, Diabetes Surveillance Council, Diabetes Initiative of South Carolina (1994-2003) Member, Diabetes Center Council of the Diabetes Initiative of South Carolina (1995-1998) Member, Department of Medicine Clinical Appointments and Privileges Committee (1995) C] UNIVERSITY OF ALABAMA AT BIRMINGHAM Academic Chair, Department of Nutrition Sciences (2003 – 2018) Director, UAB Diabetes Research Center, P60 DK079626, (2008 – present) Associate Director, Nutrition Obesity Research Center, P30 DK056336, (2003 – present) Director/PI, T32 Obesity Training Program for post-doctoral fellows DK-062710 (2018-present) Member, Internal Advisory Committee for the UAB Nathan Shock Center for the Study of Aging (2015-present) Member, Geriatric Research Education and Clinical Center – GRECC (2003– present) Member, Graduate School Faculty (2003 – present) Member, Nephrology Research and Training Center (2005 – present) GRECC Investigator, Birmingham VA Medical Center (2003 – present) Member, Faculty, UAB Medical Scientist Training Program (MSTP), 2007 – present. Member, UAB Strategic Plan Steering Committee (2005 – 2007) Co-Chair, Diabetes and Metabolic Diseases Subcommittee for the UAB Strategic Plan (2005-2006) Member, UAB Strategic Plan Implementation Committee (2006-present) Member, Graduate Education Subcommittee of the UAB Strategic plan Implementation Committee (2007-2008) Member, Graduate Biomedical Sciences Oversight Committee (2008 – present) University Chair, Internal Advisory Committee for the UAB Center for the Study of Community Health (2015-present) Member, Health Sciences Foundation Advisory Committee (2003 – present)

7

Member, UAB School of Medicine Executive Committee (2003 – present) Member, Osteoporosis Clinic Steering Committee (2003 – present) Member, Executive Committee of the School of Health Related Professions (2003 – present) Member, Institutional Advisory Committee for the Center for Health Promotion (July 2005 – 2008) Chair, Internal Advisory Committee for the Center for the Study of Community Health (2008 – present) Search Committees Chair, search committee for new director of the Nutrition Obesity Research Center (2017-2018) Chair, search committee for Chair of the Department of Pathology, 2006 - 2008 Member, recruitment for Director of the UAB Office of Grants and Contracts Administration, 2004-2005 Member, search committee for faculty member in the Division of Endocrinology, 2004-2005 Member, search for Chairman of the Department of Medicine, 2004-2005 Member, search committee for cancer epidemiologist in Department of Epidemiology, 2004-2005 Chair, search committee for Director of the Basic Science Section of the Division of Gerontology, 2005 Member, search committee for Diabetes Center Director (expert in Type 1 Diabetes), 2005-2007 Research Director and PI, UAB Diabetes Research Center, P30 DK079626 (2008 – present) Associate Director, NIDDK/NORC Nutrition Obesity Research Center, P30 DK056336 (2003 – present) Interim Director of Genetics Core, Clinical Nutrition Research Center (2004 – 2012) GRECC Investigator, Birmingham VA Medical Center (2003 – present) Member, UAB Clinical Research Infrastructure Advisory Committee (2003 – 2005) Member, NIH K30 Training Grant Internal Advisory Committee (2003 – 2008) Member, Multidisciplinary Advisory Committee, NIH K12 Multidisciplinary Clinical Research Career Development Program (2004-2008) Member, Scientific Advisory Committee, UAB General Clinical Research Center (2004-2008) Member, planning committee for UAB Clinical and Translational Sciences Award application (2005- 2008) Executive Committee Member of the Center for Clinical and Translational Science-CTSA (2007-2009) Training Director/PI, NIH T32 (DK-062710), Obesity Training Program, (2004 – present) Mentor, NIH T32 (DK-062710), Obesity Training Program, (2004 – present) Mentor, NIH T32 (HL007457), Mechanisms of Hypertension and Cardiovascular Diseases, (2005 – present) Mentor, NIH K30 (HL004146), UAB K30 Clinical Research Training Program, 2004- Mentor and Member of the Core Leadership Team, Howard Hughes Medical Institute Med into Grad Program, (2006 – ). Member, Faculty, NIH T32 GM08361, UAB Medical Scientist Training Program (MSTP), 2007 – present. Member, Graduate Biomedical Sciences Oversight Committee (2008-2014) Member, Graduate Biomedical Sciences Faculty Review Subcommittee (2008-2016) Member, UAB Council of the Office of Post-Doctoral Education-COPE (2007 – present) NATIONAL RESEARCH SERVICE: 1. Editorial Referee Editorial Board (current): Journal of Clinical Endocrinology and Metabolism, 2016-present Editorial Board (former): Cardiorenal Medicine, 2011-2018 Metabolic Syndrome and Related Disorders, 2011-2017

8

Diabetes Care, 2013 - 2017 Journal of Clinical Endocrinology & Metabolism, 2007-2013 Diabetes, 2002-2005; and 2005 – 2008 Annals of the New York Academy of Sciences, Editorial Advisory Board (Diabetes), 2009 – 2012 Clinical Nutrition & Obesity eJournal, Medscape Journal of Medicine Diabetes Reviews, 1993-1998 Journal of Clinical Endocrinology & Metabolism, 1999-2003 International Textbook of Diabetes, section editor, Normal Physiology of Insulin Action, 2004 – 2010 (ongoing e-publication) Recent ad hoc referee: Journal of Biological Chemistry, Journal of Clinical Investigation Diabetes, Metabolism Hormone and Metabolic Research, FASEB Journal American Journal of Physiology, Endocrinology New England Journal of Medicine, Diabetes Care American Journal of Human Genetics, FEBS Letters Science, The Journal of Cell Biology Human Molecular Genetics, Chemical Reviews Obesity Research, JAMA Journal of Clinical Endocrinology and Metabolism 2. Service to Professional Associations Member, Board of Directors of the Indiana Affiliate of the American Diabetes Association, 1990-1992. Chair, Selection Committee for the Josiah Kirby Lilly, Sr., Distinguished Service Award presented by the Indiana Affiliate of the American Diabetes Association, 1993 Member of the Program Committee and Coordinator of abstract reviews in the field of ‘hormone action’ for the national meetings of the American Diabetes Association held in Las Vegas, June, 1993. Member of the Professional Practice Committee of the American Diabetes Association, 1994-1995. Member of the Obesity Task Force of the American Diabetes Association, 2000-2001. Member, Board of Directors of the Charleston Chapter of the Juvenile Diabetes Research Foundation, 1996-2003. Member of Diabetes and Cardiovascular Disease Conference sponsored by NIDDK and NHLBI for advice on preparation of a report to congress regarding scientific advances and opportunities, January 28, 2002. Member of the Scientific Sessions Planning Committee for the 63rd national meeting of the American Diabetes Association held in New Orleans, June, 2003. Member of the Scientific and Medical Meetings Oversight Committee, American Diabetes Association, 2004 to 2006. Chair, Scientific and Medical Meetings Oversight Committee, American Diabetes Association, 2007 to 2008. Member, Publications Committee, American Diabetes Association, 2009-2011 Co-Chair, Obesity Task Force, American Association of Clinical Endocrinologists (AACE), 2011-2012 Chair, Obesity Scientific Committee, American Association of Clinical Endocrinologists (AACE), 2012- 2018 Member, Board of Advisors, American Association of Clinical Endocrinologists (AACE), 2012-2013 Chair, AACE Consensus Conference on Obesity, Washington DC, March 23-25, 2014 Member, Board of Directors, American Association of Clinical Endocrinologists (AACE), 2013-present

Chair, Obesity Disease State Network, American Association of Clinical Endocrinologists (AACE), 2018- present

Member, Committee to revise ADA Nutrition Recommendations, American Diabetes Association 2018-

9

present 3. Research Grant Review a.) Chairman, Research Review Committee of the Indiana Affiliate of the American Heart Association, 1992-1993, and member of this committee from 1989-1993. b.) Chairman, Research Review Committee of the Indiana Affiliate of the American Diabetes Association, 1992-1993, and member of this committee from 1989-1994. c.) Member of the National Research Review Committee of the American Diabetes Association, 1992-1995.

d.) Member of the Medical Science Review Committee of the Juvenile Diabetes Foundation, International, 1994-1997.

e.) Member, national grant application review committee for Mentor-Based Post Doctoral Fellowship Awards from the American Diabetes Association, 1999. f.) International Grant Review. Ad hoc Reviewer for: • US/Israel Binational Research Grant Program • United Kingdom Medical Research Council • Association Francaise contre les Myopathies • Diabetes Fonds/Netherlands Diabetes Association g.) Reviewer of pilot Grants for Diabetes Research and Training Centers: 1998, 2000, 2001, 2008,

2009, 2010, 2011 h.) American Federation for Aging Research (AFAR), Southeast Affiliate, February 2004 to 2012.

i.) Ad hoc review committees for National Institutes of Health: • Member, PO1 site-visit, NIDDK, University of Florida School of Medicine, Gainesville, 10/29-31/90. • Member, RFA DK-91-01, Diabetes Mellitus in Native American Populations, 7/15-16/91. • Member, PO1 site visit, NIDDK, University of Texas Health Science Center, San Antonio, 1994. • Member, Biochemical Endocrinology Study Section, 7/7/94. • Member, Special Emphasis Study Section: Clinical Sciences, ZRG4 CLIN-1, 11/29/94. • Member, Diabetes Research and Training Center applications NIDDK, 1995. • Chairperson, Clinical Sciences Special Emphasis Panel, 7/19/95. • Member, Metabolism Study Section, 10/24-25/95. • Member, Metabolism Study Section, 2/22-23/96. • Member, Metabolism Study Section, 7/2-3/97. • Member, ad hoc committee, HG-98-24 “Coordinating Center for the African American Diabetes Mellitus Study Network”, 7/8/98

• Chairman, Special Emphasis Panel of the REN Study Section, NIH/NIDDK, June 17, 2001. • Member, Endocrinology & Reproductive Sciences Study Section (END), NIH, 10/25/02 • Member, Metabolism Study Section (MET), NIH, 10/24/02 • Member, Special Emphasis Panel (ZRG1 END 02), NIH, 6/30/03 • Member, Special Emphasis Panel [ZRG1 F06(20)L] F32 and F31 training grants, 7/12- 13/04. • Member, Clinical and Integrative Diabetes and Obesity study section, ZRG1 EMNR-K (90), 2/16-17/2006 • Member, Special Emphasis Panel (ZRG1 EMNR-E 03 M), 6/29/07 • Member, Health of the Population IRG with asynchronous electronic discussion (AED), ZRG1 HOP-T-3), 2/19-2/20/2008 • Member, The Metabolic Syndrome of Aging (ZAG1 ZIJ-5), review of PO1-AG032961, June 19, 2008 • Member, ARRA Challenge Grants Review, ZRG1-EMNR-C58, June, 2009

10

• Member, NIH College of CSR Reviewers, 2010 – 2012: includes stage 1 reviews for Director’s Challenge Grants RFA-OD-10-005, May, 2010. • Member, PAR Panel: Adverse Metabolic Side Effects of Second Generation

Psychotropic Medications Leading to Obesity and Diabetes. 2012/01 ZRG1 EMNR-R (55) R, October 27, 2011.

j.) Standing Member of review committees for National Institutes of Health: • Member, Metabolism (MET) Study Section, NIH/NIDDK, 1998–2002. k.) Member, Department of Veterans Affairs Medical Research Service Merit Review Subcommittee

for Endocrinology, 1996-2000. l.) Member, American Diabetes Association Grant Review Committee, 2005-2008.

4. Data Safety Monitoring Board

a.) Chair of the Vascular SCCOR Data Safety Monitoring Board, National Heart Lung and Blood Institute/NIH. 2006 – 2016.

RESEARCH FUNDING: Previous Funding 1. Pfizer Scholars Award, Pfizer Pharmaceuticals. Role of cellular glucose transporters in type II diabetes

mellitus. P.I.: W. Timothy Garvey, M.D., $100,000, 7/1/87 to 7/1/89. 2. Pfizer Post-Doctoral Fellowship Award, Pfizer Pharmaceuticals. Mechanisms of insulin resistance in type

II diabetes mellitus. P.I. W. Timothy Garvey, M.D., $90,000, 7/1/84 to 6/30/87. 3. Pfizer Scholars Award, Pfizer Pharmaceuticals. Role of cellular glucose transporters in type II diabetes

mellitus. P.I. W. Timothy Garvey, M.D., $100,000, 7/1/87 to 7/1/89. 4. Research and Development Award, American Diabetes Association. Glucose transport proteins in type II

diabetes mellitus. P.I. W. Timothy Garvey, M.D., $120,000, 7/1/87 to 6/30/89. 5. United States-Israel Binational Science Foundation Research Grant, Mechanism of insulin resistance in

NIDDM patients. Co-investigator with Eddy Karnieli, M.D., $238,000, 7/1/87 to 6/30/90. 6. International Summer Student Program, Juvenile Diabetes Foundation. P.I. W. Timothy Garvey, M.D.,

$12,500, 6/1/91 to 9/30/91. 7. First Independent Research Support and Transition Award, National Institutes of Health. Role of glucose

transport proteins in diabetes mellitus (DK38765). P.I. W. Timothy Garvey, M.D., $350,000, 7/1/88 to 6/30/93.

8. American Diabetes Association, Clinical Research Grant. Heredity of Human Insulin Resistance. P.I.: W. Timothy Garvey, M.D., $66,500, 7/1/93 to 6/30/94.

9. Merit Review Research Grant, Veterans Administration. Glucose transporters and insulin resistance. P.I. W. Timothy Garvey, M.D., $489,000, 4/1/90 to 3/31/95.

10. Diabetes Research and Training Center, National Institutes of Health. P.I.: Charles M. Clark, M.D., and Co-P.I.: W. Timothy Garvey, M.D., $1,250,000 per year, 12/1/92 to 11/30/97.

11. National Institutes of Health, DK-43640. Renal glucose transport in diabetes (DK 43640). P.I.: Jesus Dominguez, M.D., and Co-P.I.: W. Timothy Garvey, M.D., $303,000, 10/1/92 to 9/30/95.

12. Grant-In-Aid, American Heart Association. Cardiac glucose transport and glycogen metabolism in diabetes. P.I. W. Timothy Garvey, M.D., $120,000, 7/1/92 to 6/30/95.

13. Sankyo, Co., Ltd, Tokyo, Japan. Unrestricted Research Gift. P.I.: W. Timothy Garvey, M.D., $100,000, 5/9/95.

14. Glaxo Research Institute, Inc. NIDDM genes in the Pima Indians. P.I.: W. Timothy Garvey, M.D., $750,000, 4/1/94-3/31/97.

15. National Institutes of Health, DK-38765. Heredity and Mechanisms of Human Insulin Resistance. P.I.: W. Timothy Garvey, M.D., $710,962, 9/30/93 to 9/29/98 (no cost extension to 9/29/99).

11

16. National Institutes of Health, DK-47461. Genetic Markers for NIDDM & Pathogenic Metabolic Traits. P.I.: W. Timothy Garvey, M.D., $800,000, 9/30/93 to 9/29/98 (no cost extension to 9/29/99).

17. Merit Review Research Grant, Department of Veterans Affairs. The Glucose Transport System and Insulin Resistance. P.I.: W. Timothy Garvey, M.D., $451,600, 4/1/95 to 3/31/2000.

18. The W.M. Keck Foundation. The Sea Island Families Project: Positional Cloning of Genes Causing Complex Diseases. P.I.: W. Timothy Garvey, M.D., $750,000, 2/1/97-1/31/00.

19. American Diabetes Association, Clinical Research Grant. Mechanisms of Abnormal Muscle Fat Metabolism in Human Insulin Resistance. P.I.: W. Timothy Garvey, MD. $300,000, 7/1/99 to 6/30/02. Funding discontinued on 10/1/00 due to overlap with newly acquired RO1 grant.

20. National Institutes of Health (NHLBI) and the Juvenile Diabetes Foundation International, PO1-HL55782. “Markers and Mechanisms of Macrovascular Disease in IDDM”. PI: W. Timothy Garvey. Total = $5,073,368. 9/1/96 to 8/31/01.

21. National Institutes of Health (NCRR), R25-RR15422, Mentored Medical Student Clinical Research. Sponsor: W. Timothy Garvey, MD. Medical student: Pamela Binns. $30,236, 7/1/00 to 6/30/01.

22. GENNID Study Center, The American Diabetes Association. PI: W. Timothy Garvey. Total = $140,000. 1/1/99 to 4/1/01 with no cost extension to 6/30/02.

23. Pfizer Pharmaceuticals, Inc. Pfizer Visiting Professorship in Diabetes (supported visiting professorship of Dr Paul Robertson to MUSC). PI: W. Timothy Garvey. Total = $7,500. March, 2002.

24. South Carolina Center of Biomedical Excellence (COBRE) for Oral Health, P20 RR17696. PI: Dr Steve London; Mentor: W. Timothy Garvey. Total = $11,493,693. 9/1/02 to 8/31/07.

25. EXPORT Center on Metabolic Syndrome and Minority Health, P60 MD000267, P.I.: Dr. Sabra Slaughter; Director of Research Development Core: W. Timothy Garvey. $3,747,470, 9/1/02 to 8/31/07.

26. The W.M. Keck Foundation. The Sea Island Families Project: Positional Cloning of Genes Causing Complex Diseases. PI: W. Timothy Garvey. Total = $450,000. 7/1/01-6/30/04.

27. Janssen Pharmaceuticals, (investigator initiated). ‘Differential Effects of Atypical Anti-psychotic Drugs on Insulin Action in Adipocytes. PI: W. Timothy Garvey. Total = $79,811. 10/1/02 to 12/12/03.

28. The Duke Endowment. MUSC/HBCU Partners in Wellness. Collaboration with the Historically Black Colleges and Universities in South Carolina. PI: W. Timothy Garvey. Total = $250,000. 7/1/01 to 12/31/03.

29. National Institutes of Health, General Clinical Research Center (M-01). P.I.: Jerry Reves, M.D., Director: Lyndon Key, MD, and Associate Program Director: W. Timothy Garvey, M.D., $11,787,355, 12/1/00-11/30/2005.

30. The American Diabetes Association, Mentor-Based Post-Doctoral Fellowship Award. PI: W. Timothy Garvey. Total = $132,000, 7/1/99 to 6/30/04.

31. National Institutes of Health, DK-38765. “Mechanisms of Human Insulin Resistance”. PI: W. Timothy Garvey. Total = $1,408,480. 7/1/00 to 6/30/05.

32. Merit Review Research Grant, Department of Veterans Affairs. “Muscle Metabolism, Low Birth Weight, and the Insulin Resistance Syndrome”. PI: W. Timothy Garvey. Total = $802,600. 10/1/00 to 9/30/05.

33. Roche Research Institute, Unrestricted support for studies involving cDNA microarray analyses. PI: W. Timothy Garvey. Total = $100,000. 1/1/02 to 1/1/05.

34. LipoScience, Inc., Unrestricted support for studies involving NMR lipoprotein subclass analyses. PI: W.Timothy Garvey. Total = $150,000. 10/1/02 to 9/30/05.

35. Merck & Co., Inc., 006-00. “A Study to Assess the Safety and Efficacy of L-000899055 in Obese Patients”. PI: W. Timothy Garvey. Direct = $64,446, Total = $76,689. 7/12/04 to 3/12/05.

36. Novartis Pharmaceuticals Corporation, CLAF237A2311E1. “A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to placebo as add-on therapy in patients with type 2 diabetes treated with insulin”. PI: W. Timothy Garvey. Direct = $64,403, Total = $76,400. 7/1/04 to 9/1/06.

12

37. Ross Products Division/Abbott Laboratories, SRD B30. “Effect of Weight Loss Meal Replacements and Nutritional Bars in a Structured Weight Loss Program on body Weight and Metabolic Parameters in Individuals with Type 2 Diabetes”. PI: W. Timothy Garvey. Direct = $224,102, Total = $266,681. 7/31/04 to 12/31/05.

38. Novartis Pharmaceuticals Corporation. “A 28-week extension to a multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to placebo as add-on therapy in patients with type 2 diabetes treated with insulin”. PI: W. Timothy Garvey. Direct = $19,374, Total = $23,055. 1/1/05 to 8/1/06.

39. National Institutes of Health (NHLBI), Program Project Grant PO1-HL55782. “Markers and Mechanisms of Vascular Disease in Diabetes”. Total = $9,073,368. 9/1/01 to 8/31/06. PI: W. Timothy Garvey from 9/1/01 to 5/1/03 and PI: Maria Lopes-Virella from 5/1/03 to 8/31/06. Project Leader: W. Timothy Garvey. “Project 4: Core Leader: W. Timothy Garvey. “Core C: Molecular and Statistical Genetics Core”.

40. National Institutes of Health (NIDDK), P30 DK 56336. “Clinical Nutrition Research Unit”. PI: David Allison, co-PI: W. Timothy Garvey. Direct = $2,822,300, Total = $4,064,112. 6/1/00 to 6/30/07. Core Leader: W. Timothy Garvey. “Core C: Genetics Core”. Direct = $368,968, Total = $531,314.

41. National Institutes of Health, NHLBI Proteomics Initiative, NO1-HV-28181. “The MUSC Cardiovascular Proteomics Institute”. PI: Dan Knapp. Total = $15,230,008. 10/1/02 to 9/30/09. Project 3: “Application of Proteomics Analyses to Cardiovascular Disease Risk: Insulin Resistance”, Project Leader: W.T. Garvey.

42. Daiichi-Sankyo, WEL-201, “Effect of Colesevelam on Insulin Sensitivity in Type 2 Diabetes Mellitus”. PI: W. Timothy Garvey. Total = 146,799. 10/1/06 – 12/31/08.

43. Vivus, Inc., OB-202 Phase II, “Randomized, Double-Blind Study Comparing Efficacy and Safety of VI-0521 to Placebo in the Glycemic Management of Obese Diabetic Adults”. PI: W. Timothy Garvey. Total $105,407. 6/25/07 – 6/24/08.

44. Merck & Co., Inc., “A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability, and Efficacy of L-000889055 in Obese Patients”. PI: W. Timothy Garvey, Total = $208,765. 6/27/05 – 3/11/08.

45. Daiichi-Sankyo, WEL-A 305/306, “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol in Type 2 Diabetes Mellitus. Total $54,134. 4/24/09-6/2/10.

46. Genzyme Corp., ISIS 301012-CS12, “A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of ISIS 301012 (Mipomersen) as Add-On Therapy in High Risk Hypercholesterolemic Patients. Total $24,484. 6/3/09-6/2/10.

47. Merck & Company, Inc, MERCK 009-00, Phase lla, Multicenter, Randomized, Placeb0 and Active-Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus who have Inadequate Glycemic Control. Total $17,574. 6/18/09-6/17/10.

48. Merit Review Research Grant, Department of Veterans Affairs. “Pathogenesis of the Metabolic Syndrome”. PI: W. Timothy Garvey. Total = $500,000. 10/1/05 to 9/30/10.

49. National Institutes of Health, R01 DK-38765. “Mechanisms of Human Insulin Resistance”. PI: W. Timothy Garvey. Total = $2,935,340. 7/1/06 to 6/30/11

50. National Institutes of Health (NIDDK), P60 DK-079626, “UAB Diabetes Research and Training Center”. PI: W. Timothy Garvey. Direct = $6,250,000; Total = $9,300,000 2008-2013

51. National Institutes of Health (NIDDK), P30 DK-079626, “UAB Diabetes Center”. PI: W. Timothy Garvey. Direct = $4,000,000; Total = $5,700,000 2013-2018

52. National Institutes of Health, RO1 DK083562. “NR4A Orphan Receptors and Insulin Resistance”. PI: W. Timothy Garvey. Total = $2,131,340. 08/01/09 – 07/31/13

13

53. National Institutes of Health (NIDDK), P30 DK 56336. “Clinical Nutrition Research Unit”. PI: David Allison, co-PI: W. Timothy Garvey. Direct = $4,003,500, Total = $5,065,875. 7/1/00 to 6/30/12. Core Leader: W. Timothy Garvey. “Core C: Genetics Core”. Direct = $479,975, Total = $695,963.

54. National Institutes of Health (NIDDK), P30 DK 56336. “Clinical Nutrition Research Unit”. PI: David Allison, co-PI: W. Timothy Garvey. Direct = $4,003,500, Total = $5,065,875. 7/1/12 to 6/30/17.

55. Merit Review Research Grant, Department of Veterans Affairs. “Pathogenesis of the Metabolic Syndrome”. PI: W. Timothy Garvey. Total = $600,000. 10/1/10 to 9/30/14.

56. RO1 DK-084350 NIH/NIDDK M. Sale (PI). “Genetic Contributions to Diabetes and Dyslipidemia in African Americans”. Garvey is co-investigator and PI of the subcontract from U. of Virginia. $21,515 (subcontract), 7/1/09-6/30/13

57. RO1 DK-078328, NIH/NIDDK. S. Adams (PI). “Identification of Muscle Specific Biomarkers of Fatty Acid Beta Oxidation”. Garvey is co-investigator and PI of the subcontract from USDA $56,146 (subcontract), 8/4/09 - 9/30/2012.

58. Merck & Company, Inc./Duke U, Garvey (PI). MERCK 082-00. TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy. $39.513, 5/27/10 to 5/26/16

59. Amylin/Duke U, Garvey (PI). BCB 109. Phase llI, A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus. $80,643, 7/27/10 to 7/26/16

Current Funding 60. Merit Review Research Grant, CX000432 Garvey (PI), Department of Veterans Affairs, “Mechanisms

of Insulin Resistance in Diabetes”, $600,000, 04/01/15 - 03/31/19 61. National Institutes of Health (NIDDK), P30 DK-079626, “UAB Diabetes Research Center”. PI: W. Timothy

Garvey. Direct = $5,000,000; Total = $7,500,000 2018-2023 62. American Heart Association , Strategically Focused Obesity Research Center SFRN33570038, Garvey

(PI), “Intergenerational Transmission of Obesity and Cardiometabolic Disease” $4,000,000, 04/01/17 - 03/31/21

63. DK-11-010, NIH/NIDDK, GRADE Trial (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study). UAB Site selected with Co-PIs: WT Garvey and A Cherrington. Investigator start-up meeting 2012-present

64. NIH / NIDDK, R25 DK113652, “UAB STEP-UP: Promoting Diversity through Mentored Research Experiences”, Fouad, M and Garvey, WT (co-PIs) 1,120,000. 04/01/17– 03/31/22

65. Pfizer/Merk, B1521021, Garvey (site PI), “Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Access Cardiovascular Outcomes Following Treatment with Ertugliflozin (MK-8835/PF-04971729) in Subjects with Type 2 Diabetes Mellitus and Established Vascular Disease” 01/22/15– 01/21/20

66. Novo Nordisk NN9924-4224, Garvey (site PI), PIONEER Study “Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects with Type 2 Diabetes” 08/15/16– 01/31/19

67. Novo Nordisk NN9931-4296, Garvey (site PI), NASH Study “Investigation of Efficacy and Safety of Three Doses of Subcutaneous Semaglutide Once Daily Vesus Placebo in Subjects with Non-alcoholic Steatohepatisis” 02/07/17– 02/06/21

68. Novo Nordisk NN8022-4272, Garvey (PI), SCALE Study “Effect and Safety of Liraglutide 3.0 mg in Subjects with Overweight or Obesity and Type 2 Diabetes Mellitus Treated with Basal” 01/26/17– 01/25/19

69. Novo Nordisk NN2211-4315, Garvey (PI), LIRA Study“Liraglutide vs. placebo as add on to SGLT2 inhibitor, Phase 3b”, 05/01/17– 02/07/19

14

70. NIH/NIDDK, R01DK116726, Gower (PI), Garvey (co-PI), “Depletion of pancreatic lipid improves beta-cell function in early type 2 diabetes”. Direct $358,758/year, 04/01/18– 03/31/22

TRAINING RECORD: I. Faculty Training • Fabio B. Lima, MD, PhD, Fogarty International Research Fellow, July 1986 – July, 1988. Current Position: Professor of Medicine and Physiology Chair, Depart. Fisiologia e Biofisica Inst. Ciencisas Biomedicas University of Sao Paulo, Brazil • Pilar Mayor, PhD, Visiting Scientist, February 1988 – August 1988. Current Position: Associate Professor of Biochemistry Depart. Bioquimica, Fac. Medicina Univ. Complutense Madrid, Spain • Steven M. Willi, MD, NIH/NCRR Clinical Associate Physician Award through the General Clinical Research Center. 1996 – 1999. Current Position: Associate Professor of Pediatrics

Director, Diabetes Center for Children CHOP, University of Pennsylvania • Yuchang Fu, PhD, 2000- present. Supported through Center of Biomedical Research Excellence (COBRE) Award from NIH/NCRR (P20 RR16434) with Dr. Garvey as primary research mentor from 10/01 to present. Current Position: Associate Professor Department of Nutrition Sciences University of Alabama at Birmingham • Deyi Zheng, PhD, 2002 –2004. Supported through South Carolina Center of Biomedical Excellence (COBRE) for Oral Health, P20 RR17696. PI: Dr Steve London. Five year budget is $11,493,693. Dr. Garvey serves as primary mentor for Dr Zheng for Project 1: “Interrelationships between diabetes and periodontal health in minority children and adolescents”. Current Position: Assistant Professor Department of Biometry and Epidemiology Medical University of South Carolina • Jamy Ard, MD, 2003 – present. Awarded K23 training grant from NIDDK [K23-DK068223, “Improving Weight Loss Outcomes in African Americans”] with Dr. Garvey as mentor, 8/15/2004 to 7/31/2009. Awarded the Robert Wood Johnson Harold Amos Medical Faculty Development Award with Dr. Garvey as mentor, 1/1/05 to 12/31/08, “Improving Weight Loss Outcomes for African Americans using a Diet High in Fruits and Vegetables”. Current Position: Associate Professor Department of Nutrition Sciences University of Alabama at Birmingham • Fernando Ovalle, MD, 2003 – present. Submission of K23 grant application to NIH in October, 2004.

15

• Jeevan K. Prasain, PhD, 2007 – 2012. Co-mentor for work on anti-diabetic plant-derived compounds and for KO1 application entitled “Puerarin and its Anti-diabetic Activity”. • Andrea Cherrington, MD, 2007 – 2011. Co-mentor for community-based research on diabetes and diabetes prevention, and member of her Scholarship Advisory Committee. Mentor for K23 application. Also Mentor for Robert Wood Johnson Foundation Career Development Award – “Weight Loss and Diabetes Prevention in Latina Immigrants: Advancing Methods of Community-Based Intervention Delivery” 7/1/08 to 6/30/11. • Orlando Gutierrez, MD, 2011 – 2013. Mentor for Dr. Gutierrez’s K23 grant (K23-DK081673) entitled “Racial Differences in Phosphorus Metabolism in Health and in Kidney Disease”. 2/21/11 – 6/30/13 • April Carson PhD Mentor for Dr. Carson K01 DK095928, “The Role of Nontraditional Glycemic Markers in Diabetes and Albuminuria, 2013-2016. II. Post-Doctoral Fellows • Rogerio Sertie, PhD, 2018 – present. Funded by AHA Strategically Focused Obesity Research Center “Intergenerational Transmission of Obesity” • Lua Wilkinson, PhD, 2017-present. Funder by postdoctoral T32 Obesity Training Program at UAB • Ling Tian, PhD, 2011 – 2013. Enrolled in the Washington University School of Medicine, 2013 • Xuxia Wu, PhD, 2004 - 2008. Current position as Instructor, Department of Nutrition Sciences, UAB 2008-2010; then Internal Medicine Residency Program, Brooklyn NY • Douglas Moellering, PhD, 2003 – 2008. Dr. Moellering was the recipient of the 2004-2005 Postdoctoral Career Enhancement Award from the UAB Office of Postdoctoral Education. Current position: Associate Professor, Department of Nutrition Sciences, and research core manager REDOX Biology Core –DRTC. • Cristina Lara-Castro, MD, PhD, 2003 – 2009. Dr. Lara-Castro received support from an ADA Mentor-Based Postdoctoral Fellowship Award in 2003-2004, and NIH T32 (HL007457), “Mechanisms of Hypertension and Cardiovascular Diseases” training grant. Current position: Research Instructor, Division of Endocrinology at the University of Michigan; then Residency in Internal Medicine, Ann Arbor MI 2010 - present • Helliner Vestri, MD, PhD, 2002 – 2011. Current position: Scientific medical liaison for Novo-Nordisk • Yian Chen, PhD, 2001-2003. Last known position: Post-Doctoral Fellow, Cancer Center, Medical University of South Carolina • Ju-hong Zhu, PhD, 1990-2000. Last known position: Molecular Core Laboratory, GCRC, Medical University of South Carolina • Nikki Rogers, PhD, 1999-2000. Last known position: Post-doctoral Fellow, Department of Anthropology, Dayton University

16

• Angela Brown, PhD, 1996-2000 . Last known position: Post-Doctoral Fellow, Division of Cardiology, Medical University of South Carolina • Pei-Mao Lin, PhD, 1989-1993. Last known position: Research Assistant Professor, Indiana University, Indianapolis, IN • Shichun Bao, PhD, 1997-1999. Current Position: Instructor, Division of Endocrinology, Vanderbilt University, Nashville, TN

• George Argyropoulos, PhD, 1995-1997. Current Position: Faculty member, Pennington Center for Obesity Research, Louisiana State University • Claire Allen, PhD, 1995-1996. Last known position: Director of Clinical Genomics, Glaxo-Wellcome, Inc., United Kingdom III. Graduate Training, PhD Candidates A] Graduate Committees or Ph.D. Thesis/Advisory Committee Chair • Chair, Shichun Bao, Physiology, Indiana University, PhD awarded 1997. • Chair, David McLean, Molecular & Cellular Biology & Pharmacology, Medical University of South Carolina, PhD awarded 2003. • Co-chair, Kerin McCormack, Molecular & Cellular Biology & Pharmacology, Medical University of South Carolina, 2001-2004, MS awarded in 2004.

• Chair (UAB component), Katie Heimburger, MS, 1/1/07 to 6/1/07 and 11/1/08 to 11/1/09, Visiting Graduate Student, Department of Kinesiology, Georgia State U., PhD awarded in 2009,

• Chair, Ling Tian, BS, 2007-2010, Graduate Student, Department of Cell Biology • Chair, Jiarong (Rona) Liu, MS, 2006-2011, Graduate Student, Department of Pathology • Chair, Xiaolin (Frank) Zhu, BS, 2006-2010, Graduate Student, Department of Cell Biology

• Chair, Rosicka Grace Walton, MS, 2006-2011, Graduate Student, Department of Nutrition Sciences • Co-Chair, Qinglan (Helen) Liu, BS, 2009-2013, Graduate Student, Department of Pathology • Chair, Wei Zhang, MS, 2009-2014, Graduate student, Department of Nutrition Sciences. • Chair, Dennis Steverson, Jr, 2009 – 2015. Graduate student in the HHMI Med-to-Grad program and the Department of Pathology

• Chair, Veeradej Pisprasert, MD, 2009-2013, Graduate Student in the Department of Nutrition Sciences, UAB

• Chair, Elizabeth Ma, 2013-2017, MSTP Student in the School of Medicine (MD/PhD Degree candidate), PhD awarded in 2017, MD awarded in 2019

• Chair, Minsung Kang, 2013-2018, Graduate Student in the Department of Nutrition Sciences, UAB • Chair, Xiaobing Liu, 2015 to present

Member • Member, Sima Ertefai, Engineering Sciences, U. of CA, San Diego, PhD awarded 1989. • Member, Chris Potter, MD/PhD candidate, Neurobiology, Indiana University, PhD awarded 1995.

• Member, Malabika Ghosh, Immunology, MUSC, PhD awarded 1997. • Member, Mark Horney, MD/PhD candidate, Endocrinology/MCBP, MUSC, PhD awarded 1998.

17

• Member, Jenifer Haskill, Epidemiology, MUSC, PhD awarded 1998. • Member, Nikki Rogers, Anthropology, University of Tennessee, PhD awarded 1999. • Member, Bryce Nelson, MD/PhD candidate, Endocrinology/MCBP, PhD awarded 2003. • Member, Joyce Fan, PhD candidate, Epidemiology, 2001-2003. PhD awarded 2003. • Thesis defense and viva voce examination, Bhaswati Pandit, Ph.D., “Genetic Instability in Chinese Hamster V79 Cells”, University of Calcutta • Member, Jeannine Lawrence Clunk, PhD candidate, Nutrition Sciences, UAB, 2003 – 2007. • Member, Paul Higgins, PhD candidate, Nutrition Sciences, UAB, 2004 – 2007. • Member, David Kosek, PhD candidate, Physiology, UAB, 2004-2007 • Member, David Mayhew, MD/PhD candidate, Physiology, UAB, 2006 – 2010. • Katie Heimburger, MS, PhD Degree Candidate in Kinesiology at Georgia State University, 2007- present, and research mentor as a visiting graduate student at UAB 1/1/07 – 6/1/07 and 11/1/09 to 2010. • Member, Patricia Jumbo-Lucioni, PhD Degree candidate in Nutrition Sciences, UAB, 2007-2009 • Member, Lidong Zhai, PhD Degree Candidate in Pathology, UAB, 2008-2010

• Member, Joshua Speed, PhD, K99 HL127178, “Endothelin – Mechanisms in Hypertension and Obesity”, 2015-2017, appointed Assistant Professor at U Mississippi for R00 component

B] Primary Research Mentorships for Graduate Students and PhD or MD/PhD Candidates

• Xiaobing Liu, 2015-present • Minsung Kang, 2013-2018, Graduate Student in the Department of Nutrition Sciences, UAB

• Elizabeth Ma, 2013-2017, MSTP Student in the School of Medicine (MD/PhD Degree candidate), PhD awarded in 2017, MD awarded in 2019

• Veeradej Pisprasert, MD, 2009-2013, Graduate Student in the Department of Nutrition Sciences, UAB

• Qinglan (Helen) Liu, BS. 2009-2013, Graduate Student in the Department of Pathology, UAB • Wei Zhang, BS. 2009-2014, Graduate Student in the Department of Nutrition Sciences, UAB

• Dennis Steverson, Jr, BS. 2009-2015, Graduate Student in HHMI Med-to-Grad Program and the Department of Pathology, UAB • Rosicka Grace Walton, MS, 2007-2011, Graduate Student, Department of Nutrition Sciences, UAB. Current Position: Post-Doctoral Fellow at the University of Kentucky with mentor Dr. Phil Kern. • Ling Tian, 2007-2011, Graduate Student in the Department of Cell Biology, Current Position: Research Associate Department of Nutrition Sciences, UAB • Jiarong (Rona) Liu, MS, 2006-2011, Graduate Student, Department of Pathology, UAB. Current Position: Law School at Arizona State University (interest in biomedical patent law) • Xiaolin (Frank) Zhu, BS, 2006-2011, Graduate Student, Department of Cell Biology. Current Position: Post-doctoral Fellow with Dr Yuchang Fu at UAB

18

• Katie Heimburger, MS, 1/1/07 to 6/1/07 and 11/1/08 to 11/1/09, Visiting Graduate Student, Department of Kinesiology, Georgia State U., PhD awarded in 2009, Currently Post-Doctoral Fellow in Biostatistics at UAB • Kerin McComack, 2001-2004, MS in Biological Sciences, 2004, MUSC. Current Position: Assistant Professor of Biology, Trident Technical College, Charleston, SC • David McLean 1998-2003, PhD in Population Genetics, 2003, MUSC. Current Position: Assistant Professor, Claflin University, Orangeburg, SC • Shichun Bao 1992-1997, PhD in Physiology, 1997, Indiana University. Current Position: Assistant Professor, Division of Endocrinology, Vanderbilt University, Nashville, TN • Nikki Rogers 1997-1999, PhD in Anthropology, 1999, University of Tennessee. Last known Position: Post-doctoral fellow, Anthropology, University of Dayton, OH • Chris Potter 1991-1994, MD/PhD, 1995, Indiana University. Last known position: Medical housestaff St. Vincent’s Hospital, Indianapolis, IN

• Research Mentor for: Helliner Vestri, MD, 2000-2001. Recipient of the ‘Sandwich Fellowship’ Award from the Brazilian Government, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (Processing number 200670/00-0) for graduate student at the University of Sao Paulo. 12/1/00 to 8/24/01. Current position: Scientific medical liaison for Novo-Nordisk.

IV. Graduate Research Training for MD, Clinical Fellows Primary research mentor for clinical fellows in Endocrinology or Nutrition:

• Dana Hardin, MD, July 1990 to July 1993. Dr. Hardin was the recipient of a National Research Service Award from the NIH. Current Position: Associate Professor Pediatric Endocrinology, University of Texas/Southwestern, Medical Center, Dallas, TX

• Adele Kennedy, MD, July 1996 to July 1999. Dr. Kennedy was an awardee of an Endocrine Fellows Association research grant in 1996. Current Position: Consultant Physician Whiteabbey Hospital Northern Ireland

• Steven J. Hunter, MD, July 1997 to July 1999. Current Position: Consultant Physician in Endocrinology and Diabetes Royal Victoria Hospital Honorary Senior Lecturer Queen’s University Belfast, Northern Ireland

• Kim Pugh, MD, July 1999 to August 2001. Current Position: Instructor in Medicine Medical University of South Carolina, then private endocrine practice, Charleston SC

• Soonho Kwon, MD, July 2000 to July, 2004. Dr. Kwon was recognized as an ‘Endocrinology Fellows Forum of Excellence Winner’ for work presented at the 61st annual meeting of the ADA in 2001. He was also the recipient of Mentor Based Post-doctoral Fellowship Award from the American Diabetes Association. Current Position: Assistant Professor, Division of Endocrinology, Medical

19

University of South Carolina

• Jyotika Fernandes, MD, May 1, 2002 to July 1, 2004. This fellow has been clinically trained at Baylor University and MD Anderson Hospital in Houston, TX. She is now engaged in clinical research training for future academic career. Her fellowship is funded by the American Diabetes Association Mentor-Based Post-Doctoral Fellowship Award. Current Position: Associate Professor, Division of Endocrinology, Medical University of South Carolina

• Julian Munoz, MD, MPH, September, 2004 to 2007. Dr. Garvey served as Dr. Munoz’s mentor for research training as a fellow in clinical nutrition at UAB. Current Position: Assistant Professor Department of Nutrition Sciences, UAB; then clinical fellow, Division of Endocrinology at the University of Michigan

V. Research Training for Medical Residents • Julian Munoz, MD, MPH, Resident in Internal Medicine, Carraway Medical Center. Research rotation (Effects of Hypocaloric Diet on the Relationship between Intramyocellular Lipid and Insulin Resistance)

• Donna Morato-Alzaga, MD, Resident in Internal Medicine, Carraway Medical Center. Research rotation (Effect of apoE gene polymorphism on lipoprotein subclasses in Gullah speaking African Americans), September and October, 2005

• Jennifer Rowell, MD, Resident in Internal Medicine, University of Alabama at Birmingham. Research rotation (Weight loss, insulin sensitivity, and intramyocellular lipid), September and October, 2005. • Marjan Karejar, MD, Resident in Internal Medicine, Carraway Medical Center. Research rotation (Effects of Race on the Metabolic Syndrome Trait Cluster), September and October, 2006 • Jan Noguiera, MD, Resident in Pediatrics, University of Alabama at Birmingham. Research experience (Adipokine secretion in hepatosteatosis and NAFLD), 2006.

VI. Medical Students

• Barry Melbert, (Indiana U), Research Fellowship Program for Medical Students, Summer 1989, Summer 1990.

• Michael Wilhelm, (Indiana U), Research Fellowship Program for Medical Students, Summer 1992. • Michael Fisher, (Indiana U), Research Fellowship Program for Medical Students, Summer 1993.

• Kevin Spicer, (MUSC), Summer Health Professionals Program, Research Fellowship for Medical Students, Summer, 1995. • Nicole Redmond, MUSC Summer Research Fellowship for Medical Students, Summer, 1996. Nicole Redmond was recipient of the Medical Student Fellowship Award from the American Diabetes Association in 1997. • Leon Robinson, MUSC Medical Student, Academic Medicine Fellow during 1997. (Fellowship Program in Academic Medicine sponsored by Bristol-Myers Squibb, National Medical Fellowships, Inc.) • Angela Taylor, MUSC Medical Student, Research Fellowship for one year in between medical school graduation and internship in Internal Medicine, 1997-1998. • Pamela Binns, MUSC Medical Student. Recipient of NIH R25 RR15422 Mentored Medical Student Clinical Research grant from 7/1/00 to 6/30/01. • Yaw Donkoh, MUSC Medical Student. MUSC Summer Research Fellowship, Summer, 2002. • Patrick Conan Tapia, second year UAB Medical student, UAB Summer Research Fellowship under the program established by NIH T35-HL007473 - Short-Term Training in Health Professional

20

Schools, 2005 • David Mayhew, UAB medical student, MD/PhD candidate in third year of post-graduate training, laboratory rotation, July – September, 2005. • Erin C. Doud, UAB Medical Student, GCRC summer research fellow, 2006 • Christopher B. Clayton, UAB Medical Student, UAB Summer Research Fellowship under the program established by NIH T35-HL007473, 2007. • Lori Graves, UAB Medical Student, Scholarly Activity Rotation, 2009. “Mechanism of Action of Rosiglitazone and its Effect on Body Composition” • Harrison Irons, UAB Medical Student, DRTC Summer Research Fellowship for Medical Students P60 DK-79626, Summer 2009. “Effect of Osteocalcin on Insulin Action and Proinflammatory Cytokine Secretion in Adipocytes” • Zsu Zsu Chen, UAB Medical Student, Medical Student Training in Aging Research (MSTAR) Program, award from the American Federation for Aging Research (AFAR), Summer 2010. “Co-regulation of NR4A3 and myostatin in skeletal muscle as a function of aging and high fat feeding” • Karen Mai, UAB Medical Student, DRTC Summer Research Fellowship for Medical Students P60 DK-79626, Summer 2010. “Differential regulation of pro- and anti- inflammatory cytokines in adipose tissue in aging and high fat feeding”.

VII. Undergraduate Students • David Blackwell (Indiana U), Undergraduate Summer Research Fellowship, Summer, 1991.

• Sylvia Ertel, (Indiana U), Intercampus Undergraduate Summer Research Fellowship, Howard Hughes Institute Undergraduate Initiative, Summer, 1993.

• Joshua Berg (Indiana U.), MUSC Summer Undergraduate Research Fellowship, 1998. • Naila Allen (Savannah State), MUSC Summer Undergraduate Research Fellowship, 1998. • Blaire Stowe (Washington & Lee University), MUSC Summer Undergraduate Research Fellowship, 1999. • Jennifer Clore (North Carolina State University), MUSC Summer Undergraduate Research Fellowship, 1999. • Sara Fiorentino (Mississippi State University), MUSC Summer Undergraduate Research Fellowship, 2000. • Tiara V. Bryant (Benedict College), MUSC Summer Undergraduate Research Fellowship, 2001. • JoiAisha Evans (University of South Carolina), MUSC Summer Undergraduate Research Fellowship, 2001. • Erin Nussbaum (Porter-Gaud High School, Charleston County), Medical research experience to fullfill requirements for National Honor Society, 2000. • Jennifer Forsythe (Academic Magnet High School, Charleston County) Senior Research Thesis, 2000-2001. • Jason Perey, Clemson University, summer research, 2002. • Malinda Anderson, Lawson State College, summer research (UAB Bridges Scholars Student Program), 2004. • Jacob McGuiness, pre-medical student at Samford University, January-February, 2005 • Amy Stevenson, pre-medical student at UAB, summer research as a McNair Scholar (federal Ronald E. McNair Post-Baccalaureate Achievement Program), 2005

• Angelia Flemming, pre-health care professional student at Talladega College, summer research as a McNair Scholar (federal Ronald E. McNair Post-Baccalaureate Achievement Program), 2006.

21

• Erica Little, 2006 graduate of Carver High School, UAB Summer Science Institute (SSI) Research Internship for high school students, summer 2006. • Oraine Snaith and Delisa Abednego, undergraduates from Oakwood College, mentor during the summer for these students enrolled in the UAB Project EXPORT Minority Health Disparities Program, 2007. • Ebony Hodges, pre-health care professional student from Alabama State University, summer research as a McNair Scholar (federal Ronald E. McNair Post-Baccalaureate Achievement Program), 2007. • Janine Mwenja, scientific thesis, International Baccalaureate Program at Shades Valley High School, Birmingham AL, “Identification of Genetically Modified Foods in our Grocery Stores”, 2009 • Crystyna Malone, nursing student from Troy University, summer research as a McNair Scholar (federal Ronald E. McNair Post-Baccalaureate Achievement Program), Project: “Effects of thiazolidinediones on fuel metabolism”, 2010. • Danyell Creer, Huffman High School student, grade 11, interested in pre-med program in college, Summer Research Intern in the Center for Community OutReach Development (CORD) program, Project: “CTEP polymorphisms and lipids in Gullah-speaking African Americans”, 2010 • Tullia Rushton, Pre-med student at Duke University. Summer research. “Circadian gene expression in KSRP null mice”, 2011

• Director of MUSC/HBCU Partners in Wellness, 1998-2003. This has involved establishment of a didactic and experiential course on community health at historically black colleges and universities in South Carolina, including South Carolina State University, Voorhees College, Benedict College, Morris College, and Claflin College.

PUBLICATIONS IN SCIENTIFIC JOURNALS 1. Garvey, W.T., and R.E. Olson. In vitro vitamin-K-dependent conversion of precursor to prothrombin

in chick liver. Journal of Nutrition. 108:1078-1086, 1978. 2. Marshall S., W.T. Garvey, and M. Geller. Primary culture of isolated adipocytes: A new model to

study insulin receptor regulation and insulin action. Journal of Biological Chemistry. 259:6376-6384, 1984.

3. Garvey, W.T, J.M. Olefsky, J. Griffin, R.F. Hamman, and O.G. Kolterman. The effect of insulin treatment on insulin secretion and insulin action in Type II diabetes mellitus. Diabetes. 34:222-234, 1985.

4. Garvey, W.T., R.R. Revers, O.G. Kolterman, and J.M. Olefsky. Modulation of insulin secretion by insulin and glucose in Type II diabetes mellitus. Journal of Clinical Endocrinology and Metabolism. 60:559-568, 1985.

5. Garvey, W.T., J.M. Olefsky, and S. Marshall. Insulin receptor downregulation is linked to an insulin-induced postreceptor defect in the glucose transport system in rat adipocytes. Journal of Clinical Investigation. 76:22-30, 1985.

6. Garvey, W.T., J.M. Olefsky, and S. Marshall. Insulin induces insulin resistance in cultured rat adipocytes: Sequential effects at receptor and multiple postreceptor sites. Diabetes. 35:258-267, 1985.

7. Garvey, W.T., S.M. Grundy, and R. Eckel. Xanthogranulomatosis in an adult: Lipid analysis of xanthomata and plasma. Journal of American Academy of Dermatology. 16:183-187, 1987.

22

8. Garvey, W.T., J.M. Olefsky, S. Matthaei, and S. Marshall. Glucose and insulin co-regulate the glucose transport system in primary cultured adipocytes: A new mechanism of insulin resistance. Journal of Biological Chemistry. 262:189-197, 1987.

9. Sebrechts, C., W.T. Garvey, D.J. Sartoris, and D. Resnick. Case Report: Radiography and magnetic resonance imaging in lipoatrophic diabetes. Skeletal Radiology. 15:179-180 and 16:320-323, 1987.

10. Marshall, S., W.T. Garvey, and R. Monzon. Shunting of insulin from a retroendocytotic pathway to a degradative pathway by sodium vanadate. Journal of Biological Chemistry. 262:12005-12012, 1987.

11. Matthaei, S., W.T. Garvey, R. Horuk, T.P. Huecksteadt, and J.M. Olefsky. Human adipocyte glucose transport system: Biochemical and functional heterogeneity of hexose carriers. Journal of Clinical Investigation. 79:703-709, 1987.

12. Garvey, W.T., J.M. Olefsky, A.H. Rubenstein, and O.G. Kolterman. Day-long integrated serum insulin and C-peptide profiles in patients with Type II diabetes mellitus: Correlation with urinary C-peptide excretion. Diabetes. 37:590-599, 1988.

13. Garvey, W.T., T.P. Huecksteadt, S. Matthaei, and J.M. Olefsky. The role of glucose transporters in the cellular insulin resistance of Type II non-insulin-dependent diabetes mellitus. Journal of Clinical Investigation. 81:1528-1536, 1988.

14. Olefsky, J.M., Garvey, W.T., Henry R.R., Mattaei, S., Brillon, D., and Friedenberg, G.R. Cellular mechanisms of insulin resistance in non-insulin dependent (Type II) diabetes mellitus. American Journal of Medicine. 85 (Suppl. 5A): 86-105, 1988.

15. Heidenreich, K.A., P.R. Gilmore, and W.T. Garvey. Characterization of glucose uptake in primary cultured neurons. Journal of Neuroscience Research. 22:397-407, 1989.

16. Garvey, W.T., T.P. Huecksteadt, R. Monzon, and S. Marshall. Dexamethasone regulates the glucose transport system in primary cultured adipocytes: Different mechanisms of insulin resistance following acute and chronic exposure. Endocrinology. 124:2063-2073, 1989.

17. Garvey, W.T., T.P. Huecksteadt, F.B. Lima, and M.J. Birnbaum. Expression of a glucose transporter gene cloned from brain in cellular models of insulin resistance: Dexamethasone decreases transporter mRNA in primary cultured adipocytes. Molecular Endocrinology. 3:1132-1141, 1989.

18. Garvey, W.T., T.P. Huecksteadt, and M.J. Birnbaum. Suppression of an insulin-responsive glucose transporter gene in diabetes mellitus. Science. 125-2341-2349, 1989.

19. Drazin, B., D. Lewis, N. Houlder, N. Sherman, M. Adamo, W.T. Garvey, D. LeRoith, and K. Sussman. Mechanism of insulin resistance induced by sustained levels of cytosolic free calcium in rat adipocytes. Endocrinology. 125-2341-2349, 1989.

20. Freidenberg, G.R., R.R. Henry, W.T. Garvey, D.J. Brillon, and J.M. Olefsky. Post-binding alterations of insulin action in human obesity and non-insulin-dependent diabetes mellitus: Studies of the insulin receptor kinase and glucose transport systems. Journal of Diabetes, Nutrition, and Metabolism. 1:344-362, 1989.

21. Garvey, W.T., L. Maianu, T.P. Huecksteadt, M.J. Birnbaum, J.M. Molina, and T.P. Ciaraldi. Pretranslational suppression of a glucose transporter protein causes cellular insulin resistance in non-insulin-dependent diabetes mellitus and obesity. Journal of Clinical Investigation. 87:1072-1081, 1991.

22. Lima, F.B., R.S. Theis, and W.T. Garvey. Glucose and insulin regulate insulin sensitivity in primary cultured adipocytes without affecting insulin receptor kinase activity. Endocrinology. 128-2415-2426, 1991.

23. Yu, X.P., F.G Hustmyer, W.T. Garvey, and S.C. Manolagas. Demonstration of a novel 1,25(OH)2D3-responsive protein in human lymphocytes: Immunological crossreactivity and inverse regulation with the vitamin D receptor. Proceedings of the National Academy of Sciences, USA. 88:8347-8351, 1991.

24. Mayor, P., L. Maianu, and W.T. Garvey. Glucose and insulin regulate insulin action via different mechanisms in BC3H-1 myocytes: Effects on glucose transporter gene expression. Diabetes. 41:274-285, 1991.

23

25. Marshall, S., Garvey, W.T., and Traxinger R. New insights into the metabolic regulation of insulin action and insulin resistance: Role of glucose and amino acids. FASEB Journal. 5:3031-3036, 1991.

26. Garvey, W.T., L. Maianu, J.A. Hancock, A.M. Golichowski, and A. Baron. Gene expression of GLUT 4 glucose transporters in skeletal muscle from insulin-resistant patients with obesity, impaired glucose tolerance, gestational diabetes, and non-insulin-dependent diabetes mellitus. Diabetes. 41:465-475, 1992.

27. Dominguez, J.H., K. Camp, L. Maianu, and W.T. Garvey. The glucose transporters of rat renal proximal tubule: Differential expression and subcellular localization. American Journal of Physiology. 262:F807-F812, 1992.

28. Garvey, W.T., D. Hardin, M. Juhaszova, and J.H. Dominguez. Effects of diabetes on the myocardial glucose transport system in rats: Implications for diabetic cardiomyopathy. American Journal of Physiology. 264:H837-H842, 1993.

29. Pilch, P.F., W. Wilkinson, W.T. Garvey, T.P. Ciaraldi, T.P. Huecksteadt, and J.M. Olefsky. Insulin responsive human adipocytes express two glucose transporter isoforms and target them to different vesicles. Journal of Clinical Endocrinology and Metabolism. 77:286-289, 1993.

30. Hardin, D., J.H. Dominguez, and W.T. Garvey. Muscle group-specific regulation of GLUT 4 glucose transporters in control, diabetic and insulin-treated diabetic rats. Metabolism. 42:1310-1315, 1993.

31. Karnieli, E., W.T. Garvey, J.M. Olefsky, T.P. Huecksteadt, C. Harel, L. Maianu, and M. Armoni. Potential role of insulin and cycloheximide in regulating the intrinsic activity of glucose transporters in rat adipocytes. Endocrinology. 133:2943-2950, 1993.

32. Garvey, W.T., L. Maianu, J-H. Zhu, J.A. Hancock, and A.M. Golichowski. Multiple defects in the adipocyte glucose transport system cause cellular insulin resistance in gestational diabetes: Heterogeneity in the number and a novel abnormality in subcellular localization of GLUT 4 glucose transporters. Diabetes. 42:1773-1785, 1993.

33. Lima, F.B., and W.T. Garvey. Biologic actions of insulin are differentially regulated by glucose and insulin in primary cultured adipocytes: Chronic ability to increase glycogen synthase activity. Diabetes. 43:53-63, 1994.

34. Dominguez, J.H., K. Camp, L. Maianu, H. Feister, and W.T. Garvey. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. American Journal of Physiology. 266:F283-F290, 1994.

35. Dominguez, J.H., B. Song, L. Maianu, W.T. Garvey, and M. Qulali. Gene expression of epithelial glucose transporters: The role of diabetes mellitus. Journal of the American Society of Nephrology, 5:S29-S36, 1994.

36. Ryan, A.B., G.C. Gardner, G.P. Shragg, A.M. Tan, R.M. Braun, W.T. Garvey, and M.H. Weisman. The syndrome of limited joint mobility (SLJM) in diabetes: A study of 70 patients. Submitted, 1994.

37. Hardin, D., B. Azzarelli, J. Edwards, J. Wigglesworth, L. Maianu, G. Brechtel, A. Johnson, A. Baron, and W.T. Garvey. Mechanisms of enhanced insulin sensitivity in endurance-trained athletes. Journal of Clinical Endocrinology and Metabolism, 80:2437-2446, 1995.

38. Baron, A.D., J-S Zhu, H. Weldon, G. Brechtel, L. Maianu and W.T. Garvey. Glucosamine induces insulin resistance in vivo by affecting GLUT4 translocation in skeletal muscle: Implications for glucose toxicity. Journal of Clinical Investigation, 96:2792-2801, 1995.

39. Bao, S, R.M. Smith, L. Jarett, and W.T. Garvey. The effects of Brefeldin A on the glucose transport system in rat adipocytes: Implications regarding the intracellular locus of insulin-sensitive GLUT4. The Journal of Biological Chemisty, 270:30199-30204, 1995.

40. Morre, D.M., D.W. Sammons, J. Yim, M. Bruno, T. Snyder, T Reust, L. Maiana, W.T. Garvey, and D.J. Morre. Isolation by preparative free-flow electrophoresis and aqueous two-phase partitioning from rat adipocytes of an insulin-responsive small vesicle fraction with glucose transport activity. The Journal of Chromatography. 680:201-212, 1996.

24

41. Saghizadeh, M., J.M. Ong, W.T. Garvey, R.R. Henry, and P.A. Kern. The expression of TNFα by human muscle: Relationship to insulin resistance. The Journal of Clinical Investigation. 97:1111-1116, 1996.

42. Garvey, W.T., L. Maianu, A. Kennedy, P. Wallace, E. Ganaway, L.L. Hamacher, D.P. Yarnall, J.M. Lenhard, and D.K. Burns. Muscle Rad expression and human metabolism: potential role of the novel Ras-related GTPase in energy expenditure and body composition. Diabetes. 46:444-450, 1997.

43. Allan, C.J., G. Argyropoulos, M. Bowker, J. Zhu, P-M. Lin, K. Stiver, A. Golichowski, and W.T. Garvey. Gestational diabetes mellitus and gene mutations which affect insulin secretion. Diabetes Research and Clinical Practice. 36:135-141, 1997.

44. Paulik, M.A., L.L. Hamacher, D.P. Yarnall, C.J. Simmons, L. Maianu, R.E. Pratley, W.T. Garvey, D.K. Burns, and J.M. Lenhard. Identification of Rad's effector-binding domain, intracellular localization, and analysis of expression in Pima Indians. Journal of Cellular Biochemistry. 65:527-541, 1997.

45. Kennedy, A., T.W. Gettys, P. Watson, P. Wallace, E. Ganaway, Q. Pan, and W.T. Garvey. The metabolic significance of leptin in humans: Gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. Journal of Clinical Endocrinology and Metabolism. 82:1293-1300, 1997.

46. Norman, R.A., D.B. Thompson, C. Bogardus, T. Foroud, W.T. Garvey, P. Bennett, E. Ravussin, and the Pima Diabetes Genes Group. Genome wide search for genes influencing percent body fat in Pima Indians: Suggestive linkage at chromosome 11q22. American Journal of Human Genetics. 60:166-173, 1997.

47. Shankar, R.R., A. Haider, W.T. Garvey, and G.R. Freidenberg. Multiple endocrinopathies in an infant with fatal neurodegenerative disease. American Journal of Medical Genetics. 69:271-279, 1997.

48. Bao, S., and Garvey W.T. Exercise in transgenic mice hyperexpressing GLUT4 glucose transporters: Effects on substrate metabolism and glycogen regulation. Metabolism, 46:1349-1357, 1997.

49. Hanson, R.L., Ehm, M.G., Pettitt, D.J., Prochazka, M., Thomson, D.B, Timberlake, D., Foroud, T., Kobes, S., Baier, L., Burns, D.K., Almasy, L., Blangero, J., Garvey, W.T., Bennett, P.H., and Knowler, W.C. An autosomal genomic scan for loci linked to type II diabetes mellitus and body mass index in Pima Indians: an obesity-diabetes locus at 11q23-25. American Journal of Human Genetics: 63:1130-1138, 1998.

50. Pratley, R.E., Thompson, D.B., Prochazka, M., Baier, L., Mott, D., Ravussin, E., Sakul, H., Ehm, M.G., Burns, D.K., Foroud, T., Garvey, W.T., Hanson, R.L., Knowler, W.C., Bennett, P.H., and Bogardus C. An autosomal genomic scan for loci linked to pre-diabetic phenotypes in Pima Indians. Journal of Clinical Investigation, 101:1757-1764, 1998.

51. Norman, R.A., Tataranni, A., Pratley, R., Thompson, D.B., Hanson, R.L., Prochazka, M., Baier, L., Ehm, M.G., Sakul, H., Foroud, T., Garvey, W.T., Burns, D., Knowler, W.C., Bennett, P.H., Bogardus, C., and Ravussin E. Autosomal genomic scan for loci linked to obesity and energy metabolism in Pima Indians. American Journal of Human Genetics, 62:659-668, 1998.

52. Bao, S., and W.T. Garvey. Cloning of Rab GTPase isoforms expressed in human skeletal muscle: Studies in insulin resistant subjects. Hormone and Metabolic Research, 30:656-662, 1998.

53. Argyropoulos, G., Brown, A.M., Peterson, R., Likes, C.E., Watson, D.K., Garvey, W.T. Structure and organization of the human uncoupling protein 2 gene and identification of a common biallelic variant in caucasian and african-american subjects. Diabetes. 47:685-687, 1998.

54. Argyropoulos, G., Jenkins, A., Klein, R.L., Lyons, T., Wagenhost, B., St-Amand, J., Marcovina, S.M., Albers, J.J., Pritchard, P.H., Garvey, W.T. Transmission of two novel mutations in a pedigree with familial lecithin: cholesterol acyltransferase deficiency: structure-function relationships and studies in a compound heterozygous proband. Journal of Lipid Research, 39:1870-1876, 1998.

55. Garvey, W.T., Maianu, L., Zhu, J-H., Brechtel-Hook, G., Wallace, P., Baron, A.D. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. Journal of Clinical Investigation. 101:2377-2386, 1998.

56. Argyropoulos, G., Brown, A.M., Willi, S.M., Zhu, J-H., He, Y., Reitman, M., Gevao, S.M., Spruill, I., and Garvey, W.T. Effects of mutations in the human uncoupling protein 3 gene on the respiratory quotient

25

and fat oxidation in severe obesity and type 2 diabetes. Journal of Clinical Investigation. 102:1345-1351, 1998.

57. Bao, S., Kennedy, A., Wojciechowski, B., Wallace, P., Ganaway, E., and Garvey, W.T. Expression of mRNAs encoding uncoupling proteins in human skeletal muscle: effects of obesity and diabetes. Diabetes: 47:1935-1940, 1998.

58. Hunter, S.J., and Garvey, W.T. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. American Journal of Medicine. 105:331-345, 1998.

59. Brown, A.M., Dolan, J.W., Willi, S.M., Garvey, W.T., and Argyropoulos, G. Endogenous mutations in human uncoupling protein 3 alter its functional properties. FEBS Letters, 464:189-193, 1999.

60. Cooksey, R.C., Hebert, L.F., Zhu, J-H., Wofford, P., Garvey, W.T., McClain, D.A. Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase: decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione. Endocrinology. 140:1151-1157, 1999.

61. Argyropoulos, G., Brown, A.M., and Garvey, W.T. Aberrant DNA sequence pattern caused by a heterozygosity. BioTechniques. 26:604-606, 1999.

62. Paradisi, G., Smith, L., Burtner, C., Leaming, R., Garvey, W.T., Hook, G., Johnson, A., Cronin, J., Steinberg, H.O., Baron, A.D. Dual energy x-ray absorptiometry assessment of fat mass distribution and its association with the insulin resistance syndrome. Diabetes Care. 22:1310-1317, 1999.

63. Brown, A.M., Willi, S.M., Argyropoulos, G., and Garvey, W.T. A novel missense mutation R70W in the human uncoupling protein 3 gene in a family with type 2 diabetes. Human Mutation. 13:506, 1999.

64. Oexmann, M.J., Thomas, J.C., Taylor, K.B., O’Neil, P.M., Garvey, W.T., Lackland, D.T., and Egan, B.M. Short-term impact of a church-based approach to lifestyle change on cardiovascular risk in African Americans. Ethnicity and Disease. 10:17-23, 2000.

65. Brewerton, T.D., Lesem, M.D., Kennedy, A., Garvey, W.T. Reduced plasma leptin concentrations in Bulimia nervosa. Psychoneuroendocinology 25:649-658, 2000

66. Parra EJ, Kittles RA, Argyropoulos G, Pfaff CL, Hiester K, Bonilla C, Sylvester N, Parrish-Gause D, Garvey WT, Jin L, McKeigue PM, Kamboh MI, Ferrell RE, Pollitzer WS, Shriver MD. Ancestral proportions and admixture dynamics in geographically defined African Americans living in South Carolina. American Journal of Physical Anthropology. 114:18-29, 2001.

67. Brown, A.M., Robinson, L., Wojciechowski, B., Argyropoulos, G., and Garvey, W.T. A biallelic variant in the uncoupling protein 2 gene: correlation with percent body fat in African-Americans and functional studies in yeast. Submitted, 2001.

68. Maianu, L., Keller, S.R., and Garvey, W.T. Adipocytes express abnormalities in translocation and trafficking of vesicles containing GLUT4 and insulin-regulated aminopeptidase in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 86:5450-5456, 2001.

69. Mayfield DK, Brown, AM, Page G, Garvey WT, Shriver MD, Argyropoulos G. A role for the agouti related protein promoter in obesity and type 2 diabetes. Biochemical Biophysical Research Communications, 287:568-573, 2001.

70. Willi, S.M., Kennedy, A., Wallace, P., Rogers, N.L., and Garvey, W.T. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes, 51:2895-2902, 2002.

71. Willi, S.M., Bryant, B.P., Wallace P., Shaughnessy, S., Rogers, N.L., Garvey, W.T. Troglitazone is an Effective Therapeutic Agent in Patients with Glucocorticoid-induced Diabetes. Diabetes Research and Clinical Practice, 58:87-96, 2002.

72. Fu Y, Luo N, Lopes-Virella MF, Garvey WT. The Adipocyte Lipid Binding Protein (ALBP/aP2) Gene Facilitates Foam Cell Formation in Human THP-1 Macrophages. Atherosclerosis, 165:259-269, 2002.

73. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL, and the DCCT/EDIC Research Group. Serum Lipoproteins in the Diabetes Control and Complications

26

Trial/Epidemiology of Diabetes Intervention and Complications Cohort: Associations with Gender and Glycemia. Diabetes Care, 26:810-818, 2003.

74. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Pugh K, Jenkins AJ, Klein RL, Liao Y. The Effects of Insulin Resistance and Type 2 Diabetes Mellitus on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic Resonance. Diabetes, 52:453-462, 2003.

75. Garvey WT, McLean, DC Jr., Spruill I. The Search for Obesity Genes in Isolated Populations: Gullah-Speaking African Americans and the Role of Uncoupling Protein 3 as a Thrifty Gene. Progress in Obesity Research: 9. Eds: G. Medeiros-Neto, A. Halpern, C. Bouchard. John Libbey Eurotext Ltd. 9:373-380, 2003.

76. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL, and the DCCT/EDIC Research Group. Lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort: associations with Diabetic Nephropathy. Kidney International, 64:817-828, 2003.

77. Klein RL, Hunter SJ, Zheng D, Semler A, Clore J, Page G, and Garvey WT, and the DCCT/EDIC Study Group. Fibrinogen is a marker for nephropathy and peripheral vascular disease in Type 1 Diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care, 26:1439-1448, 2003.

78. Jaffa AA, Durazo-Arvizu R, Zheng D, Lackland DT, Srikanth S, Garvey WT, Schmaier AH, the DCCT/EDIC Study Group. Plasma Prekallikrein: a Risk Marker for Hypertension and Nephropathy in Type 1 Diabetes. Diabetes, 52:1215-1221, 2003.

79. Garvey WT. The role of uncoupling protein 3 in human physiology. Journal of Clinical Investigation, 111:438-441, 2003.

80. McLean DC, Spruill I, Gevao S, Morrison EY, Bernard OS, Argyropoulos G, Garvey WT. Three novel mtDNA restriction site polymorphisms allow exploration of population affinities of African Americans. Human Biology, 75:147-161, 2003.

81. Klein RL, McHenry MB, Lok KH, Hunter SJ, Le N-A, Jenkins AJ, Zheng D, Semler A, Brown WV, Lyons TJ, Garvey WT, and the DCCT/EDIC Research Group. Apolipoprotein C-III Protein Concentrations and Gene Polymorphisms in Type 1 Diabetes: Associations with Lipoprotein Subclasses. Metabolism, 53:1296-1304, 2004.

82. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, Klein RL, and the DCCT/EDIC Research Group. Diabetic retinopathy and serum lipoprotein in the DCCT/EDIC Cohort, Investigative Ophthalmology and Visual Science, 45:910-918, 2004.

83. Vestri HS, Fu Y, Sumida DH, Lopes FM, Sandra Andreotti S, Franzói-de-Moraes SM, Alonso MIC, Machado MA, Peres SB, Sant’anna Ferreira RA, Carvalho CRO, Maianu L, Heimman JC, Santelli GMM, Garvey WT, Lima FB. Dietary sodium modulation of insulin action and gene expression in adipocytes. Submitted, 2003.

84. Fu Y, Maianu L, Melbert BR, Garvey WT. Facilitative Glucose Transporter Gene Expression in Human Lymphocytes, Monocytes, and Macrophages: a Role for GLUT Isoforms 1, 3, and 5 in the Immune Response and Foam Cell Formation, Blood Cells, Molecules, & Diseases, 32:182-190, 2004.

85. Martin K, Wallace P, Rust PF, Garvey WT. Estimation of Resting Energy Expenditure Considering Effects of Race and Diabetes Status, Diabetes Care, 27:1405-1411, 2004.

86. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, Klein RL, Garvey WT. Critical Evaluation of ATP III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care, 27:978-983, 2004.

87. Garvey WT, Lara-Castro C. Diet, Insulin Resistance, and Obesity: Zoning in on Data for Atkins Dieters Living in South Beach. Journal of Clinical Endocrinology and Metabolism, 89:4197-4205, 2004.

88. Nagy TR, Blaylock ML, Garvey WT. Role of UCP2 and UCP3 in nutrition and obesity. Nutrition, 20:139-144, 2004.

27

89. McLean DC, Spruill I, Argyropoulos G, Page GP, Shriver MD, Garvey WT. Mitochondrial DNA (mtDNA) Haplotypes Reveal Maternal Population Affinities of Sea Island Gullah-speaking African Americans. American Journal of Physical Anthropology, 127:427-438, 2005

90. Klein RL, McHenry MB, Lok KH, Hunter SJ, Le N-A, Jenkins AJ, Zheng D, Semler A, Page G, Brown WV, Lyons TJ, Garvey WT, and the DCCT/EDIC Research Group. Apolipoprotein C-III Protein Concentrations and Gene Polymorphisms in Type 1 Diabetes: Associations with Microvascular Disease Complications in the DCCT/EDIC Cohort. Journal of Diabetes and its Complications, 19:18-25, 2005.

91. Jackson BA, Wilson JL, Kirbah S, Sidney SS, Rosenberger J, Bassie L, Alie JAD, McLean DC, Garvey WT, Ely B. Mitochondrial DNA Genetic Diversity among Four Ethnic Groups in Sierra Leone. American Journal of Physical Anthropology, 128:156-163, 2005.

92. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin Promotes Adipocyte Differentiation, Insulin Sensitivity, and Lipid Accumulation: Potential Role in Auto-Regulation of Adipocyte Metabolism and Adipose Mass. Journal of Lipid Research, 46:1369-1379, 2005

93. Fu Y, Luo L, Luo N, Garvey WT. Lipid Metabolism Mediated by Adipocyte Lipid Binding Protein (ALBP/aP2) Gene Expression in Human THP-1 Macrophages. Atherosclerosis, 188:102-111, 2006.

94. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes, 55:249-259, 2006.

95. Chen M, Aprahamian CJ, Celik A, Georgeson KE, Garvey WT, Harmon CM, Yang Y. Molecular characterization of human melanocortin-3 receptor ligand-receptor interaction. Biochemistry. 45:1128-1137, 2006.

96. Lyons TJ, Jenkins AJ, Zheng D, Klein RL, Otvos JD, Yu Y, Lackland DT, McGee D, McHenry MB, Lopes-Virella MF, Garvey WT, and The DCCT/EDIC Research Group. Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-medial thickness. Diabetic Medicine, 23:955-966, 2006.

97. Garvey WT. UCP3 and Human Metabolism. Journal of Clinical Endocrinology and Metabolism, 91:1226-1228, 2006.

98. Fu Y, Luo L, Luo N, Garvey WT. Overexpression of resistin induces insulin resistance and stimulates production of proinflammatory cytokines in 3T3-L1 cells. Nutrition and Metabolism, 3:28, 2006.

99. He L, Game BA, Nareika A, Garvey WT, Huang Y. Administration of pioglitazone in low-density lipoprotein receptor-deficient mice inhibits lesion progression and MMP expression in advanced atherosclerotic plaques. Journal of Cardiovascular Pharmacology, 48:212-222, 2006.

100. Munoz J, Lok KH, Gower BA, Fernandez JR, Hunter GR, Lara-Castro C, De Luca M, Garvey WT. A polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in non-diabetic women. Diabetes, 55:3630-3634, 2006.

101. McLean DC, Spruill I, Argyropoulos G, Page GP, Shriver MD, Garvey WT. Y-chromosome haplotypes show closer genetic distance to Sierra Leoneans and reduced European American admixture in Gullah-speaking African Americans. Submitted, 2006.

102. Semler AJ, McHenry MB, Lackland DT, Lipsitz SR, Lopes-Virella MF, Garvey WT, Klein RL, and the DCCT/EDIC Research Group. Associations of adiponectin with retinopathy in the DCCT/EDIC cohort: influence of insulin resistance. Submitted, 2006.

103. Vestri HS, Maianu L, Moellering DR, Garvey WT. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and anti-lipolysis. Neuropsychopharmacology, 32:765-772, 2007.

104. Fan ZJ, Lipsitz SR, Nicholas JS, Egan BM, Tim Garvey W, Hutchison FS, Lackland DT. Geographical patterns of end-stage renal disease incidence and risk factors in rural and urban areas of South Carolina. Health & Place, 13:179-187, 2007.

105. Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, Wilson PF, Lackland DT, Lyons T, Jenkins AJ, Virella G, Garvey WT, and the DCCT/EDIC Research Group. Immune complexes containing

28

modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis. 190:359-369, 2007

106. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating the risk of metabolic and cardiovascular disease. Current Opinion in Lipidology, 18:263-270, 2007

107. Wu X, Page GP, Wang J, Maianu L, Rhees B, Rosinski J, So V, Willi SM, Osier MV, Hill HS, Allison DB, Martin M, Garvey WT. The Effect of Insulin on Expression of Genes and Biochemical Pathways in Human Skeletal Muscle. Endocrine, 31:5-17, 2007

108. Fu Y, Luo L, Luo N, Zhu X, Garvey WT. NR4A Orphan Nuclear Receptors Modulate Insulin Action and the Glucose Transport System: Potential Role in Insulin Resistance. Journal of Biological Chemistry, 282:31525-31533, 2007

109. Gadegbeku CA, Dhandayuthapani A, Taylor TP, Shrayyef Z, Gerich J, Garvey WT, Egan BM. Insulin’s actions on plasma free fatty acids are normal in patients with stage 2 to 3 chronic kidney disease. J Am Soc Hyperten, 1:414-422, 2007

110. Jenkins AJ, Rothen M, Klein RL, Moller K, Eldridge L, Zheng D, Durazo-Arvizu R, McGee D, Lackland D, Thorpe SR, Garvey WT, Lyons TJ, and the EDIC/DCCT Study Group. Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. Journal of Diabetes and Its Complications, 22:153-163, 2008

111. Lara-Castro C, Newcomer BR, Rowell J, Wallace P, Shaughnessy SM, Munoz AJ, Shiflett AM, Rigsby DY, Lawrence JC, Bohning DE, Buchthal S, Garvey WT. Effects of short-term very low calorie diet on intramyocellular lipid and insulin sensitivity in nondiabetic and type 2 diabetic subjects. Metabolism, 57:1-8, 2008

112. Ader M, Garvey WT, Phillips LS, Nemeroff CB, Gharabawi G, Mahmoud R, Greenspan A, Berry SA, Musselman DL, Morein J, Zhu Y, Mao L, Bergman RN. Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. Journal of Psychiatric Research, 42:1076-1085, 2008

113. Voss AC, Maki KC, Garvey WT, Hustead DS, Alish C, Fix B, Mustad VA. Effect of two carbohydrate-modified tube-feeding formulas on metabolic responses in patients with type 2 diabetes. Nutrition, 24:990-997, 2008

114. Higgins PB, Férnández JR, Garvey WT, Granger WM, Gower BA. Entero-insular axis and postprandial insulin differences in African American and European American children. American Journal of Clinical Nutrition, 88:1277-1283, 2008

115. Lara-Castro C, Doud EC, Tapia PC, Munoz AJ, Fernandez JR, Hunter GR, Gower BA, Garvey WT. Adiponectin Multimers and Metabolic Syndrome Traits: Relative Ad Resistance in African-Americans. Obesity, 16:2616-2623, 2008

116. Lopes-Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins AJ, Lyons TJ, Garvey WT, Virella G, and the DCCT/EDIC Study Group. Risk Factors related to Inflammation and Endothelial Dysfunction in the DCCT/EDIC Cohort and their Relationship with Nephropathy and Macrovascular Complications. Diabetes Care, 31:2006-2012, 2008

117. Lara-Castro C, Garvey WT. Intracellular Lipid Accumulation in Liver and Muscle and the Insulin Resistance Syndrome. Endocrinology and Metabolism Clinics of North America 37:841-856, 2008

118. Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, Garvey WT, Gavin JR 3rd, Grunberger G, Horton ES, Jellinger PS, Jones KL, Lebovitz H, Levy P, McGuire DK, Moghissi ES, Nesto RW. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocrine Practice 14:933-946, 2008.

119. Sale MM, Lu L, Spruill IJ, Fernandes JK, Lok KH, Divers J, Langefeld CD, Garvey WT. A genome-wide linkage scan in Gullah speaking African American families with Type 2 Diabetes: the Sea Islands Genetic African American Registry (Project SuGAR). Diabetes 58:260-267, 2009

29

120. Tian L, Luo N, Klein RL, Chung BH, Garvey WT, Fu Y. Adiponectin Reduces Lipid Accumulation in Macrophage Foam Cells. Atherosclerosis, 202:152-161, 2009

121. Siddiqui NR, Garvey WT, Khaled MA. H. pylori-induced higher C-reactive protein in obese African Americans. Artery Research, 3:39-42, 2009

122. Lara-Castro C, Garvey WT. Role of Nutrition in the Pathophysiology, Prevention, and Treatment of Type 2 Diabetes and the Spectrum of Cardiometabolic Disease. Fourth Edition of Preventive Nutrition, Eds. Bendich A and Deckelbaum R. Humana and Springer, New York NY, 2009

123. Cytryn KN, Garvey WT, Hayes SM, Myhal G, Cann L, Murray S. A qualitative assessment of educational opportunities for primary care providers in Type 2 Diabetes Care. Diabetes Spectrum 22 (4):248-253, 2009

124. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH, Newman JW, Garvey WT. Plasma Acylcarnitine Profiles Suggest Incomplete Long-Chain Fatty Acid {beta}-Oxidation and Altered Tricarboxylic Acid Cycle Activity in Type 2 Diabetic African-American Women. Journal of Nutrition 139:1073-1081, 2009

125. Deng ZB, Poliakov A, Hardy RW, Clements R, Liu C, Liu Y, Wang J, Zhang S, Mikalek S, Grizzle WE, Garvey T, Mobley J, Zhang HG. Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance. Diabetes 58:2498-2505, 2009

126. Rahman AA, Cope MB, Sarker SA, Garvey WT, Chaudhury HS, Khaled MA. Helicobacter pylori Infection and Inflammation: Implications for Pathophysiology of Diabetes Mellitus and Coronary Heart Disease. Journal of Life Sciences 1:45-50, 2009

127. Liu J, Garvey WT. The Power of Fat. commentary, Cell Science Reviews 5:75-82, 2009 128. Divers J, Sale MM, Lu L, Chen WM3,6, Lok KH, Spruill IJ8, Fernandes JK, Langefeld CD, Garvey

WT. The genetic architecture of lipoprotein subclasses in Gullah-speaking African American families enriched for type 2 diabetes: The Sea Islands genetic African American registry (project SuGAR). Journal of Lipid Research, 51:586-597, 2010

129. Liu J*, Wu X*, Franklin JL, Messina JL, Martin M, Garvey WT. Mammalian Tribbles Homolog 3 Impairs Insulin Action in Skeletal Muscle: Role in Glucose-Induced Insulin Resistance. American Journal of Physiology, 298:E565-E576, 2010 *=co-first authors

130. Luo N, Liu J, Chung BH, Yang Q, Klein RL, Garvey WT, Fu Y. Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes 59:791-799, 2010

131. Wu X, Garvey WT. Insulin Action. In: Textbook of Diabetes, 4th edition. Eds: Holt RIG, Goldstein B, Flyvbjerg A, Cockram CS. Wiley-Blackwell, 2010

132. Alish CJ, Garvey WT, Maki KC, Sacks G, Hustead DS, Hegazi RA, Mustad VA. A Diabetes-Specific Enteral Formula Improves Glycemic Variability in Patients with Type 2 Diabetes. Diabetes Technology and Therapeutics, 12:419-425, 2010

133. Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and diabetic African-American women. PLoS One, 5(12):e15234, 2010

134. Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, Lai Y-L, Jin X, Misir S, Nagendran S, Jones MR. Initial combination therapy with metformin and colesevelam safely achieves glycemic and lipid goals in early Type 2 Diabetes. Endocrine Practice, 16:629-640, 2010

135. Handelsman Y, Goldberg RB, Garvey WT, Fonseca VA, Rosenstock J, Jones MR, Lai Y-L, Jin X, Misir S, Nagendran S, Abby SL. Colesevelam HCl to Treat Hypercholesterolemia and Improve Glycemia in Prediabetes: A Randomized, Prospective Study. Endocrine Practice, 16:617-628, 2010

136. Lawrence JC, Gower BA, Garvey WT, Munoz AJ, Darnell BE, Oster RA, Buchtal SD, Goran MI, Newcomer BR. Relationship between insulin sensitivity and muscle lipids may differ with muscle group and ethnicity. Open Obesity Journal, 2:137-144, 2010

30

137. Wu X, Patki A, Lara-Castro C, Cui X, Zhang K, Walton RG, Osier MV, Gadbury GL, Allison DB, Martin M, Garvey WT. Genes and Biochemical Pathways in Human Skeletal Muscle Affecting Resting Energy Expenditure and Fuel Partitioning. Journal of Applied Physiology 110:746-755, 2011

138. Del Corral P, Bryan DR, Garvey WT, Gower BA, Hunter GR. Dietary adherence during weight loss predicts weight regain. Obesity, 19:1177-1181, 2011

139. Ingram KH, Lara-Castro C, Gower BA, Makowski R, Newcomer BR, Munoz AJ, Lawrence JC, Lopez-Ben R, Rigsby D, Garvey WT. Intramyocellular Lipid and Insulin Resistance: Differential Relationships in European and African Americans. Obesity, 19:1469-1475, 2011

140. Luo N, Wang X, Chung BH, Lee M-H, Klein R, W. Garvey WT, Fu Y. Effects of Macrophage-Specific Adiponectin Expression on Lipid Metabolism in Vivo. American Journal of Physiology (Endocrinol Metab), 301:E180-E186, 2011

141. Wood AC, Glasser S, Garvey WT, Kabagambe EK, Borecki IB, Tiwari HK, Tsai MY, Hopkins PN, Ordovas JM. Arnett DK. Lipoprotein lipase S447X variant associated with VLDL, LDL and HDL diameter clustering in the MetS. Lipids in Health and Disease, 10:143-146, 2011

142. Newton L, Garvey WT. “Nutritional and Medical Management of Diabetes Mellitus in Hospitalized Patients”. In: The A.S.P.E.N. Adult Nutrition Support Core Curriculum. 2rd edition, Ed. C.M. Mueller. American Society for Parenteral and Enteral Nutrition, Silver Springs MD, 2012

143. Frazier-Wood AC, Glasser S, Garvey WT, Kabagambe EK, Borecki IB, Tiwari HK, Tsai MY, Hopkins PN, Ordovas JM, Arnett DK. A clustering analysis of lipoprotein diameters in the metabolic syndrome. Lipids in Health and Disease, 10:237-245, 2011

144. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. Controlled-Release Phentermine-Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP). Obesity, 20:330-342, 2012

145. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Two-year sustained weight-loss and metabolic benefits with phentermine/topiramate controlled-release in obese and overweight adults (SEQUEL): a placebo-controlled, phase 3 extension study. American Journal of Clinical Nutrition, 95:297-308, 2012

146. Henry RR, Aroda V, Mudaliar SR, Garvey WT, Chou H, Jones MR. Effects of Colesevelam on Glucose Absorption and Hepatic/ Peripheral Insulin Sensitivity in Patients with Type 2 Diabetes Mellitus. Diabetes, Obesity, and Metabolism, 14:40-46, 2012

147. Tian L, Luo N, Zhu X, Chung BH, Garvey WT, Fu Y. Adiponectin-AdipoR1/2-APPL1 signaling axis suppresses human foam cell formation: Differential ability of AdipoR1 and AdipoR2 to regulate inflammatory cytokine responses. Atherosclerosis, 221:66-75, 2012

148. Ingram KH, Hill HS, Moellering DR, Lara-Castro C, Hill BG, Newcomer B, Brandon LJ, Ingalls CP, Penumetcha M, Rupp JC, Garvey WT. Skeletal muscle lipid peroxidation and insulin resistance in humans. Journal of Clinical Endocrinology and Metabolism, 97:E1182-E1186, 2012

149. Kohler CS; Publications Policy Committee of the American Diabetes Association. Updates to policies and procedures related to potential scientific and academic misconduct in the journals of the American Diabetes Association. Diabetes. 61(1):38-39, 2012

150. Liu J, Zhang W, Chuang GC, Hill HS, Tian L, Fu Y, Moellering DR, Garvey WT. Role of TRIB3 in Regulation of Insulin Sensitivity and Nutrient Metabolism during Short-term Fasting and Nutrient Excess. American Journal of Physiology, 303:E908-E916, 2012

151. Sawant A, Chanda D, Isayeva T, Tsuladze G, Garvey WT, Ponnazhagan S. Noggin is a novel inducer of mesenchymal stem cell adipogenesis: implications for bone health and obesity. Journal of Biological Chemistry, 287:12241-12249, 2012

152. Heyward FD, Walton RG, Carle MS, Coleman MA, Garvey WT, Sweatt JD. Adult mice maintained on a high-fat diet exhibit object location memory deficits and reduced hippocampal SIRT1 gene expression. Neurobiology of Learning and Memory. 98:25-32, 2012

31

153. Grapov D, Adams SH, Pedersen TL, Garvey WT, Newman JW. Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins, and endocannabinoids. PLoS One, 7(11):e48852, 2012

154. Frazier-Wood, AC, Garvey WT, Dall T, Honigberg R, Pourfarzib R. Opportunities for Using Lipoprotein Subclass Profile by Nuclear Magnetic Resonance Spectroscopy in Assessing Insulin Resistance and Diabetes Prediction. Metabolic Syndrome and Related Disorders, 10:244-251, 2012

155. Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocrine Practice, 18(5):642-648, 2012

156. Elbers CC, Guo Y, Tragante V, van Iperen EP, Lanktree MB, Castillo BA, Chen F, Yanek LR, Wojczynski MK, Li YR, Ferwerda B, Ballantyne CM, Buxbaum SG, Chen YD, Chen WM, Cupples LA, Cushman M, Duan Y, Duggan D, Evans MK, Fernandes JK, Fornage M, Garcia M, Garvey WT, Glazer N, Gomez F, Harris TB, Halder I, Howard VJ, Keller MF, Kamboh MI, Kooperberg C, Kritchevsky SB, Lacroix A, Liu K, Liu Y, Musunuru K, Newman AB, Onland-Moret NC, Ordovas J, Peter I, Post W, Redline S, Reis SE, Saxena R, Schreiner PJ, Volcik KA, Wang X, Yusuf S, Zonderland AB, Anand SS, Becker DM, Psaty B, Rader DJ, Reiner AP, Rich SS, Rotter JI, Sale MM, Tsai MY, Borecki IB, Hegele RA, Kathiresan S, Nalls MA, Taylor HA Jr, Hakonarson H, Sivapalaratnam S, Asselbergs FW, Drenos F, Wilson JG, Keating BJ. Gene-centric meta-analysis of lipid traits in African, East Asian and Hispanic populations. PLoS One, 7(12):e50198, 2012. Epub 2012 Dec 7.

157. Zhu X, Walton RG, Tian L, Luo N, Ho S-R, Fu Y, Garvey WT. Prostaglandin A2 Enhances Cellular Insulin Sensitivity via a Mechanism that Involves the Orphan Nuclear Receptor NR4A3. Hormone and Metabolic Research, 45:213-220, 2013

158. Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, Heinberg LJ, Kushner R, Adams TD, Shikora S, Dixon JB, Brethauer S. Clinical practice guidelines for the perioperative, nutritional, metabolic, and non-surgical support of the bariatric surgery patient – 2013 update: co-sponsored by the American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic and Bariatric Surgery. Obesity, 21(Suppl 1):S1-S27, 2013, and Endocrine Practice, 19(2):337-372, 2013

159. Pisprasert V, Ingram KH, Lopez-Davila MF, Munoz AJ, Garvey WT. Limitations in the Use of Indices Employing Glucose and Insulin Levels to Predict Insulin Sensitivity: Impact of Race and Gender and Superiority of the Matsuda Index in African American Males. Diabetes Care, 36:845-853, 2013

160. Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, Garber AJ, Garg A, Garvey WT, Grunberger G, Henry RR, Lavin N, Tapiador CD, Weyer C. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocrine Practice, 19(1):107-116, 2013

161. Strickland LS, Guo F, Lok K, Garvey WT. Type 2 Diabetes with Partial Lipodystrophy of the Limbs: a New Lipodystrophy Phenotype. Diabetes Care, 36:2247-2253, 2013

162. Luo N, Chung B-H, Wang X, Klein RL, Tang C-K, Garvey WT, Fu Y. Enhanced adiponectin actions by overexpression of adiponectin receptor 1 in macrophages. Atherosclerosis, 228:124-135, 2013

163. Yang Y, Cao Z, Tian L, Garvey WT, Cheng G. VPO1 Mediates ApoE Oxidation and Impairs the Clearance of Plasma Lipids. PLoS One, 8(2):e57571, 2013

164. Thorpe KE, Yang Z, Long KM, Garvey WT. The impact of weight loss among seniors on Medicare spending. Health Economics Review, 3:7, 2013

165. Henry RR, Chilton R, Garvey WT. New options for the treatment of obesity and type 2 diabetes. Journal of Diabetes and its Complications, 27:508-518, 2013

32

166. Garvey WT. Phentermine and Topiramate Extended-Release: a New Treatment for Obesity and its Role in a Complications-Centric Approach to Obesity Medical Management. Expert Opinion on Drug Safety, 12:741-756, 2013

167. Luo N, Wang X, Zhang W, Garvey WT, Fu Y. AdR1-TG/TALLYHO mice have improved lipid accumulation and insulin sensitivity. Biochem Biophys Res Commun, 433(4):567-572, 2013

168. Monda KL, Chen GK, Taylor KC, Palmer C, Edwards TL, Lange LA, Ng MC, Adeyemo AA, Allison MA, Bielak LF, Chen G, Graff M, Irvin MR, Rhie SK, Li G, Liu Y, Liu Y, Lu Y, Nalls MA, Sun YV, Wojczynski MK, Yanek LR, Aldrich MC, Ademola A, Amos CI, Bandera EV, Bock CH, Britton A, Broeckel U, Cai Q, Caporaso NE, Carlson CS, Carpten J, Casey G, Chen WM, Chen F, Chen YD, Chiang CW, Coetzee GA, Demerath E, Deming-Halverson SL, Driver RW, Dubbert P, Feitosa MF, Feng Y, Freedman BI, Gillanders EM, Gottesman O, Guo X, Haritunians T, Harris T, Harris CC, Hennis AJ, Hernandez DG, McNeill LH, Howard TD, Howard BV, Howard VJ, Johnson KC, Kang SJ, Keating BJ, Kolb S, Kuller LH, Kutlar A, Langefeld CD, Lettre G, Lohman K, Lotay V, Lyon H, Manson JE, Maixner W, Meng YA, Monroe KR, Morhason-Bello I, Murphy AB, Mychaleckyj JC, Nadukuru R, Nathanson KL, Nayak U, N'diaye A, Nemesure B, Wu SY, Leske MC, Neslund-Dudas C, Neuhouser M, Nyante S, Ochs-Balcom H, Ogunniyi A, Ogundiran TO, Ojengbede O, Olopade OI, Palmer JR, Ruiz-Narvaez EA, Palmer ND, Press MF, Rampersaud E, Rasmussen-Torvik LJ, Rodriguez-Gil JL, Salako B, Schadt EE, Schwartz AG, Shriner DA, Siscovick D, Smith SB, Wassertheil-Smoller S, Speliotes EK, Spitz MR, Sucheston L, Taylor H, Tayo BO, Tucker MA, Van Den Berg DJ, Edwards DR, Wang Z, Wiencke JK, Winkler TW, Witte JS, Wrensch M, Wu X, Yang JJ, Levin AM, Young TR, Zakai NA, Cushman M, Zanetti KA, Zhao JH, Zhao W, Zheng Y, Zhou J, Ziegler RG, Zmuda JM, Fernandes JK, Gilkeson GS, Kamen DL, Hunt KJ, Spruill IJ, Ambrosone CB, Ambs S, Arnett DK, Atwood L, Becker DM, Berndt SI, Bernstein L, Blot WJ, Borecki IB, Bottinger EP, Bowden DW, Burke G, Chanock SJ, Cooper RS, Ding J, Duggan D, Evans MK, Fox C, Garvey WT, Bradfield JP, Hakonarson H, Grant SF, Hsing A, Chu L, Hu JJ, Huo D, Ingles SA, John EM, Jordan JM, Kabagambe EK, Kardia SL, Kittles RA, Goodman PJ, Klein EA, Kolonel LN, Le Marchand L, Liu S, McKnight B, Millikan RC, Mosley TH, Padhukasahasram B, Williams LK, Patel SR, Peters U, Pettaway CA, Peyser PA, Psaty BM, Redline S, Rotimi CN, Rybicki BA, Sale MM, Schreiner PJ, Signorello LB, Singleton AB, Stanford JL, Strom SS, Thun MJ, Vitolins M, Zheng W, Moore JH, Williams SM, Ketkar S, Zhu X, Zonderman AB; NABEC Consortium; UKBEC Consortium; BioBank Japan Project; AGEN Consortium, Kooperberg C, Papanicolaou GJ, Henderson BE, Reiner AP, Hirschhorn JN, Loos RJ, North KE, Haiman CA. A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nature Genetics, 45:690-696, 2013

169. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH. AACE Comprehensive Diabetes Management Algorithm 2013. Endocrine Practice, 19(2):327-336, 2013

170. Garvey WT. New Tools for Weight Loss Therapy Enable a More Robust Medical Model for Obesity Treatment: Rationale for a Complications-Centric Approach. Endocrine Practice, 19:864-874, 2013

171. Garvey WT. Use of available glucose-lowering agents in patients with different levels of renal impairment. Endocrine Practice, 19 (Suppl 1):14-18, 2013

172. Jenkins AJ, Yu J, Alaupovic P, Basu A, Klein RL, Lopes-Virella M, Baker NL, Hunt KJ, Lackland DT, Garvey WT, Lyons TJ; DCCT/EDIC Research Group. Apolipoprotein-defined lipoproteins and apolipoproteins: Associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes Complications, 27:447-453, 2013

173. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE, Davidson MH. American association of

33

clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement - executive summary. Endocrine Practice, 19(3):536-557, 2013

174. Daniel S, Soleymani T, Garvey WT. A complications-based clinical staging of obesity to guide treatment modality and intensity. Current Opinion in Endocrinology and Diabetes. 20:377-388, 2013

175. Liu CT, Monda KL, Taylor K, Lange L, Demerath EW, Palmas W, Wojczynski MK, Ellis JC, Vitolins MZ, Liu S, Papanicolaou GJ, Irvin MR, Xue L, Griffin PJ, Nalls MA, Adeyemo A, Liu J, Li G, Ruiz-Narvaez EA, Chen WM, Chen F, Henderson BE, Millikan RC, Ambrosone CB, Strom SS, Guo X, Andrews JS, Sun YV, Mosley TH, Yanek LR, Shriner D, Haritunians T, Rotter JI, Speliotes EK, Smith M, Rosenberg L, Mychaleckyj J, Nayak U, Spruill I, Garvey WT, Pettaway C, Nyante S, Bandera EV, Britton AF, Zonderman AB, Rasmussen-Torvik LJ, Chen YI, Ding Z, Lohman K, Kritchevsky SB, Zhao W, Peyser PA, Kardia SLR, Kabagambe E, Broeckel U, Chen G, Zhou J, Smoller S, Neuhouser ML, Rampersaud E, Psaty B, Kooperberg C, Manson JE, Kuller LH, Ochs-Balcom HM, Johnson KC, Sucheston L, Ordovas JM, Palmer JR, Haiman CA, McKnight B, Howard BV, Becker DM, Bielak LF, Liu Y, Allison M, Grant SFA, Burke GL, Patel SR, Schreiner PJ, Borecki IB, Evans MK, Taylor H, Sale M, Howard V, Carlson C, Rotimi CN, Cushman M, Harris TB, Reiner A, Cupples LA, North KE, Fox CS. Genome-wide Association of Body Fat Distribution in African Ancestry Populations Reveals Evidence for New Loci. PLoS Genetics. Aug;9(8):e1003681, 2013

176. Zhang W, Liu J, Tian L, Liu Q, Fu Y, Garvey WT. TRIB3 Mediates Glucose-Induced Insulin Resistance Via a Mechanism that Requires the Hexosamine Biosynthetic Pathway. Diabetes. 62:4192-4200, 2013

177. Mechanick JI, Garber AJ, Handlesman Y, Garvey WT, McMahon MM, Hurley DL. In response. Endocrine Practice, 19(1):170, 2013

178. Liu Q, Zhu X, Xu L, Fu Y, Garvey WT. 6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3. American Journal of Physiology (Endocrinol Metab), 305(9):E1081-E1092, 2013

179. Campbell C,Grapov D, Fiehn O, Chandler CJ, Burnett DL, Souza EC, Casazza GA, Gustafson MB, Keim NL, Newman JW, Hunter GR, Fernandez JR, Garvey WT, Harper ME, Hoppel CL, Meissen JK, Take K, Adams SH. Improved metabolic health alters host metabolism in parallel with changes in systemic xeno-metabolites of gut origin. PLoS One, 9(1):e84260, 2014

180. Guo F, Moellering DR, Garvey WT. The Progression of Cardiometabolic Disease: Validation of a New Cardiometabolic Disease Staging System Applicable to Obesity. Obesity, 22:110-118, 2014

181. Xu L, Akscyn RM, Liu Q, Walton RG, Garvey WT. Orphan nuclear receptor NR4A3 inhibits skeletal muscle cell differentiation by suppressing MEF2c expression and HDAC5 phosphorylation. Submitted, 2014

182. Hill HS, Grams J, Walton RG, Liu J, Moellering DR, Casazza K, Gundberg CM, Garvey WT. Carboxylated and uncarboxylated forms of osteocalcin directly modulate the glucose transport system and inflammation in adipocytes. Hormone and Metabolic Research, 46:341-347, 2014

183. Thalacker-Mercer AE, Ingram KH, Guo F, Ilkayeva O, Newgard CB, Garvey WT. BMI, RQ, diabetes, and gender affect the relationships between amino acids and clamp measures of insulin action in humans. Diabetes, 63:791-800, 2014

184. Garvey WT, Ryan DH, Henry R, Bohannon NJ, Toplak H, Schwiers M, Troupin B, Day WW. Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended-Release. Diabetes Care, 37:912-921, 2014

185. Guo F, Moellering DR, Garvey WT. Use of HbA1c for Diagnoses of Diabetes and Prediabetes: Comparison with Diagnoses Based on Fasting and 2-Hour Glucose Values and Effects of Gender, Race, and Age. Metabolic Syndrome and Related Disorders, 12:258-268, 2014

186. Zhang F, He Q, Tsang WP, Li G, Chan KM, Chan WY, Garvey WT, Brüning JC, Clemens TL, Wan C. Deletion of the Insulin Receptor in Chondrocytes Enhances IGF-1R Expression and Action. Submitted, 2014

34

187. Zhang W, Garvey WJ, Luo N, Garvey WT, Fu Y. MINOR (NR4A3) Overexpression in mouse skeletal muscle enhances insulin action. Journal of Molecular and Genetic Medicine, S1: 021, 2014

188. Chou CF, Lin YY, Wang HK, Zhu X, Giovarelli M, Briata P, Gherzi R, Garvey WT, Chen CY. KSRP Ablation Enhances Brown Fat Gene Program in White Adipose Tissue through Reduced miR-150 Expression. Diabetes. 63(9):2949-2961, 2014

189. Basu A, Jenkins AJ, Stoner JA, Thorpe SR, Klein RL, Lopes-Virella MF, Garvey WT, Lyons TJ; DCCT/EDIC Research Group. Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: A prospective study. Atherosclerosis. 236(1):188-195, 2014

190. Shalaurova I, Connelly MA, Garvey WT, Otvos JD. Lipoprotein Insulin Resistance Index: A Lipoprotein Particle-Derived Measure of Insulin Resistance. Metabolic Syndrome & Related Disorders 12(8):422-429, 2014

191. Wyrozumska P, Ashley JW, Ramanadham S, Liu Q, Garvey WT, Sztul E. Novel effects of Brefeldin A (BFA) in signaling through the insulin receptor (IR) pathway and regulating FoxO1-mediated transcription. Cellular Logistics. 4(1):e27732, 2014

192. Luo N, Garvey WT, Wang D-Z, Fu Y. MicroRNA-150 regulates lipid metabolism and inflammatory response. Journal of Metabolic Syndrome 3:131, 2014.

193. Lopes HF, Klein RL, Garvey WT, Goodfriend T, Egan BM. Influence of acute hyperlipidemia on adipocyte-derived hormones in lean normotensives and subjects with metabolic syndrome. Diabetology & Metabolic Syndrome 6(1):132, 2014

194. Hunt KJ, Kistner-Griffin E, Spruill I, Teklehaimanot AA, Garvey WT, Sale M, Fernandes J. Cardiovascular risk in Gullah African Americans with high familial risk of type 2 diabetes mellitus: project SuGAR. Southern Medical Journal. 107:607-614, 2014

195. Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G, On Behalf Of The AACE Obesity Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on obesity: building an evidence base for comprehensive action. Endocrine Practice. 20:956-976, 2014

196. Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G, On Behalf Of The AACE Obesity Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocrine Practice. 20:977-989, 2014

197. Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, Troupin B. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 37:3309-3316, 2014

198. Cefalu WT, B ray GA, Home PD, Garvey WT, Klein S, Pi-Sunyer FX, Hu FB, Raz I, Van Gaal L, Wolfe BM, Ryan DH. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a Diabetes Care editors’ expert forum. Diabetes Care 38(8):1567-1582, 2015

199. Chou CF, Zhu X, Lin YY, Gamble KL, Garvey WT, Chen CY. KSRP is critical in governing hepatic lipid metabolism through controlling Per2 expression. Journal of Lipid Research 56(2):227-240, 2015

200. Langlais PR, Mandarino LJ, Garvey WT. Mechanisms of Insulin Signal Transduction. IN: International Textbook of Diabetes Mellitus, 5th edition. Eds. R.A. DeFronzo, E. Ferrannini, H. Keen, P. Zimmet. John Wiley & Sons, Ltd. London, 2015.

201. Garvey WT. The conundrum of whole foods versus macronutrient composition in assessing effects on insulin sensitivity. American Journal of Clinical Nutrition. 101:1109-1110, 2015

202. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB,

35

Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH. Aace/Ace comprehensive diabetes management algorithm 2015. Endocrine Practice. 21:438-447, 2015

203. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovič L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocrine Practice. 21:1-87, 2015

204. Grams J, Garvey WT. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action. Current Obesity Reports. 4:287-302, 2015.

205. Guo F, Garvey WT. Development of a weighted cardiometabolic disease staging (CMDS) system for the prediction of future diabetes. Journal of Clinical Endocrinology and Metabolism. 100(10):3871-3877, 2015

206. Apovian CM, Garvey WT, Ryan DH. Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies. Obesity (Silver Spring). 23 (Suppl 2):S1-S26, 2015

207. Gonzalez-Campoy JM, Garvey WT, Harrell RM. AACE Response to a Candid Discussion of Obesity. American Journal of Medicine. Oct;128(10):e57, 2015

208. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2015 Executive Summary. Endocrine Practice. 21(12):1403-1414, 2015

209. Basu A, Jenkins AJ, Zhang Y, Stoner JA, Klein RL, Lopes-Virella MF, Garvey WT, Lyons TJ; DCCT/EDIC Research Group. Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes. Atherosclerosis. 31;244:93-100, 2016

210. Zhang W, Hartmann R, Tun HM, Elson CO, Khafipour E, Garvey WT. Deletion of the Toll-Like Receptor 5 Gene Per Se Does Not Determine the Gut Microbiome Profile That Induces Metabolic Syndrome: Environment Trumps Genotype. PLoS One. Mar 7, 11(3):e0150943, 2016

211. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2016 Executive Summary. Endocrine Practice. 22(1):84-113, 2016

212. Guo F, Garvey WT. Cardiometabolic Disease Risk in Metabolically Healthy and Unhealthy Obese: Stability of Metabolic Health Status in Adults. Obesity, 24(2):516-525, 2016

213. Soleymani T, Daniel S, Garvey WT. Weight maintenance: challenges, tools, and strategies for primary care physicians. Obesity Reviews 17(1):81-93, 2016

214. Steverson D Jr, Tian L, Fu Y, Zhang W, Ma E, Garvey WT. Tribbles homolog 3 Promotes Foam Cell Formation Associated with Decreased Pro-Inflammatory Cytokine Production in Macrophages: Evidence for Reciprocal Regulation of Cholesterol Uptake and Inflammation. Metabolic Syndrome & Related Disorders. 14(1):7-15, 2016

215. O’Neil PM, Miller-Kovach K, Tuerk PW, Becker LE, Wadden TA, Fujioka KN, Hollander PL, Kushner RF, Garvey WT, Rubino DM, Malcolm RJ, Weiss DP, Raum WJ, Salyer JL, Hermayer KL, Rost SL, Veliko JL, Sora ND. Randomized controlled trial of a nationally available weight control program tailored for adults with Type 2 Diabetes. Obesity. 24(11):2269-2277, 2016

36

216. Walton RG, Zhu X, Tian L, Heywood E, Liu J, Hill H, Lamiquiz J, Bruemmer D, Yang Q, Fu Y, Garvey WT. AP2-NR4A3 transgenic mice display reduced serum epinephrine due to increased catecholamine catabolism in adipose tissue. American Journal of Physiology. 311(1):E69-81, 2016

217. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity. Endocrine Practice. 22(7):842-884, 2016. Epub May 24, 2016

218. Garvey WT, Arathuzik J. Lifestyle Therapy for Diabetes Mellitus. in Lifestyle Medicine: a Manual for Clinical Practice. Eds. Mechanick JI and Kushner RF. Springer International Publishing Co. New York, 2016

219. Garvey WT, Arathuzik J. Miller GD, Ard J. Lifestyle Therapy in the Management of Cardiometabolic Risk: Diabetes Prevention, Hypertension, and Dyslipidemia. in Lifestyle Medicine: a Manual for Clinical Practice. Eds. Mechanick JI and Kushner RF. Springer International Publishing Co. New York, 2016

220. Pi-Sunyer X, Shanahan W, Fain R, Ma T, Garvey WT. Impact of Lorcaserin on Glycemic Control in Overweight and Obese Patients With Type 2 Diabetes: Analysis of Week 52 Responders and Nonresponders. Postgraduate Medicine, 128(6):591-597, 2016

221. Zhang W, Wu M, Kim T, Jariwala RH, Garvey WJ, Luo N, Kang M, Ma E, Tian L, Steverson D, Yang Q, Fu Y, Garvey WT. Skeletal Muscle TRIB3 Mediates Glucose Toxicity in Diabetes and High Fat Diet-Induced Insulin Resistance. Diabetes. 65(8):2380-2391, 2016

222. Mechanick JI, Harrell RM, Allende-Vigo MZ, Alvayero C, Arita-Melzer O, Aschner P, Camacho PM, Castillo RZ, Cerdas S, Coutinho WF, Davidson JA, Garber JR, Garvey WT, González FJ, Granados DO, Hamdy O, Handelsman Y, Jiménez-Navarrete MF, Lupo MA, Mendoza EJ, Jiménez-Montero JG, Zangeneh F. Transculturalization recommendations for developing Latin American clinical practice algorithms in endocrinology – proceedings of the 2015 Pan-American Workshop by the American Association of Clinical Endocrinologists and the American College of Endocrinology. Endocrine Practice. 22(4):476-501, 2016

223. Carson AP, Muntner P, Selvin E, Carnethon MR, Li X, Gross MD, Garvey WT, Lewis CE. Do Glycemic Marker Levels Vary by Race? Differing Results from a Cross-sectional Analysis of Individuals with and without Diagnosed Diabetes. BMJ Open Diabetes Research & Care. Jun 10;4(1):e000213, 2016

224. Guo F, Garvey WT. Trends in Cardiovascular Health Metrics in Obese Adults: National Health and Nutrition Examination Survey (NHANES), 1988-2014. Journal of the American Heart Association. Jul 13;5(7). pii:e003619, 2016

225. Jacobson D, Alexander A, Tagoe C, Garvey WT, Williams S, Tishkoff S, Modiano D, Sirima S, Kalidi I, Toure A, Buxbaum J. The Prevalence and Distribution of the Amyloidogenic Transthyretin (TTR) V122I Allele in Africa. Molecular Genetics & Genomic Medicine. 4(5):548-556, 2016

226. O'Neil PM, Garvey WT, Gonzalez-Campoy M, Mora P, Ortiz RV, Guerrero G, Claudius B, Pi-Sunyer X. Effects of Liraglutide 3.0 mg on Weight and Risk Factors in Hispanic vs non-Hispanic Populations: Subgroup Analysis from SCALE Randomized Trials. Endocrine Practice. 22(11):1277-1287, 2016

227. Wheeler E, Leong A, Liu C-T,…..Garvey WT,……Barroso I, Meigs JB (202 authors). Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. PLoS Medicine. Sep 12;14(9):e1002383, 2017

228. Mechanick JI, Zhao S, Garvey WT. The adipokine-cardiovascular-lifestyle network: translation to clinical practice. Journal of the American College of Cardiology, 68(16):1785-1803, 2016

37

229. Li L, Shelton RC, Chassan RA, Hammond JC, Gower BA, Garvey TW. Impact of Major Depressive Disorder on Prediabetes by Impairing Insulin Sensitivity. J Diabetes Metab. 2016 Apr;7(4).pii: 664, 2016

230. Zhang J, Light AR, Hoppel C, Campbell C, Chandler CC, Burnett D, Souza E, Casazza G, Hughen R, Keim N, Newman JW, Hunter GR, Fernandez J, Garvey WT, Harper ME, Fiehn O, Adams SH. Acylcarnitines as markers of exercise-associated fuel partitioning, xenometabolism, and potential signals to muscle afferent neurons. Experimental Physiology. 102(1):48-69, 2017

231. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity. Endocrine Practice. 22(Suppl 3):1-203, 2016

232. Garvey WT. Ablation of the Duodenal Mucosa as a Strategy for Glycemic Control in Type 2 Diabetes: Role of Nutrient Signaling or Simple Weight Loss. Diabetes Care. 2016 Dec;39(12):2108-2110

233. Mechanick JI, Hurley DL, Garvey WT. Adiposity-Based Chronic Disease as a New Diagnostic Term: American Association of Clinical Endocrinologists and the American College of Endocrinology Position Statement. Endocrine Practice. 23(3):372-378, 2017

234. Lee JH, Kang M, Wang H, Naik G, Mobley JA, Sonpavde G, Garvey WT, Darley-Usmat VM, Ponnazhagan S. Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-medicated oxidative stress. FASEB Journal. 31(4):1608-1619, 2017

235. Guo F, Garvey WT. Cardiometabolic Disease Staging Predicts Effectiveness of Weight Loss Therapy to Prevent Type 2 Diabetes: Pooled Results from Phase 3 Clinical Trials Assessing Phentermine/Topiramate-Extended Release. Diabetes Care. 40(7):856-862, 2017

236. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. Consensus statement by the American Association of Clinical Endocrinologists and the American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2017 executive summary. Endocrine Practice. 23(2):207-238, 2017

237. Garvey WT. Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2016;39:1186-1201. Diabetes Care. Feb;40(2):e21-e22, 2017

238. Semla TP, Ruser C, Good CB, Yanovski SZ, Ames D, Copeland LA, Billington C, Ferguson UI, Aronne LJ, Wadden TA, Garvey WT, Apovian CM, Atkins D. Pharmacotherapy for Weight Management in the VHA. J Gen Intern Med. 32(Suppl 1):70-73, 2017

239. Holland-Carter L, Tuerk PW, Wadden TA, Fujioka KN, Becker LE, Miller-Kovach K, Hollander PL, Garvey WT, Weiss D, Rubino DM, Kushner RF, Malcolm RJ, Raum WJ, Hermayer KL, Veliko JL, Rost SL, Sora ND, Salyer JL, O'Neil PM. Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial. J Diabetes Complications. 31(5):891-897, 2017

240. Ma E, Ingram K, Milne G, Garvey WT. F2-Isoprostanes Reflect Oxidative Stress Correlated with Lean Mass and Bone Density but Not Insulin Resistance. Journal of the Endocrine Society. Apr 7;1(5):436-448, 2017

241. Smith SR, Garvey WT, Greenway FL, Zhou S, Fain R, Pilson R, Fujioka K, Aronne L. Co-administration of lorcaserin and phentermine for weight management: a 12-week randomized pilot safety study. Obesity. 25(5):857-865, 2017

242. Li L, Garvey WT, Gower B. Childhood maltreatment Is an independent risk factor for Type 2 Diabetes. Frontiers in Endocrinology. Jun 30;8:151. doi: 10.3389/fendo.2017.00151, 2017

38

243. Aslibekyan S, Garvey WT. Obesity: Obesity and cardiometabolic disease - more than meets the eye. Nature Reviews Endocrinology. 13(10):566-568, 2017

244. Mechanick JI, Zhao S, Garvey WT. Leptin, an adipokine with central importance in the global obesity problem. Global Heart. 2017 Dec 13, Epub ahead of print

245. Ma E, Fu Y, Garvey WT. Relationship of circulating miRNAs with insulin sensitivity and associated metabolic risk factors in humans. Metab Syndr Relat Disord. Mar;16(2):82-89, 2018

246. Nieto-Martínez R, González-Rivas JP, Ugel E, Brajkovich I, Risquez A, Garvey WT, Mechanick JI. Application of the AACE/ACE advanced framework for the diagnosis of obesity and cardiometabolic disease staging in a general population from three regions of Venezuela: the VEMSOLS Study. Endocrine Practice. Jan;24(1):6-13, 2018

247. Candida J. Rebello CJ, Nikonova EV, Zhou S, Aronne LJ, Fujioka K, Garvey WT, Smith SR, Coulter AA, Greenway FL. Effect of lorcaserin alone and in combination with phentermine on food cravings after 12-week treatment: a randomized substudy. Obesity. 26:332-339, 2018

248. Kang M, Liu X, Fu Y, Timothy Garvey W. Improved systemic metabolism and adipocyte biology in miR-150 knockout mice. Metabolism. June 83:139-148, 2018

249. Chou CF, Hsieh YH, Grubbs CJ, Atigadda VR, Mobley JA, Dummer R, Muccio DD, Eto I, Elmets CA, Garvey WT, Chang PL. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis. J Dermatol Sci. Jun; 90(3):343-356, 2018

250. Basu A, Jenkins AJ, Stoner JA, Zhang Y, Klein RL, Lopes-Virella MF, Garvey WT, Schade DS, Wood J, Alaupovic P, Lyons TJ. Apolipoprotein-defined Lipoprotein Subclasses, Serum Apolipoproteins and Carotid Intima-Media Thickness in Type 1 Diabetes. J Lipid Res. May; 59(5):872-883, 2018

251. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. Consensus statement by the Americn Association of Clinical Endocrinologists and American College of Endicrinology on the comprehensive type 2 diabetes management algorithm – 2018 executive summary. Endocr Pract. Jan;24(1):91-120, 2018

252. Rebello CJ, Nikonova EV, Zhou S, Aronne LJ, Fujioka K, Garvey WT, Smith SR, Coulter AA, Greenway FL. Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy. Obesity (Silver Spring). Feb;26(2):332-339, 2018

253. Kang M, Liu X, Fu Y, Timothy Garvey W. Improved systemic metabolism and adipocyte biology in miR-150 knockout mice. Metabolism. June; 83:139-148, 2018

254. Garvey WT. Clinical Definition of Overweight and Obesity. IN: Bariatric Endocrinology. Eds. J. M. Gonzalez-Campoy, D.L. Hurley, W. T. Garvey. Springer. Switzerland, 2018

255. Garvey WT, Van Gaal L, Leiter LA, Vijapurkar U, List J, Cuddihy R, Ren J, Davies MJ. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. Aug;85:32-37, 2018

BOOK CHAPTERS, MONOGRAPHS, AND REVIEWS 1. Olefsky, J.M., R.R. Revers, M. Prince, R. Henry, W.T. Garvey, J. Scarlett, and O.G. Kolterman.

Insulin resistance in non-insulin-dependent (Type II) and insulin dependent (Type I) diabetes mellitus. Adv. Exp. Med. Biol., Plenum Press, New York, pp. 189:176-205, 1985.

39

2. Karnieli, E., and W.T. Garvey. Glucose transporters: Overview and implications for the brain. IN: Insulin, Insulin-Like Growth Factors, and their Receptors in the Central Nervous System. Eds. M.K. Raizada, M.I. Phillips, and D. Leroith, Plenum Press, New York, pp. 71-92, 1987.

3. Garvey, W.T. Pathogenesis and cellular mechanisms of insulin resistance in Type II non-insulin-dependent diabetes mellitus, IN: Pathogenesis of Non-Insulin-Dependent Diabetes Mellitus. Ed. Grill, W., Raven Press, New York, pp. 171-200, 1988.

4. Garvey, W.T., and O.G. Kolterman. Correlations between in vivo and in vitro actions of insulin in obesity and diabetes. IN: Diabetes/Metabolism Reviews. Ed. R. DeFronzo, John Wiley and Sons, New York pp. 44:543-570, 1988.

5. Garvey, W.T. Cellular and molecular pathogenesis of insulin resistance. IN: Insulin Action: volume II Molecular and Cellular Biology of Diabetes Mellitus. Eds. B. Draznin, S. Melmed, and D. LeRoith, Alan R. Liss, Inc., New York, pp. 79-95, 1989.

6. Baron, A.D., Kolterman, O.G., Prager, R., Freidenberg, G.R., Henry, R.R., Garvey, W.T., and Olefsky, J.M. "Mechanisms of insulin resistance in obese Type II diabetic subjects". IN: Diabetes Mellitus: Pathophysiology and Therapy. Bayer AG Centenary Symposium. Eds. Creutzfeldt, W. and Lefebvre, P., Spinger-Verlag, Berlin, pp. 107-126, 1989.

7. Garvey, W.T. Glucose and insulin chronically regulate the glucose transport system. Proceedings of the 13th International Diabetes Federation Congress. Excerpta Medica International Congress Series, Eds. Larkins, R.G., Zimmet, P.A., and Chisholm, D.J., Elsevier Science Publishers, Amsterdam, pp. 341-344, 1989.

8. Garvey, W.T. Insulin resistance non-insulin-dependent diabetes mellitus: Which horse is pulling cart? IN: Diabetes/Metabolism Reviews. Ed. R. DeFronzo, John Wiley and Sons, New York, 5:727-742, 1989.

9. Garvey, W.T. Glucose transport and non-insulin dependent diabetes mellitus. Diabetes Care (Review Issue) 15:396-417, 1992.

10. Garvey, W.T., and M.J. Birnbaum. Cellular insulin action and insulin resistance, IN: Bailliere's Clinical Endocrinology and Metabolism: Insulin Resistance and Disease. Ed. E. Ferrannini, Bailliere Tindall, London, 7:785-873, 1994.

11. Garvey, W.T. Glucose transporter proteins and insulin sensitivity in humans. Brazilian Journal of Medical and Biological Research, 27:933-939, 1994.

12. Garvey, W.T. GLUT 4 glucose transporters and insulin action in humans: regulation at the level of gene expression and cellular trafficking. IN: Molecular Biology of Diabetes. Eds. B. Draznin, and D. LeRoith, The Humana Press Inc., Totowa NJ, vol. II, p 437-471, 1994.

13. Garvey, W.T., and A. Kennedy. The Insulin Resistance Syndrome. In: On the Cutting Edge (a publication of the DCE practice group of the American Dietetic Association). Ed. K.A. O'Keefe. 18:6-9, 1997.

14. Willi, S.M., O’Rear, D., Garvey, W.T., Colwell, J.A., Buse, M.G., Jaffa, A., Lopes-Virella, M., Wood, D., Mayfield, R.K., Wallace, P., Hermayer, K.L., Jenkins, A.J., Lyons, T., and Mayer-Davis, E. Diabetes research in South Carolina: past, present, and future. Journal of the South Carolina Medical Association. 94:502-508, 1998.

15. Hermayer, K., and Garvey, W.T. The Insulin Resistance Syndrome. In: clinicalCORNERSTONE--Diabetes Mellitus. Ed. Garvey, W.T. Excerpta Medica, Inc., New York. Volume 1 (3), 1998.

16. Garvey, W.T. Treatment of Diabetes Mellitus in Adults. In: Conn’s Current Therapy. Ed. R.E. Rakel. W.B. Saunders Company. Philadelphia, Year 2000 edition, pp 546-566, 2000.

17. Jenkins, A.J., Garvey, W.T., and Klein R.L. "Lipoprotein Abnormalities in Type 1 Diabetes". Current Opinion in Endocrinology and Diabetes. Lippincott Williams & Wilkins, London, UK. 10(4):245-250, 2003.

18. Ovalle, F, and Garvey, W.T. “Type 2 Diabetes Mellitus”. In: Encyclopedia of Endocrine Diseases. Ed. L. Martini. Academic Press/Elsevier Science (USA), Burlington, MA, USA. 2004.

19. Allison DB, Barnes S, and Garvey WT. Individual differences in the response to ingested nutrients. Nutrition. 20:1, 2004.

40

20. “Nutrigenomics”, Special Issue of Nutrition, Volume 20, Issue 1, Pages 1-172 (January 2004). Co-edited by: David B. Allison, PhD, Stephen Barnes, PhD, and W. Timothy Garvey, MD.

21. Garvey, W.T. ‘Mechanisms of Insulin Signal Transduction’. Section Editor of “Normal Physiology of Insulin Action”: W.T. Garvey. In: International Textbook of Diabetes, 3rd Edition. Eds. R.A. DeFronzo, E. Ferrannini, H. Keen, P. Zimmet. John Wiley & Sons, Ltd. London, 2004.

22. Lara-Castro, C, and Garvey, WT. “Metabolic Syndrome and Diets”. In: Healthy Aging. 1(4):25-26, November/December, 2005. (www.advanceweb.com/healthyaging)

23. Lara-Castro C, Garvey WT. “Nutritional Therapy for the Metabolic Syndrome”. In: The Handbook of Clinical Nutrition, 4th Edition. Eds. D. Heimburger, J Ard. Mosby-Year Book, Inc., St. Louis, In Press, 2005.

24. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating the risk of metabolic and cardiovascular disease. Current Opinion in Lipidology, In Press, 2007

25. American College of Endocrinology Writing Team. The Diagnosis and management of Pre-Diabetes in the Continuum of Hyperglycemia – When do the risks of diabetes begin. A CONSENSUS STATEMENT. Endocrine Practice, 14:933-946, 2008

26. Lara-Castro C, Garvey WT. Role of Nutrition in the Pathophysiology, Prevention, and Treatment of Type 2 Diabetes and the Spectrum of Cardiometabolic Disease. Fourth Edition of Preventive Nutrition, Eds. Bendich A and Deckelbaum R. Humana and Springer, New York NY, 2009

27. Liu J, Garvey WT. The Power of Fat. commentary, Cell Science Reviews 5: In Press, 2009 28. Wu X, Garvey WT. “Insulin Action”. In: Textbook of Diabetes, 4th edition. Eds: Holt RIG, Goldstein

B, Flyvbjerg A, Cockram CS. Wiley-Blackwell, 2010 29. Newton L, Garvey WT. “Nutritional and Medical Management of Diabetes Mellitus in Hospitalized

Patients”. In: The A.S.P.E.N. Adult Nutrition Support Core Curriculum. 2rd edition, Ed. C.M. Mueller. American Society for Parenteral and Enteral Nutrition, Silver Springs MD, 2012

30. Mechanick JI, Garber AJ, Handelsman Y, Garvey WT, McMahon MM, Hurley DL. Authors' Response to Lorenzo Donini, MD. Endocrine Practice 21:1-4, 2013

31. Langlais PR, Mandarino LJ, Garvey WT. Mechanisms of Insulin Signal Transduction. IN: International Textbook of Diabetes Mellitus, 5th edition. Eds. R.A. DeFronzo, E. Ferrannini, H. Keen, P. Zimmet. John Wiley & Sons, Ltd. London, 2015.

32. Garvey WT. Clinical Definition of Overweight and Obesity. IN: Bariatric Endocrinology. Eds. J. M. Gonzalez-Campoy, D.L. Hurley, W. T. Garvey. Springer. Switzerland, 2018

33. Eds. J. M. Gonzalez-Campoy, D.L. Hurley, W. T. Garvey. Bariatric Endocrinology. Springer. Switzerland, 2018

ABSTRACTS: 1. Garvey, W.T., J. Griffin, R. Revers, J. Olefsky, and O. Kolterman. The effect of insulin treatment on

insulin secretion and action in Type II diabetes (NIDDM). Clin. Res. 31:92A, 1983. 2. Garvey, W.T., J. Griffin, R. Revers, J. Olefsky, and O. Kolterman. The effect of insulin treatment on

insulin secretion and action in Type II diabetes (NIDDM). Clin. Res. 31:386A, 1983. 3. Garvey, W.T., R. Revers, A. Rubenstein, J.M. Olefsky, and O.G. Kolterman. Modulation of insulin

secretion by insulin and glucose in Type II diabetes (NIDDM). Clin. Res. 32:47A, 1984. 4. Garvey, W.T., R. Revers, A. Rubenstein, J.M. Olefsky, and O.G. Kolterman. Modulation of insulin

secretion by insulin and glucose in Type II diabetes (NIDDM). Clin. Res. 32:395A, 1984. 5. Garvey, W.T., and O.G. Kolterman. Urinary C-peptide measurements do not predict insulin secretion in

Type II diabetes (NIDDM). Diabetes 33 (Suppl. 1):318, 1984.

41

6. Garvey, W.T. and S. Marshall. Insulin-induced receptor downregulation is necessary for induction of a post-receptor defect in glucose transport. Diabetes 33 (Suppl. 1):133, 1984.

7. Garvey, W.T., J.M. Olefsky, and S. Marshall. Progressive development of insulin-induced cellular insulin resistance. Clin. Res. 33:102A, 1985.

8. Garvey, W.T., and S. Marshall. Progressive development of insulin-induced cellular insulin resistance. Diabetes 34 (Suppl. 1):78A, 1985.

9. Marshall, S., and W.T. Garvey. Evidence for phosphorylation directed routing of insulin-receptor complexes. Diabetes 35 (Suppl. 1):2A, 1986.

10. Garvey, W.T., and S. Marshall. Glucose and insulin co-regulate the glucose transport system in cultured adipocytes: A new mechanism of insulin resistance. Diabetes 35 (Suppl 1):80A, 1986.

11. Garvey, W.T., T.P. Huecksteadt, and J.M. Olefsky. Role of glucose transport proteins in the insulin resistance of Type II diabetes mellitus. Clin. Res. 35:150A, 1986.

12. Garvey, W.T., T.P. Huecksteadt, and J.M. Olefsky. Role of glucose transport proteins in the insulin resistance of Type II diabetes mellitus. Diabetes 36 (Suppl. 1):84A, 1987.

13. Heidenreich, K.A., P.R. Gilmore, and W.T. Garvey. Insulin receptors and glucose transport in primary neuronal cultures. Diabetes 36 (Suppl. 1):149A, 1987.

14. Garvey, W.T., T.P. Huecksteadt, E. Karnieli, and F.B. Lima. 5'-nucleotidase activity is increased in adipocytes in diabetes mellitus. Clin. Res. 36:152A, 1988.

15. Lima, F.B. and W.T. Garvey. The cellular effects of insulin are differentially regulated in primary cultured adipocytes. Clin. Res. 36:156A, 1988.

16. Garvey, W.T., T.P. Huecksteadt, J.J. Birnbaum, and F.B. Lima. Dexamethasone regulates glucose transporters and transporter mRNA in primary cultured adipocytes. Diabetes 37 (Suppl. 1):50A, 1988.

17. Lima, F.B., and W.T. Garvey. The cellular effects of insulin are differentially regulated in primary cultured adipocytes. Diabetes 37 (Suppl. 1):28A, 1988.

18. Biby, C., W. Young, P. Elliott, P. Shragg, T. Garvey, and O. Kolterman. Self blood glucose monitoring (SBGM) is essential for the maintenance of glycemic control in type II diabetics. Diabetes Res. Clin. Practice, Congress of the International Diabetes Federation, 5 (Suppl. 1):S498, 1988.

19. Houlder, N., Lewis D., Sherman, N., Adams, M., Garvey, W.T., Sussman, K.E., LeRoith, and Draznin, B. Mechanisms of Ca++-induced insulin resistance in isolated rat adipocytes. Clin. Res. 37:159A, 1989.

20. Garvey, W.T., T. Huecksteadt, and M.J. Birnbaum. Differential effect of diabetes on the expression of glucose transporter genes: suppression of an insulin-responsive species. Diabetes 38:85A, 1989.

21. Garvey, W.T., L. Maianu, T.P. Hueckstedt, M.J. Birnbaum, M. Molina, and T.P. Ciaraldi. Pretranslational suppression of GLUT 4 glucose transporters causes insulin resistance in type II diabetes. Diabetes. 39:120A, 1990.

22. Yu, X.P., H. Mocharla, F.G. Hustmyer, L. Maianu, W.T. Garvey, and S.C. Manolagas. Identification of a novel 1,25(OH)2D3-responsive protein in human lymphocytes: immunologic crossreactivity and inverse regulation with VDR. J. of Bone and Mineral Res. 5:S208, 1990.

23. Ryan, A.B., G.C. Gardner, M.H. Weisman, W.T. Garvey, A.M. Tan, R. Braun, and G.P. Shragg. Syndrome of limited joint mobility (SLJM): A study of 70 patients. Arthritis and Rheumatism. 33 (Suppl.):589, 1990.

24. Hardin, D.S., J. Dominguez, and W.T. Garvey. Expression of GLUT 4 glucose transporters varies as a function of skeletal muscle group in control and diabetic rats. Diabetes. 40:292A, 1991.

25. Dominguez, J.H., L. Maianu, J.K. Rothrock, and W.T. Garvey. Differential expression of facilitative glucose transporters 1 and 2 in rat proximal tubule. J. Am Society Nephrol. 1:A739, 1990.

26. Garvey, W.T., L. Maianu, K. Camp, and J.H. Dominguez. Diabetes alters glucose transporter gene expression in rat proximal tubule. J. Am. Society Nephrol. 1:A718, 1990.

27. Dominguez, J.H., L. Maianu, K. Camp, and W.T. Garvey. Diabetes and glucose transporter gene expression in rat kidney. Diabetes. 40:44A, 1991.

28. Garvey, W.T., L. Maianu, L. Jones, and A. Baron. Regulation of GLUT 4 glucose transporters in skeletal muscle from insulin resistant patients. Diabetes. 40:7A, 1991.

42

29. Garvey, W.T. Glucose transporters and insulin resistance in type II diabetes mellitus. Journal of Cellular Biochemistry. Supplement 15B:15(CB-023), 1991.

30. Hardin, D.S., J.H. Dominguez, and W.T. Garvey. Regulation of tissue GLUT 4 content varies as a function of skeletal muscle group and cannot totally explain insulin resistance in diabetic rats. Clin. Res. 39:354A, 1991.

31. Dominguez, J.H., K. Camp, L. Maianu, and W.T. Garvey. GLUT 1, GLUT 2, and Na+GLUT gene expression in proximal tubules from normal and diabetic rats. J. Am. Society Nephrol. 2:A288, 1991.

32. Garvey, W.T., K. Camp, L. Maianu, J. Rothrock, and J.H. Dominguez. Adaptations of the rat renal proximal tubule to uncontrolled diabetes. Clin. Res. 39:307A, 1991.

33. Feister, H., K. Camp, S.B. Kleiboeker, C.C. Hale, W.T. Garvey, and J.H. Dominguez. Diabetes depresses the rat cardiac Na+/Ca2+ exchanger. Clin. Res. 40:257A, 1992.

34. Potter, C.G., R.G. Peterson, and W.T. Garvey. Suppression of peripheral nerve glucose uptake in experimental diabetes. Diabetes. 41(Suppl. 1):22A, 1992.

35. Hardin, D., G. Brechtel, A. Johnson, L. Maianu, J. Edwards, J. Wigglesworth, A. Baron, and W.T. Garvey. GLUT 4 glucose transporters are differentially expressed and selectively regulated by exercise as a function of skeletal muscle group in humans. Diabetes. 41(Suppl. 1):64A, 1992.

36. Qulali, M., H. Feister, L. Maianu, W.T. Garvey, and J.H. Dominguez. Effects of diabetes and dietary sodium intake on small intestine. J. Am. Society of Nephrol. 3:764A, 1992.

37. Hardin, D., G. Brechtel, A. Johnson, B. Azzarelli, A. Baron, and W.T. Garvey. Mechanisms of enhanced insulin action in endurance-trained athletes. Clin. Res. 40:733A, 1992.

38. Potter, C.G., R.G. Peterson, L. Maianu, and W.T. Garvey. Mechanisms underlying peripheral nerve glucose uptake suppression in diabetes. Diabetes 42(Suppl.1):102A, 1993.

39. Garvey, W.T., L. Maianu, G. Brechtel, A. Johnson, K. Sunblad, and D. Hardin. Muscle GLUT 4 expression is a familiar trait and determines insulin sensitivity in humans independent of obesity. Diabetes 43 (Suppl. 1):69A, 1994.

40. Bao, S., R.M. Smith, L. Jarett, and W.T. Garvey. The golgi apparatus is not required for insulin stimulation of glucose transport and GLUT 4 translocation in rat adipocytes. Diabetes 43 (Suppl. 1):119A, 1994.

41. Baron, A.D., G. Brechtel, A. Johnson, K. Sunblad, D. Hardin, H.O. Steinberg, and W.T. Garvey. Use of dual energy X-ray absoptionmetry (DEXA) to assess intraabdominal fat and its association with insulin sensitivity and blood pressure. Internatl. J. Obesity, In Press, 1994.

42. Baron, A.D., J-S Zhu, J-H Zhu, H. Weldon, L. Maianu, and W.T. Garvey. Glucosamine (Glmn) induces insulin resistance (IR) in vivo by affecting GLUT4 translocation in skeletal muscle. Implications for glucose toxicity. Diabetes 44 (Suppl. 1):15A, 1995.

43. Garvey, W.T., J-H Zhu, L. Maianu, G. Brechtel, and A. Baron. Abnormalities in GLUT4 translocation and trafficking in skeletal muscle cause insulin resistance in humans. Diabetes 44 (Suppl. 1):164A, 1995.

44. Yarnall, D.P., J.M. Lenhard, L. Hamacher, S. Marshall, J.M. Rumberger, L. Maianu, W.T. Garvey, and D.K. Burns. Rad expression in skeletal muscle of Type II Diabetics. Diabetes 44 (Suppl. 1):186A, 1995.

45. Leaming, R.D., L. Smith, C. Burtner, G. Hook, A. Johnson, J. Cronin, D. Hardin, W.T. Garvey, H.O. Steinberg, and A.D. Baron. Dual energy X-ray absorptiometry assessment of fat mass and distribution and its association with the Insulin Resistance Syndrome. Diabetes 45:106A, 1996.

46. Maianu, L., S. Keller, and W.T. Garvey. Fat and muscle tissue express a common abnormality in translocation/trafficking of GLUT4/vp165 containing vesicles in NIDDM. Diabetes 45:157A, 1996.

47. Baier, L., and the Pima Diabetes Genes Group. Suggestive linkage of genetic markers on chromosome 4q.12 to NIDDM and insulin action in Pima Indians: new evidence to extend associations reported in other populations. Diabetes 45:30A, 1996.

48. Kennedy A., T. Gettys, P. Watson, P. Wallace, E. Ganaway, and W.T. Garvey. The metabolic significance of leptin in humans. Diabetes 45:254A, 1996.

43

49. Spruill, I., and W.T. Garvey. Project SuGAR: Familial Identification of Diabetes Genes in African-American Rural South Carolina Communities. Human Genome Project: The Social Ethical and Legal Implications (Tuskegee University) #A16, p25, 1996.

50. Maianu, L., A. Kennedy, E. Ganaway, P. Wallace, B. Wojciechowski, and W.T. Garvey. NIDDM and obesity are associated with protein kinase C abnormalities in skeletal muscle. Diabetes 46:23A,1997.

51. Hebert, L.F., J.-H. Zhu, W.T. Garvey, and D.A. McClain. Decreased insulin-stimulated 2-deoxyglucose uptake and impaired GLUT4 translocation in skeletal muscle of transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase. Diabetes 46: 66A, 1997.

52. Willi, S.M., P. McBurney, A. Kennedy, B. Wojciechowski, and W.T. Garvey. Ketosis prone NIDDM in African-American children. Diabetes 46:67A, 1997.

53. Hanson, R., and the Pima Diabetes Genes Group. Genomic scan for markers linked to Type II diabetes in Pima Indians. Diabetes 46:51A, 1997.

54. Imperatore, G., R.L. Hanson, D.J. Pettitt, P.H. Bennett, W.C. Knowler, and the Pima Diabetes Genes Group. Lack of linkage to retinopathy despite linkage to nephropathy. Diabetes 46:76A, 1997.

55. Prately, R., D.B. Thompson, M. Prochazka, L. Baier, and the Pima Diabetes Genes Group. A genome scan for linkage to quantitative traits predicting NIDDM in Pima Indians. Diabetes 46:170A, 1997.

56. Hanson, R.L., W.C. Knowler, the Pima Diabetes Genes Group. Variance components and Haseman-Elston sib-pair linkage analysis in a genomic scan for markers linked to obesity. American Journal of Human Genetics. In Press, 1997.

57. Robinson, L., and Garvey, W.T. Structure and organization of the gene encoding human uncoupling protein 2 and allele frequencies for a common gene variant. National Medical Fellowships, Inc. Proceedings of the Fellowship Program in Academic Medicine Research Symposium. 1998.

58. Willi, S.M., Maianu, L., Kennedy, A., Wojciechowski, B., Bao, S., Wallace, P., Ganaway, E., Garvey, W.T. The role of uncoupling proteins in metabolic fuel partitioning and human obesity. Diabetes. 47:A13, 1998.

59. Hunter, S.J., Klein, R., Argyropoulos, G., Jenkins, A., Lyons, T., Zheng, D., Lackland, D.T., Garvey, W.T. Apolipoprotein CIII polymorphism confers altered chemical composition of triglyceride-rich lipoprotein in Type 1 Diabetes. Diabetes. 47:A32, 1998.

60. Willi, S.M., Kennedy, A., Wojciechowski, B., Garvey, W.T. Insulin resistance and defective glucose-insulin coupling in ketosis-prone Type 2 Diabetes of African-American youth. Diabetes. 47:A306, 1998.

61. Brown, A.M., Dolan, J.W., Garvey, W.T., Argyropoulos, G. Functional analysis of novel mutations in the uncoupling protein 3 gene from obese and diabeteic individuals American Journal of Human Genetics, In Press, 1998.

62. Norman, R.A., Tataranni, P.A., Prately, R., Thompson, D.B., Prochazka, M., Baier, L., Sakul, T., Garvey, W.T., Burns, D., Knowler, W.C., Bennett, P.H., Hanson, R., Bogardus, C., Ravussin, E. Results from a genome-wide scan for obesity susceptibility genes in Pima Indians. 8th International Congress on Obesity, Paris, France, August 3-September 3, 1998.

63. Wojciechowski. B., Willi, S.M., Berg, J.B., Wallace, P., Ganaway, E., and Garvey, W.T. Toward rational diagnostic criteria for the Insulin Resistance Syndrome. Diabetes. 48:A29, 1999.

64. Willi, S.M., Kennedy, A., Wallace, P., Ganaway, E., Wojciechowski, B., and Garvey, W.T. Troglitazone prevents glucocorticoid-induced insulin resistance in humans. Diabetes. 48:A75, 1999.

65. Maianu, L., Zhu, J-H., and Garvey, W.T. Low birth weight is associated with reduced expression of GLUT4 and carnitine palmitoyltransferase–1 in adult skeletal muscle. Diabetes. 48:A274, 1999.

66. Zheng, D., Hunter, S.J., Lackland, D.T., Garvey, W.T., Klein, R.L., and the EDIC Research Group. Plasminogen activator inhibitor-1 is increased in type 1 diabetes patients with hypertension. Diabetes. 48:A43, 1999.

67. Hunter, S.J., Zheng, D., Lackland, D.T., Garvey, W.T., Klein, R.L., and the EDIC Research Group. Hyperfibrinogenemia is associated with nephropathy in type 1 diabetes. Diabetes. 48:A139, 1999.

68. Brown, A.M., Garvey, W.T., and Argyropoulos G. Role of human mitochondrial translocators in the import of nuclear encoded proteins. Presented at the American Society of Human Genetics meeting, 1999.

44

69. Douzdjian V, Baillie GM, Garvey WT. Early pancreas graft function in simultaneous pancreas-kidney recipients induced with FK506. National meeting of the American Society of Transplant Surgeons. Chicago, IL.

70. Willi, S.M., Wallace, P., O’Rear, D.S., Wojciechowski, B., and Garvey, W.T. Troglitazone is an effective therapeutic agent in patients with steroid-induced diabetes. Diabetes. 49:A129, 2000.

71. Jenkins, A.J., Klein, R.L., Zheng, D., Hunter, S., Smith, K., Lyons, T.J., Lackland, D.T., and Garvey, W.T. Paraoxonase genotype (192 Gln-Arg) and serum paraoxonase-arylesterase activity: relationship with type 1 diabetes and nephropathy. Diabetes. 49:A157, 2000.

72. Jenkins, A.J., Zheng, D., Otvos J.D., Klein, R.L., Garvey, W.T., Lyons, T.J., and the DCCT/EDIC Research Group. Nuclear magnetic resonance (NMR)-determined lipoprotein subclass profile in the DCCT/EDIC cohort: effects of gender, HbA1c, and DCCT randomization group. Diabetes. 49:A267, 2000.

73. Lyons, T.J., Zheng, D., Otvos, J.D., Klein, R.L., Lackland, D.T., Garvey, W.T., Jenkins, A.J., and the DCCT/EDIC Research Group. Nuclear magnetic resonance (NMR)-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with retinopathy and nephropathy. Diabetes. 49:A269, 2000.

74. Maianu, L., Zhu, J.-H., Rogers, N.L., and Garvey, W.T. In utero events determine the relationship between body fat and serum leptin levels and the degree of adiposity in adult rats. Diabetes. 49:A313, 2000.

75. T.J. Lyons, J.D. Otvos, R.L. Klein, D. Zheng, W.T. Garvey, A.J. Jenkins, and the DCCT/EDIC Research Group. Nuclear Magnetic Resonance (NMR)-Determined Lipoprotein Subclass Profile: Effects of Hyperglycemia, Lipoprotein Glycation, and Comparison with Standard Lipid Profile. Diabetes 2000; 49(Suppl. 1):A268.

76. Lyons, T.J., Klein, R.L., Zheng, D., Otvos, J., Garvey, W.T., Jenkins, A.J., and the DCCT/DIC Study Group. Nuclear magnetic resonance (NMR)-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with retinopathy. Nuclear Magnetic Res Comm Pharmacol Toxicol, 6:177, 2001. Presented at International Society of Ocular Toxicity. Kiawah Island, SC, October, 2000.

77. Lyons, T.J., Zheng, D., Otvos, J.D., Klein, R.L., Lackland, D.T., Garvey, W.T., Jenkins, A.J., and The DCCT/EDIC Research Group. Nuclear Magnetic Resonance (NMR)-Determined Lipoprotein Subclass Profile in the DCCT/EDIC Cohort: Associations with Carotid Intima-Media Thickness. International Diabetes Federation, Mexico City, September, 2000.

78. Pugh KB, Waring E, Huang P, Wallace P, Shaughnessy SM, Kwon S, Jenkins AJ, Klein RL, Garvey WT. Effects of race on the NMR lipoprotein profile and insulin resistance syndrome: lipids and blood pressure are not influenced by insulin resistance in African Americans. Diabetes 50:A306, 2001.

79. Waring E, Pugh KB, Huang P, Wallace P, Shaughnessy SM, Kwon S, Jenkins AJ, Klein RL, Garvey WT. Effect of insulin resistance and Type 2 Diabetes on the nuclear magnetic resonance lipoprotein subclass profile. Diabetes 50:A591, 2001.

80. Maianu L, Garvey WT. SNARE proteins (syntaxin4, VAMP2, Munc18) and skeletal muscle insulin resistance in rats and humans. Diabetes 50:A270, 2001.

81. Nicholson S, Garvey WT, Wallace P, Dawson M, Ruey P, Wolf B, Cockram D. Postprandial glucose and insulin responses to dextrin-containing medical nutrition bars in persons with Type 2 Diabetes. Diabetes 50:A366, 2001.

82. McLean DC, Page GP, Garvey WT. Mitochondrial DNA and Y-chromosome haplotypes of Gullah-speaking African Americans show closer genetic distance to Sierra Leoneans and lower Caucasian admixture than other new world African populations. American Journal of Human Genetics 69:#258 2001.

83. Page GP, So V, Ding J, Maianu L, Rosinski J, Rhees B, Martin M, Garvey WT. Microarray analysis of changes in skeletal muscle gene expression in response to insulin. American Journal of Human Genetics 69:451, 2001.

45

84. McCormack KA, McLean DC, Zheng D, Klein R, Jenkins AJ, Lyons TJ, Page G, Garvey WT, and the DCCT/EDIC Research Group. Hepatic lipase gene polymorphism is a major determinant of HDL level and HDL size in men with Type 1 Diabetes in the DCCT/EDIC. Diabetes 51:A20, 2002.

85. Maianu L, Kwon S, Shaughnessy SM, Hutto A, Wallace P, Bickel PE, Garvey WT. Flotillin-1 expression in skeletal muscle is altered in insulin resistant humans. Diabetes 51:A302, 2002.

86. Jaffa AA, Weitz S, Zheng D, Usinger WR, Garvey WT, and the DCCT/EDIC Research Group. Connective tissue growth factor (CTGF) N fragment: a marker for progressive diabetic nephropathy. 35th Annual Meeting of the American Society of Nephrology, November, 2002.

87. Garvey WT. Genetics of obesity in isolated populations: the Gullah population. 9th International Congress on Obesity, Sao Paulo. International Journal of Obesity 26(Suppl. 1):S220, 2002.

88. Fernandes J, Shaughnessy SM, Kwon S, Martin K, Hutto AW, Dawkins CR, Newcomer BR, Vestri HS, Wallace P, Maianu L, Garvey WT. Relationship Between Insulin Sensitivity And Intramyocellular Lipid During Short Term Very Low Calorie Diet In Obese Type 2 Diabetics. Diabetes 52 (Suppl. 1):A328, 2003.

89. Maianu L, Chen Y, Simmons A, Wallace P, Hutto A, Shaughnessy SM, Fernandes JK, Garvey WT. Alterations in skeletal muscle caveolins 1 and 3 in human insulin resistance and obesity. Diabetes 52 (Suppl. 1):A330, 2003.

90. Williams K, Ferrannini E, Bogardus C, DeFronzo RA, Hunt KJ, Garvey WT, Reaven GM, Michael P Stern MP. A model to identify individuals likely to be insulin resistant. 18th International Diabetes Federation Congress, Paris, France, August 24-29, 2003.

91. Page GP, So V, Martin M, Garvey T. The Effect of Insulin on the Expression of Genes in Human Skeletal Muscle. Diabetes 53 (Suppl.2):A6, 2004.

92. Fu Y, Luo N, Garvey WT. Overexpression of Adiponectin but not Resistin Enhances Adipocyte Differentiation and Insulin Sensitivity. Diabetes 53 (Suppl.2): A79, 2004.

93. Vestri HS, Moellering DR, Maianu L, Garvey WT. Effects of Atypical Antipsychotic Drugs on Insulin Action in Adipocytes. Diabetes 53 (Suppl.2): A150, 2004.

94. Semler AJ, McHenry MB, Lackland DT, Lipsitz SR, Lopes-Virella MF, Garvey WT, Klein RL, the DCCT/EDIC Research Group. Associations of Adiponectin with Retinopathy in the DCCT/EDIC Cohort: Influence of Insulin Resistance. Diabetes 53 (Suppl.2): A254, 2004.

95. Bailey SM, Pinner A, Robinson G, Vestri HS, Garvey WT. Chronic Alcohol Consumption Induces the Metabolic Stress Chaperone Prohibitin in Liver Mitochondria. National Meetings of the American Association for the Study of Liver Diseases. Boston, 10/29-11/2, 2004.

96. Moellering D, Ulasova E, Krumdieck C, Vestri H, Darley-Usmar V, Garvey WT. Proteomic analysis of skeletal muscle mitochondria reveals decreases in complex I and IV of the electron transport chain. 11th Annual Meeting of the Society for Free Radical Biology and Medicine, 2004.

97. Ader M, Garvey WT, Phillips LS, Nemeroff CB, Weinberger DR,Gharabawi G, Mahmoud RA, Greenspan A, Morein Jacque JD, Zhu Y (2005). Glucoregulation and adiposity with antipsychotic therapy in schizophrenia. National meeting of the American Psychiatric Association, Abstract NR828 (published online at http://www.psych.org/edu/other_res/lib_archives/archives/meetings/2005nra.cfm).

98. Garvey WT. Diet, the Metabolic Syndrome, and Diabetes Prevention. 25th Annual Meeting of the Taiwan Diabetes Association and Endocrinology Society, Taipei, Taiwan, ROC. March 19-20, 2005.

99. Vestri HS, Bland AM, Dugan M, Moellering DR, D'Eugenio LR, Schey K, Arthur JM, Garvey WT. 2D-Gel Analysis of Differentially Extracted Proteins from Human Skeletal Muscle. National meeting of the NHLBI Cardiovascular Proteomic Centers, Annapolis, MD. April 20-21, 2005.

100. He L, Game BA, Garvey WT, Huang Y. Administration of Pioglitazone to LDL Receptor-Deficient Mice Inhibits Progression of Intimal Lesions and Expression of Matrix Metalloproteinases and Adhesion Molecules. Diabetes 54 (Suppl. 2):A182, 2005.

101. Fu Y, Luo L, Garvey WT. Lipid Metabolism Mediated by Adipocyte Lipid Binding Protein (ALBP/aP2) Gene Expression in Human THP-1 Macrophages. . Diabetes 54 (Suppl. 2):A118, 2005.

46

102. Lara-Castro C, Luo N, Wallace P, Garvey WT. Adiponectin Multimeric Complexes and the Metabolic Syndrome Trait Cluster. Diabetes 54 (Suppl. 2):A347, 2005.

103. Wu X, Moellering D, Vestri H, Wei H, Maianu L, Rosinski J, Rhees B, So V, Allison D, Martin M, Garvey WT. Dysregulation of Mitochondria-Related Genes and Transcription Factors Involved in Mitochondrial Biogenesis in Skeletal Muscle from Insulin Resistant Humans. Diabetes 54 (Suppl. 2):A273, 2005.

104. Moellering DR, Ulasova E, Landar AL, Vestri HS, Wallace P, Darley-Usmar V, Garvey WT. Proteomic Analysis of Skeletal Muscle Mitochondria in Type 2 Diabetes Reveals Altered Concentrations and Oxidation of Respiratory Chain Proteins. Diabetes 54 (Suppl. 2):A58, 2005.

105. Moellering DR, Vestri HS, Ulasova E, Krumdieck CL, Landar AL, Wallace P, Darley-Usmar VM, Garvey WT. Proteomic and biochemical analyses of diabetic human and obese rodent skeletal muscle mitochondria reveals altered concentration, oxidation, and activity of respiratory chain proteins. National meeting of the NHLBI Cardiovascular Proteomic Centers, Annapolis, MD. September 28-29, 2005.

106. Moellering DR, Vestri HS, Ulasova E, Krumdieck CL, Wallace P, Landar AL, Darley Usmar VM, Garvey WT. Proteomic and biochemical analyses of diabetic human and obese rodent skeletal muscle mitochondria reveals altered concentration, oxidation, and activity of respiratory chain proteins. 4th Conference on Mitochondrial Physiology - MiP2005; The Many Faces and Functions of an Organelle, 16-20 September 2005, Schröcken, Vorarlberg, Austria. http://www.mitophysiology.org/

107. Lara-Castro C, Vestri HS, Shiflett AM, Rigsby DY, Munoz AJ, Nogueira J, Semler A, Klein RL, Garvey WT. Effects of Short-Term Very Low Calorie Diet (VLCD) on Secretion of Adipocytokines in Human Adipose Tissue. Diabetes 55(Suppl.1):A313, 2006.

108. Xuxia Wu X, Hill HS, Garvey WT. A Role for C/EBP-δ in Mitochondrial Dysfunction and Insulin Resistance in Skeletal Muscle. Diabetes 55(Suppl.1):A304, 2006.

109. Garvey WT, Baumgartner J, Fernandes JK, Fernstrom MH, Lausch M, Loper J, Paule CL, Mustad VA. A Diabetes Management Program Using Diabetes-Specific Meal Replacements and Snack Bars Improves Weight Loss, Metabolic Parameters, and Quality of Life (QOL). Diabetes 55(Suppl.1):A596, 2006.

110. Lok KH, Klein RL, Lyons TJ, Lopes-Virella MF, Jenkins AJ, Yim E, Carter R, Garvey WT, and the DCCT/EDIC. CETP gene variation has pronounced independent effects on HDL particle size in Type 1 Diabetes. Diabetes 55(Suppl.1):A252, 2006.

111. Fu Y, Luo L, Luo N, Garvey WT. Resistin Autoregulates Inflammatory Cytokine Production and Induces Insulin Resistance in Adipocytes. Diabetes 55(Suppl.1):A310, 2006.

112. Nogueira JB, Vestri HS, Lara-Castro C, Munoz J, Abrams GA, Garvey WT. Adipokines and Non-Alcoholic Fatty Liver Disease. National Association for the Study of Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) Annual meeting, October 19-22, 2006, Orlando City, FL.

113. Moellering DR, Vestri HS, Andringa KK, Mantena SK, Bailey SM, W T. Garvey WT. Pioglitazone therapy restores the coupling of electron transport to ATP synthesis in skeletal muscle of obese Zucker rats. 67th Annual Scientific Sessions of the American Diabetes Association, Chicago IL, Diabetes 56 (Suppl. 1):A85-A86, 2007.

114. Nogueira J, Vestri HS, Lara-Castro C, Munoz J, Abrams AG, Garvey WT. Fat depots and adipokines in morbidly obese individuals. 67th Annual Scientific Sessions of the American Diabetes Association, Chicago IL, Diabetes 56 (Suppl. 1):A464, 2007.

115. Lara-Castro C, Doud EC, Munoz J, Hunter GR, Gower BA, Garvey WT. Ethnic Differences in Adiponectin Multimer Distribution and Relationships with Metabolic Syndrome Traits. 67th Annual Scientific Sessions of the American Diabetes Association, Chicago IL, Diabetes 56 (Suppl. 1):A361, 2007.

116. Wu X, Liu J, Franklin JL, Messina JL, W. Garvey WT. TRB 3 modulates insulin sensitivity in skeletal muscle; possible role in glucose-induced insulin resistance. 67th Annual Scientific Sessions of the American Diabetes Association, Chicago IL, Diabetes 56(Suppl. 1):A346, 2007.

47

117. Fu Y, Luo L, Luo N, Garvey WT. NR4A orphan nuclear receptors enhance insulin sensitivity and GLUT4 translocation in adipocytes. 67th Annual Scientific Sessions of the American Diabetes Association, Chicago IL, Diabetes 56 (Suppl. 1):A365, 2007.

118. Jumbo-Lucioni P, Moses M, Moellering D, Garvey WT, De Luca M. Natural Variations in Mitochondrial Bioenergetic Traits in Drosophila melanogaster. Obesity 105-OR, 2007. NAASO meetings

119. Heimburger K, Lara-Castro C, Newcomer, B, Shifflet A, Rigsby D, Garvey WT. Racial differences in intramyocellular lipids and its relationship to metabolic traits. Obesity , 2007. NAASO meetings

120. Adams SH, Hoppel CL, Lok KH, Newman JW, Garvey WT. Comprehensive plasma acylcarnitine profiles of type 2 diabetic and non-diabetic subjects with or without an uncoupling protein 3 (UCP3) missense polymorphism. Experimental Biology meetings, San Diego CA, 2008

121. Garvey WT, Troupin B, Tam P, Najarian T, Peterson C, DAY WW. Effect of VI-0521 (phentermine and topiramate) in Type 2 Diabetes. Diabetes 57 (Suppl. 1):A112, 2008.

122. Liu J, Wu X, Franklin JF, Messina JL, Garvey WT. Tribbles homolog 2 modulates insulin-stimulated glucose uptake and Glut4 translocation: Possible role in insulin resistance. Diabetes 57 (Suppl. 1):A27, 2008.

123. Munoz AJ, Lara-Castro C, Garvey WT. The HOMA Index Estimation of Insulin Resistance is Affected by Ethnicity. Diabetes 57 (Suppl. 1):A292, 2008.

124. Zhu X, Luo N, Fu Y, Garvey WT. Prostaglandin A2 Enhances Cellular Insulin Sensitivity via a Mechanism that Involves the Orphan Nuclear Receptor NR4A3. Diabetes 57 (Suppl. 1):A357, 2008.

125. Sale MM, Lu L, Spruill IJ, Fernandes JK, Lok KH, Divers J, Langefeld CD, Garvey WT. A Genome-Wide Linkage Scan in Gullah-Speaking African American Families with Type 2 Diabetes: The Sea Islands Genetic African American Registry (Project SuGAR). Diabetes 57 (Suppl. 1):A321, 2008.

126. Tian L, Luo N, Klein RL, Chung BH, Garvey WT, Fu Y. Overexpression of Adiponectin Reduces Lipid Accumulation in Human THP-1 Macrophage Foam Cells. Diabetes 57 (Suppl. 1):A631, 2008.

127. Vestri HS, Lara-Castro C, Moellering DR, Gundberg CM, Garvey WT. Osteocalcin is not Just for Bones: Effects on Fat and Correlations with Diabetes and Obesity. Diabetes 57 (Suppl. 1):A29, 2008.

128. Lara-Castro C, Clayton CB, Klein RL, Shiflett A, Rigsby D, Shifflett A, Munoz AJ, Garvey WT. Metabolic Syndrome Traits and Endothelial Dysfunction: Role of Ethnicity. Diabetes 57 (Suppl. 1):A620, 2008.

129. Bailey SM, Mantena SK, Moellering DR, Hill HS, Andringa KK, Garvey WT. Pioglitazone prevents obesity-induced mitochondrial dysfunction in liver of the diabetic Zucker fatty rat. American Association for the Study of Liver Disease. 2008

130. Garvey WT, Day WW, Peterson CA, Najarian T, Tam PY, Troupin B. The weight effects of VI-0521 in Type 2 Diabetes. Obesity 16 (Suppl. 1): S294, 2008

131. Lyons T, Yu J, Alaupovic P, Klein R, Lopes-Virella M, Carter R, Lackland D, Garvey WT, DCCT/EDIC Research Group, Jenkins A. Apolipoprotein-defined lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy in Type 1 Diabetes. Diabetes 58 (Suppl 1): A243, 2009

132. Garvey WT, Troupin B, Tam P, Najarian T, Peterson C, Day WW. One-Year Treatment with VI-0521 in Type 2 Diabetes Demonstrates Continued Glycemic Improvement and Weight Loss. Diabetes 58 (Suppl 1):A95, 2009

133. Wu X, Patki A, Lara-Castro C, Osier MV, Gadbury GL, Allison DB, Martin M, Garvey WT. Genes and biochemical pathways in human skeletal muscle affecting resting energy expenditure and fuel partitioning. Diabetes 58 (Suppl 1): A362, 2009

134. Tian L, Luo N, Chung BH, Garvey WT, Fu Y. APPL1 signaling pathway mediates regulation of lipid metabolism by adiponectin in human macrophages. Diabetes 58 (Suppl 1):A201, 2009

48

135. Garvey WT, Troupin B, Tam P, Najarian T, Peterson C, Day WW. One-Year Treatment with VI-0521 in Type 2 Diabetes Demonstrates Sustained Weight Loss and Continuous Glycemic Benefit. Obesity 17(suppl. 2): S52, 2009.

136. Fiehn O, Garvey WT, Lok K, Newman JW, Hoppel CL, Adams SH. The plasma metabolome in overweight Type 2 Diabetes Mellitus (T2DM) vs. non-diabetic subjects with or without an uncoupling protein 3 (UCP3) missense mutation reveals novel metabolite signatures reflective of genotype and diabetic status. Obesity 17(Suppl. 2): S176, 2009

137. Alish CJ, Garvey W, Maki KC Sacks GS, Hustead DS, Mustad VA. Continuous Feeding with a Diabetes –Specific Formula Improves Glycemic Variability and Reduces Insulin Requirements in Tube Fed patients with Type 2 Diabetes Managed with Insulin. 31st European Society for Parenteral and Enteral Nutrition Congress, Vienna, Austria, August 29 - September 1, 2009.

138. Garvey WT, Troupin B, Peterson C, Najarian T, Tam P, Day WW. Treatment with VI-0521 (phentermine and topiramate) leads to one year durable glycaemic benefit and weight loss in subjects with type 2 diabetes. 45th European Association for the Study of Diabetes Annual Meeting, Vienna Austria, September 29 - October 2, 2009. Diabetologia 52(Suppl.1): S77, 2009

139. Ingram KH, Brandon LJ, Ingalls CP, Rupp JC, Penumetcha M, Garvey WT. Skeletal muscle HNE is related to insulin resistance in sedentary individuals. FASEB J 24:1038.9, 2010. Experimental Biology meetings, Anaheim CA, 2010

140. Grapov D, Adams SH, Garvey WT, Lok KH, Newman JW. Type 2 Diabetes-associated changes in the plasma lipidome in obese women FASEB J 24:542.1, 2010. Experimental Biology meetings, Anaheim CA, 2010

141. Gonzalez Gonzalez JG, Hernandez-Triana E, Rosenstock J, Garvey WT, Goldberg RB, Handelsman Y, Jones MR, Abby SL, Lai Y-L, Jin X, Misir S, Nagendran S. The Use of Colesevelam HCl for Patients with Prediabetes and Hypercholesterolemia in Colombia and Mexico. Third World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy Meeting), Prague, Czech Republic, May 13-16, 2010

142. Hernandez-Triana E, Gonzalez Gonzalez JG, Rosenstock J, Garvey WT, Goldberg RB, Handelsman Y, Jones MR, Abby SL, Lai Y-L, Jin X, Misir S, Nagendran S. Metformin + Colesevelam HCl Provides Greater Glycemic Control Than Metformin Alone in Newly Diagnosed Patients With Type 2 Diabetes Mellitus From Colombia and Mexico. Third World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy Meeting), Prague, Czech Republic, May 13-16, 2010

143. Garvey WT, Gadde K, Peterson C, Day W. Weight loss with controlled release phentermine-topiramate (PHEN/TPM CR) drives improvements in obesity-related comorbidities in overweight and obese subjects over 12 months treatment. Third World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy Meeting), Prague, Czech Republic, May 13-16, 2010

144. Van Gaal LF, Garvey WT, Troupin B, Day WW. Phentermine/topiramate combination therapy significantly improves glucose impairment in overweight/obese patients. Third World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy Meeting), Prague, Czech Republic, May 13-16, 2010

145. Garvey WT, Bowden CH, Day WW. Once-daily, low-dose, controlled-release phentermine/topiramate demonstrates significant improvement in weight, related risk in overweight/.obese patients with comorbidities. Endocrine Reviews 31(Suppl. 1):S19-5, 2010. 92nd Annual Meeting & Expo of the Endocrine Society, San Diego CA, June 19-22, 2010

146. Tian L, Luo N, Zhu X, Chung BH, Garvey WT, Fu Y. Differential roles of adiponectin receptors in suppressing lipid accumulation and inflammation in human macrophage foam cells. Diabetes 59 (Suppl. 1):A244, 2010. American Diabetes Association Meetings, Orlando FL, 2010

147. Divers J, Liu L, Garvey WT, Sale MM. Admixture mapping of type 2 diabetes and lipoprotein subclasses in Gullah-speaking African Americans in Project SuGAR. Diabetes 59 (Suppl. 1):A337, 2010. American Diabetes Association Meetings, Orlando FL, 2010.

49

148. Luo N, Chung BH, Klein RL, Garvey WT, Fu Y. Lipid metabolism modulated by macrophage adiponectin expression in vivo. Diabetes 59 (Suppl. 1):A433, 2010. American Diabetes Association Meetings, Orlando FL, 2010

149. Abby SL, Garvey WT, Handelsman Y, Fonseca VA, Goldberg RB, Rosenstock J, Jones MR, Markiewicz M, Jin X, Misir S, Nagendran S. The safety and tolerability of metformin + colesevelam in drug naïve patients with early type 2 diabetes mellitus. Diabetes 59 (Suppl. 1):A173, 2010. American Diabetes Association Meetings, Orlando FL, 2010

150. Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, Lai Y-L, Jin X, Misir S, Nagendran S, Jones MR. Initial combination therapy with metformin + colesevelam safely achieves glycemic and lipid goals with less diarrhea in early type 2 diabetes mellitus. Diabetes 59 (Suppl. 1):A187, 2010. American Diabetes Association Meetings, Orlando FL, 2010

151. Garvey WT, Gadde K, Wilson LF, Peterson C. Improvements in dyslipidemia and other cardiometabolic disease risk factors with low-dose, controlled-release phentermine/topiramate (PHEN/TPM). Diabetes 59 (Suppl. 1):A290-A291, 2010. American Diabetes Association Meetings, Orlando FL, 2010

152. Zhu X, Liu J, Walton RG, Thalacker-Mercer A, Tian L, Bamman MM, Garvey WT. Effects of resistance exercise and aging on NR4A protein levels in skeletal muscle. Diabetes 59 (Suppl. 1):A319-A320, 2010. American Diabetes Association Meetings, Orlando FL, 2010

153. Walton RG, Hill HS, Wu X, Zhu X, Liu J, Luo N, Fu Y, Garvey WT. Metabolic effects of adipocyte-specific NR4A3 over-expression in mice. Diabetes 59 (Suppl. 1):A394, 2010. American Diabetes Association Meetings, Orlando FL, 2010

154. Garvey WT, Gadde K, Tam P, Peterson C. Changes in insulin sensitivity in overweight/obese patients treated with low-dose, controlled-release phentermine/topiramate (PHEN/TPM). Diabetes 59 (Suppl. 1):A481, 2010. American Diabetes Association Meetings, Orlando FL, 2010

155. Liu J, Thalacker-Mercer A, Zhu X, Walton RG, Bamman MM, Garvey WT. Muscle TRIB3 protein expression and insulin sensitivity during resistance training in young and elderly subjects. Diabetes 59 (Suppl. 1):A321, 2010. American Diabetes Association Meetings, Orlando FL, 2010

156. Hill HS, Liu J, Irons JH, Gundberg CM, Garvey WT. Osteocalcin effects on cytokine secretion by adipose tissue and glucose uptake in L6 muscle cells: linking the skeleton with insulin resistance and inflammation. Diabetes 59 (Suppl. 1):A395, 2010. American Diabetes Association Meetings, Orlando FL, 2010

157. Goldberg RB, Garvey WT, Fonseca VA, Handelsman Y, Hernandez-Triana E, Jones MR, Abby SL, Jin X, Misir S, Nagendran S, Rosenstock J. Colesevelam in Combination with Metformin Significantly Reduces Low-Density Lipoprotein Particle Concentration in Patients with Early Type 2 Diabetes. Circulation 122:A13046, 2010. American Heart Association meetings, Chicago OL, 2010

158. Van Gaal LF, Garvey WT, Troupin B, Day WW. Phentermine/topiramate combination therapy significantly improves glucose impairment in overweight/obese patients. Diabetologia 53 (Suppl. 1):S308, 2010. European Association for the Study of Diabetes (EASD) meetings, Stockholm, Sweden, 2010

159. Garvey WT, Troupin B, Day WW. Once-daily, low-dose, controlled-release phentermine/topiramate results ij significant clinical improvements in overweight/obese patients with type 2 diabetes. Diabetologia 53 (Suppl. 1):S308, 2010. European Association for the Study of Diabetes (EASD) meetings, Stockholm, Sweden, 2010

160. Hernandez-Triana E, Garvey WT, Goldberg RB, Handelsman Y, Fonseca VA, Jones MR, Abby SL, Markiewicz M, Jin X,. Misir S, Nagendran S, Rosenstock J. Initial treatment with metformin + colesevelam HCl provides greater glycemic control than metformin alone in Hispanic patients with type 2 diabetes mellitus. Diabetologia 53 (Suppl. 1):S358, 2010. European Association for the Study of Diabetes (EASD) meetings, Stockholm, Sweden, 2010

161. Handelsman Y, Goldberg RB, Rosenstock J, Garvey WT, Fonseca VA, Hernandez-Triana E, Jones MR, Lai Y-L, Jin X, Misir S, Nagendran S, Abby SL. Colesevelam for Hispanic patients with

50

hypercholesterolemia and prediabetes. Diabetologia 53 (Suppl. 1):S511, 2010. European Association for the Study of Diabetes (EASD) meetings, Stockholm, Sweden, 2010

162. Garvey WT, Peterson C, Troupin B. Low-dose controlled-release phentermine/topiramate (PHEN/TPM CR) for weight loss and management of type 2 diabetes mellitus (T2DM). Obesity 18 (Suppl. 1): S154, 2010. Obesity Society meetings, San Diego CA, 2010

163. Garvey WT, Goldberg RB, Handelsman Y, Fonseca VA, Hernandez-Triana E, Jones MR, Abby SL, Jin X, Misir S, Nagendran S, Rosenstock J. Colesevelam significantly reduces low density lipoprotein particle concentration in patients with Prediabetes and hypercholesterolemia. World Congress on Insulin Resistance (WCIR) meetings, Los Angeles CA, 2010

164. Chen W-M, Hang Y, Chen F, Keene KL, Divers J, Mychaleckyj JC, Nayak U, Hou X, Kamen DL, Hunt KJ, Spruill IJ, Fernandes JK, Cushman M, Garvey WT, Sale MM. A Genome-Wide Association Scan of Lipids and Lipoprotein subclasses in African Americans Including the Sea Island Gullah, American Society Human Genetics, Montreal, Canada, 2011

165. Huang Y, Chen WM, Hou X, Nayak U, Mychaleckyj, JC, Chen F, Keene KL, Lok KH, Kamen DL, Hunt KJ, Spruill IJ, Fernandes JK, Garvey WT, Sale MM (2011). The Sea Island Gullah African Americans: Connecting Sierra Leone and America (poster). 12th International Congress of Human Genetics, Montreal.

166. Liu J, Moellering D, Zhang W, Hill HS, Garvey WT. The role of TRIB3 in regulation of insulin sensitivity and glucose oxidation under short term nutrient excess and fasting. Diabetes 60 (Suppl. 1):A92, 2011. American Diabetes Association Meetings, San Diego CA, 2011

167. Liu Q, Tian L, Xu L, Fu Y, Garvey WT. 6-mercaptopurine, an activator of the orphan nuclear receptor NR4A3, modulates glucose transport in L6 skeletal muscle cells. Diabetes 60 (Suppl. 1):A408, 2011. American Diabetes Association Meetings, San Diego CA, 2011

168. Luo N, Chung H, Garvey WT, Fu Y. Adiponectin actions enhanced by macrophage adiponectin receptor expression. Diabetes 60 (Suppl. 1):A475, 2011. American Diabetes Association Meetings, San Diego CA, 2011

169. Garvey WT, Henry RR, Peterson CA, Bowden CH. Weight loss with controlled-release phentermine/topiramate (PHEN/TPM CR) reverses metabolic syndrome (MetS) and improves associated traits. Diabetes 60 (Suppl. 1):A506, 2011. American Diabetes Association Meetings, San Diego CA, 2011

170. Ryan DH, Garvey WT, Troupin B, Day WW. Diabetes prevention and normalization of fasting glucose in subjects with Prediabetes using controlled-release phentermine/topiramate (PHEN/TPM CR) in a two-year weight loss intervention. Diabetes 60 (Suppl. 1):A509, 2011. American Diabetes Association Meetings, San Diego CA, 2011

171. Kushner RF, Garvey WT, Troupin B, Day WW. Long-term weight loss and improvement in glycemic parameters with low-dose, controlled-release phentermine/topiramate (PHEN/TPM CR). Diabetes 60 (Suppl. 1):A515, 2011. American Diabetes Association Meetings, San Diego CA, 2011

172. Garvey WT, Troupin B, Day WW. Decreased Progression to Diabetes in Subjects With Prediabetes After 2 Years of Treatment With Controlled-Release Phentermine/Topiramate. Diabetologia 54 (Suppl. 1):S371, 2011. European Association for the Study of Diabetes (EASD) meetings, Lisbon, Portugal, 2011

173. Toplak H, Rossner S, Garvey WT, Troupin B, Bowden CH. Long-term Weight Loss With Controlled-Release Phentermine/Topiramate Reverses Metabolic Syndrome and Improves Associated Traits. Diabetologia 54 (Suppl. 1):S370, 2011. European Association for the Study of Diabetes (EASD) meetings, Lisbon, Portugal, 2011

174. Garvey WT, Peterson C, Troupin B. Weight loss with low-dose, controlled-release phentermine/topiramate therapy improves glycemic status and prevents progression to type 2 diabetes mellitus. European Congress of Obesity meetings, Istanbul, Turkey, 2011

175. Garvey WT, Day WW, Bowden CH. Long-tern treatment with controlled-release phentermine/topiramate demonstrates sustained weight loss over 108 weeks. European Congress of Obesity meetings, Istanbul, Turkey, 2011

51

176. Garvey WT, Najarian T, Peterson C. Significant weight loss with controlled release phentermine/topiramate (PHEN/TPM CR) is associated with significant reductions in use of concomitant medications for cardiometabolic diseases over 108 weeks. Obesity 19:abstract 594-P, 2011. Obesity Society meetings, Orlando FL, 2011

177. Pisprasert V, Garvey WT. Insulin sensitivity indices in European Americans and African Americans. American Society of Parenteral and Enteral Nutrition national meetings, Clinical Nutrition Week, 2012. Orlando FL, 2012

178. Huang Y, Chen W-M, Keene KL, Chen F, Nayak U, Hou X, Spruill IJ, Hunt KJ, Lok K, Divers J, Mychaleckyj JC, Kamen DL, Post W, Rich SS, Rotter JI, Gilkeson GS, W. Garvey WT, Cushman M, Sale MM. Genome-wide association studies of NMR-based lipoprotein subclasses in African American populations elucidate subfractions affected by SNP variation. American Society of Human Genetics national meetings, San Francisco, CA, 2012

179. Campbell C, Chandler CJ, Burnett DJ, Souza EC, Casazza GA, Fiehn O, Hoppel CL, Newman JW, Garvey WY, Hunter GR, Keim NL, Fernandez JR, Adams SH. Metabolite signatures reflective of muscle metabolism and insulin sensitivity following a diet and fitness intervention in obese, sedentary, insulin-resistant women FASEB J 26:637.9, 2012. Experimental Biology meetings, San Diego CA, 2012

180. Sajuthi S, Ramos PS, Huang Y, Divers J, Kaufman KM, Harley JB, Kimberly RP, Kamen DL, Langefeld CD, Sale MM, Garvey WT, Gilkeson GS. Identification of regions under selection in the Gullah African American population. American Society for Human Genetics meeting, San Francisco CA, 2012

181. Garvey WT, Rossner S, Bowden CH. Weight loss and reduction in antidiabetic medications with phentermine plus extended release topiramate over 2 years. European Congress on Obesity meetings, Lyons, France, 2012

182. Ryan D, Garvey WT, Day WW. Achievement of composite of recommended goals in obese subjects with type 2 diabetes mellitus using extended-release phentermine/topiramate in a 56-week weight loss intervention. Endocrine Society meetings, Houston TX, 2012

183. Guo F, Zhang W, Garvey WT. Differentially segmented association between HbA1c and CHD risks and FPG across ethnicities. Diabetes 61 (Suppl. 1A):LB16, 2012. Late-breaking abstract presented at the American Diabetes Association Meetings, Philadelphia, PA, June 8-12, 2012.

184. Zhang W, Liu J, Tian L, Liu Q, Fu Y, Garvey WT. TRIB3 mediates glucose-induced insulin resistance and its induction by high glucose requires the hexosamine biosynthetic pathway. Diabetes 61 (Suppl. 1): A63, 2012. Oral abstract presented at the American Diabetes Association Meetings, Philadelphia, PA, June 8-12, 2012

185. Tian L, Steverson D, Zhang W, Fu Y, Garvey WT. Adiponectin receptors and adiponectin action in circulating human CD14+ monocytes in patients with diabetes and cardiovascular disease. Diabetes 61 (Suppl. 1):A117, 2012. Poster presented at the American Diabetes Association Meetings, Philadelphia, PA, June 8-12, 2012

186. Steverson D, Tian L, Garvey WT. Tribble 3 is induced in macrophages during foam cell formation and facilitates lipid accumulation in a TLR4 manner. Diabetes 61 (Suppl. 1):A131, 2012. Poster presented at the American Diabetes Association Meetings, Philadelphia, PA, June 8-12, 2012

187. Liu Q, Zhu X, Xu L, Fu Y, Garvey WT. Small molecule agonists of NR4A3 augment glucose transport system activity and AS160 phosphorylation in L6 muscle cells. Diabetes 61 (Suppl. 1):A411, 2012. Poster presented at the American Diabetes Association Meetings, Philadelphia, PA, June 8-12, 2012

188. Luo N, Chung BH, Garvey WT, Fu Y. Overexpression of adiponectin receptor improves the phenotypes of TALLYHO diabetic mice. Diabetes 61 (Suppl. 1):A415, 2012. Poster presented at the American Diabetes Association Meetings, Philadelphia, PA, June 8-12, 2012

189. Zhu X, Walton RG, Garvey WT. The role of NR4A3 in the modulation of in vivo insulin sensitivity as a function of aging and acute exercise. Diabetes 61 (Suppl. 1):A420, 2012. Poster presented at the American Diabetes Association Meetings, Philadelphia, PA, June 8-12, 2012

52

190. Xu L, Cui X, Garvey WT. Nuclear receptor NR4A3 augments glucose transport system activity in L6 myocytes in part via AMPK activation. Diabetes 61 (Suppl. 1):A441, 2012. Poster presented at the American Diabetes Association Meetings, Philadelphia, PA, June 8-12, 2012

191. Moellering DR, Liu Q, Rigsby DY, Yang Y, Pisprasert V, Grams JM, Garvey WT. Skeletal muscle uncoupled mitochondrial respiration is decreased by short-term very low calorie diet. Diabetes 61 (Suppl. 1):A470, 2012. Poster presented at the American Diabetes Association Meetings, Philadelphia, PA, June 8-12, 2012

192. Garvey WT, Bowden CH. Diabetes prevention in subjects with prediabetes using controlled-release phentermine/topiramate (PHEN/TPM CR) over 2 years. Diabetes 61 (Suppl. 1):A517, 2012. Poster presented at the American Diabetes Association Meetings, Philadelphia, PA, June 8-12, 2012.

193. Ramos PS, Sajuthi S, Huang Y, Kamen DL, Divers J, Kaufman KM, Harley JB, Kimberly RP, Langefeld CD, Sale MM, Garvey WT, Gilkeson GS. Genes Associated with Systemic Lupus Erythematosus Show Evidence of Selection in the Gullah African American Population. 76th annual meeting of the American College of Rheumatology, Washington, DC, November 9-14, 2012. Arthritis Rheum 64 (Suppl 10):2274, 2012

194. Heyward FD, Walton RG, Carle MS, Coleman MA, Garvey WT, Sweatt JD. Adult Mice Maintained on a High-Fat Diet Exhibit Object Location Memory Deficits and Altered Hippocampal Gene Expression. Obesity 20:S116 (A281), 2012.

195. Garvey WT, Kushner RF, Day WW. Weight Loss (WL) and Reduction in Unique Antidiabetic Medication Use in Obese Subjects With Type 2 Diabetes Mellitus (T2DM) Using Extended-Release Phentermine/Topiramate (PHEN/TPM ER) Over 2 Years. Obesity 20:S155 (A459), 2012

196. Garvey WT, Troupin B. Improvements in weight and glycemia in obese and overweight subjects receiving phentermine and topiramate extended-release when stratified by baseline HbA1c. Endocrine Practice, abstract supplement, # 608, page 103, 2013

197. Guo F, Garvey WT. A new cardiometabolic disease staging system to guide treatment for obesity using a complications centric approach - validation using CARDIA and NHANES data. Endocrine Practice, abstract supplement, #603, page 100, 2013. American Diabetes Association Meetings, Chicago IL, June 21-25, 2013

198. Guo F, Zhang W, Moellering DR, Garvey WT. The Impact of HbA1c Level on All-Cause and CVD Mortality in Patients with Diabetes Diabetes 62 (Suppl 1):A278, 2013. American Diabetes Association Meetings, Chicago IL, June 21-25, 2013

199. Sajuthi S, Divers J, Huang Y, Nayak U, Chen WM, Hunt KJ, Kamen DL, Gilkeson GS, Fernandes JK, Spruill IJ, Langefeld CD, Garvey WT, Sale MM, Ramos PS. Identification of signals of recent selection in the Sea Island Gullah African Americans (Abstract #2051W). Presented at the 63rd Annual Meeting of the American Society of Human Genetics, October 23, 2013 in Boston, MA

200. Guo F, Zhang W, Moellering DR, Garvey WT. Validation of a Staging System for Cardiometabolic Disease to Guide Treatment of Obesity. Diabetes 62 (Suppl 1):A2122, 2013. American Diabetes Association Meetings, Chicago IL, June 21-25, 2013

201. Garvey WT, Day WW. Contributions of Percent and Absolute Weight Loss (WL) to Improvements in Fasting Glucose and Insulin Sensitivity Diabetes 62 (Suppl 1):A2133, 2013. American Diabetes Association Meetings, Chicago IL, June 21-25, 2013

202. Zhang W, Tian L, Steverson D, Young ME, Garvey WT. Time-of-Day-Dependent Regulation of the Metabolic Modulator TRIB3: Influence of the Cardiac Circadian Clock Diabetes 62 (Suppl 1):A1785, 2013. American Diabetes Association Meetings, Chicago IL, June 21-25, 2013

203. Liu Q, Zhang W, Fu Y, Garvey WT. Novel Agonists of the NR4A3 Orphan Nuclear Receptor Augment Glucose Transport System Activity in Skeletal Muscle Cells and Lower Blood Glucose in db/db Mice Diabetes 62 (Suppl 1):A1787, 2013. American Diabetes Association Meetings, Chicago IL, June 21-25, 2013

204. Ramos PS, Sajuthi S, Divers J, Huang Y, Nayak U, Chen WM, Hunt KJ, Kamen DL, Gilkeson GS, Fernandes JK, Spruill IJ, Langefeld CD, Garvey WT, Sale MM (2013, accepted). Identification of

53

regions under positive selection in the Gullah African American population. Presented at the 63rd Annual meeting of the American Society of Human Genetics, October 25, 2013 in Boston, MA.

205. Satria S, Divers J, Huang Y, Nayak U, Chen WM, Hunt KJ, Kamen DL, Gilkeson GS, Fernandes JK, Spruill IJ, Garvey WT, Sale MM, Ramos PS. Identification Of Autoimmune Disease Genes In Regions Under Selection In The Gullah African American Population Of South Carolina. Abstract 153, 2013 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting. San Diego, CA, October 25-30, 2013

206. Guo F Garvey WT. Validation of a cardiometabolic disease staging (CMDS) system for obesity. Obesity 20:S264 (T-301-P), 2013

207. Ramos PS, Sajuthi S, Divers J, Huang Y, Nayak U, Chen WM, Hunt KJ, Kamen DL, Gilkeson GS, Fernandes JK, Spruill IJ, Garvey WT, Sale MM, Langefeld CD. Identification of autoimmune functional variants under positive selection in the Gullah African American population of South Carolina. Arthritis Rheum 2014;66 Suppl 11:S1292 (Abstract#2956).

208. Ramos PS, Sajuthi S, Divers J, Huang Y, Nayak U, Chen WM, Hunt KJ, Kamen DL, Gilkeson GS, Fernandes JK, Spruill IJ, Garvey WT, Sale MM, Langefeld CD. Identification of functional variants under positive selection in the Gullah African American population of South Carolina (Abstract #1976M). Presented at the 64th Annual meeting of the American Society of Human Genetics, October 20, 2014 in San Diego, CA

209. Langefeld CD, Sajuthi S, Divers J, Huang Y, Nayak U, Chen WM, Teklehaimanot Teklehaimanot KJ, Kamen DL, Gilkeson GS, Fernandes JK, Spruill IJ, Garvey WT, Sale MM, Ramos PS. Identification of functional signals of recent selection in the Sea Island Gullah African Americans (Abstract #1970M). Presented at the 64th Annual meeting of the American Society of Human Genetics, October 20, 2014 in San Diego, CA

210. Smith SR, Garvey WT, Greenway F, Soliman W, Zhou S, Fain R, Fujioka K, Aronne L. Combination weight management pharmacotherapy with lorcaserin and immediate release phentermine. Obesity Week (national meetings of the Obesity Society and ASMBS), Boston MA, November 2-7, 2014

211. Steverson D, Tian L, Fu Y, Garvey WT. Tribble 3 contributes to foam cell formation and programs macrophages towards lipid accumulation over inflammation. Diabetes 63 (suppl 1): A108, 2014. 74th Scientific Session of the American Diabetes Association. San Francisco CA, June 13-17, 2014

212. Basu A, Jenkins AJ, Stoner JA, Thorpe S, Klein R, Lopes-Virella MF, Garvey WT, Lyons T, and DCCT/EDIC Research Group. Plasma homocysteine and carotid intima-media thickness in Type 1 diabetes. Diabetes 63(suppl 1): A376, 2014. 74th Scientific Session of the American Diabetes Association. San Francisco CA, June 13-17, 2014

213. Basu A, Jenkins AJ, Zhang Y, Stoner JA, Klein R, Lopes-Virella MF, Garvey WT, Lyons TJ, and DCCT/EDIC Research Group. Associations of nuclear magnetic resonance-determined lipoprotein subclasses with carotid intima-media thickness in Type 1 diabetes: a prospective study. Diabetes 63(suppl 1): A410, 2014. 74th Scientific Session of the American Diabetes Association. San Francisco CA, June 13-17, 2014

214. Zhang W, Jariwala RH, Kim T, Wu M, Garvey WJ, Tian L, Steverson D, Yang Q, Fu Y, Garvey WT. Muscle specific TRIB3 overexpression produces weight gain and insulin resistance in mice, and exacerbates glucose induced insulin resistance in diabetes. Diabetes 63(suppl 1): A440, 2014. 74th Scientific Session of the American Diabetes Association. San Francisco CA, June 13-17, 2014

215. Guo F, Garvey WT. The healthy obese are alive and well: reduced risk of diabetes, CHD, and mortality. Diabetes 63(suppl 1): A512, 2014. 74th Scientific Session of the American Diabetes Association. San Francisco CA, June 13-17, 2014

216. Ma E, Luo N, Tian L, Zhang W, Steverson D, Fu Y, Garvey WT. Role of micro-RNAs -150 and -33 in human insulin resistance. Diabetes 63(suppl 1): A514, 2014. 74th Scientific Session of the American Diabetes Association. San Francisco CA, June 13-17, 2014

54

217. Smith SR, Garvey WT, Greenway F, Soliman W, Zhou S, Fain R, Fujioka K, Louis Aronne L. Combination Weight Management Pharmacotherapy with Lorcaserin and Immediate Release Phentermine. National meetings of the Society for General Internal Medicine (SGIM), Toronto, Canada, April 22-25, 2015.

218. Zhang W, Jariwala R, Kim T, Wu M, Garvey WJ, Kang M, Steverson D, Ma E, Yang Q, Fu Y, Garvey WT. In vivo impact of muscle specific TRIB3 overexpression and knockout on glucose-induced diabetes in vivo. Diabetes 64(Suppl 1):A85, 2015. American Diabetes Association Meetings, Boston MA, June 5-9, 2015

219. Basu A, Jenkins A, Zhang Y, Stoner J, Klein R, Lopes-Virella MF, Garvey WT, Lyons TJ, The DCCT/EDIC Research group. Nuclear magnetic resonance determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes: a prospective study. Diabetes 64(Suppl 1):A450, 2015. American Diabetes Association Meetings, Boston MA, June 5-9, 2015

220. Ma E, Kang M, Cui X, Zhang W, Fu Y, Garvey WT. Circulating microRNA species and role in human insulin resistance. Diabetes 64(Suppl 1):A498, 2015. American Diabetes Association Meetings, Boston MA, June 5-9, 2015

221. Kahan S, Garvey WT, Dvorak R. Effects of phentermine and topiramate extended release (PHEN/TPR ER) on weight loss (WL) in patients with a baseline body mass index (BMI) ≥45 kg/m2. Obesity Week (national meetings of the Obesity Society and ASMBS), Los Angeles CA, November 2-7, 2015

222. Kang M, Zhang W, Ma E, Fu Y, Garvey WT. In vov miR-150 KO mice show metabolic benefits. Obesity Week (national meetings of the Obesity Society and ASMBS), Los Angeles CA, November 2-7, 2015

223. O’Neil PM, Garvey WT, Gonzalez-Campoy JM, Mora PF, Ortiz V, Guerrero G, Claudius B, Pi-Xunyer X. Hispanic people achieve clinically significant weight loss with liraglutide 3.0 mg for weight management. Endocrine Practice 21(suppl 2):121, 2015. National meetings of the American Association of Clinical Endocrinologists, Nashville TN, May 2015

224. Ramos PS, Sajuthi S, Divers J, Kaufman KM, Nayak U, Chen W_M, Hunt KJ, Kamen DL, Gilkeson GS, Fernandes JK, Spruill IJ, Kimberly RP, Harley JB, Garvey WT, Sale MM, Langefeld CD. Integrating evidence for genetic association and natural selection helps detects new systemic lupus erythematosus risk loci in African Americans. National meetings of the American College of Rheumatology/Association of Rheumatology Health Professionals, San Francisco CA, November 6-11, 2015. [abstract#88]. Arthritis Rheumatol. 67 (suppl 10), 2015

225. Ramos PS, Sajuthi S, Divers J, Nayak U, Chen W-M, Hunt KJ, Kamen DL, Gilkeson GS, Fernandes JK, Spruill IJ, Garvey WT, Sale MM, Langefeld CD. Signatures of geographically restricted adaptation in the Sea Island Gullah African Americans. 13th International Congress of Human genetics. Kyoto, Japan, April 5, 2016.

226. Basu A, Jenkins A, Stoner J, Zhang Y, Klein R, Lopes-Virella MF, Garvey WT, Alaupovic P, Lyons TJ, DCCT/EDIC Research Group. Apolipoprotein-defined lipoprotein subclasses, carotid intima-medial thickness, and diabetic nephropathy in Type 1 Diabetes. Diabetes 65(Suppl 1):A384, 2016. American Diabetes Association Meetings, New Orleans LA, June 10-14, 2016

227. Carson AP, Muntner P, Selvin E, Carnethon MR, Jacobs DR, Shay CM, Li X, Gross MD, Garvey WT, Lewis CE. Total fat mass and BMI exhibit varying associations with glycemic markers. Diabetes 65(Suppl 1):A407, 2016. American Diabetes Association Meetings, New Orleans LA, June 10-14, 2016

228. Liu X, Zhang W, Kang M, Young ME, Garvey WT. Tissue-specific diurnal patterns of TRIB3 expression coordinate whole body metabolic homeostasis: role of the cardiac circadian clock. Diabetes 65(Suppl 1A):LB62, 2016. American Diabetes Association Meetings, New Orleans LA, June 10-14, 2016

229. Kang M, Garvey WT….. miR-150 KO mice demonstrate improved systemic metabolism and adipose tissue function on a high fat diet." Obesity Week (national meetings of the Obesity Society and ASMBS), New Orleans, October 31-November 4, 2016

55

230. O’Neil PM, Garvey WT, ……Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes. Obesity Week (national meetings of the Obesity Society and ASMBS), New Orleans, October 31-November 4, 2016

231. Garvey WT,……Effects of Canagliflozin Versus Glimepiride on Serum Leptin and Adiponectin in Patients With Type 2 Diabetes Mellitus. Obesity Week (national meetings of the Obesity Society and ASMBS), New Orleans, October 31-November 4, 2016

232. Minsung Kang, Xiaobing Liu, Wei Zhang, Elizabeth Ma, Yuchang Fu, W. Timothy Garvey. miR-150 Influences Body Weight, Insulin Sensitivity, and Systemic Metabolism in Mice. 77th National Meetings of the American Diabetes Association, June 9-13, 2017, San Diego, California

233. Xiaobing Liu, Minsung Kang, Yuchang Fu, and W. Timothy Garvey. Role of the Tribbles 3 Promoter and SP1 in Glucose-Induced Gene Expression and Glucose Toxicity in Diabetes. 77th National Meetings of the American Diabetes Association, June 9-13, 2017, San Diego, California

234. Luc Van Gaal, W. Timothy Garvey, Lawrence A. Leiter, Ujjwala Vijapurkar, James List, Robert Cuddihy, Jimmy Ren, Michael J. Davies. Effects of Canagliflozin Versus Glimepiride on Inflammatory Biomarkers and Chemokines in Patients With Type 2 Diabetes Mellitus 66TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN COLLEGE OF CARDIOLOGY (ACC); MARCH 17-19, 2017; WASHINGTON, DC.

235. LAWRENCE A. LEITER, GUILLAUME CHARPENTIER, LOUIS CHAYKIN, W. TIMOTHY GARVEY, MARK L. WARREN, JULIE D. KARSBØL, DESIRÉE THIELKE, LUIS MASMIQUEL, Semaglutide Reduces Body Weight across Baseline BMI Subgroups across SUSTAIN 1-5. Diabetes 66(Suppl 1):A293, 2017. National Meetings of the American Diabetes Association, June 9-13, 2017, San Diego, California

236. ARPITA BASU, ALICIA JENKINS, JULIE STONER, YING ZHANG, RICHARD KLEIN, MARIA F. LOPES-VIRELLA, W. TIMOTHY GARVEY, DAVID S. SCHADE, JAMIE R. WOOD, PETAR ALAUPOVIC, TIMOTHY J. LYONS, THE DCCT/EDIC RESEARCH GROUP. Prospective Associations of Apolipoprotein-Defined Lipoprotein Subclasses and Serum Apolipoproteins with Carotid Intima-Media Thickness in Type 1 Diabetes. Diabetes 66(Suppl 1):A116, 2017. National Meetings of the American Diabetes Association, June 9-13, 2017, San Diego, California

237. YING ZHANG, ALICIA J. JENKINS, JULIE A. STONER, ARPITA BASU, RICHARD L. KLEIN, MARIA F. LOPES-VIRELLA, W. TIMOTHY GARVEY, BRUCE A. PERKINS, NAINA S. GREGORY, IAN H. DE BOER, TIMOTHY J. LYONS, THE DCCT/EDIC RESEARCH GROUP. Uric Acid and Incident Albuminuria in Type 1 Diabetes Patients in DCCT/EDIC: A U-Shaped Association. 77th National Meetings of the American Diabetes Association, June 9-13, 2017, San Diego, California

238. Fowler LA, Tay J, Goree LL, Goss AM, Bush NC, Garvey WT, Gower BA. The influence of visceral adipose tissue accumulation on the accuracy of surrogate indices for insulin sensitivity. Diabetes 66(Suppl 1):A66, 2017. National Meetings of the American Diabetes Association, June 9-13, 2017, San Diego, California

239. Tay J, Goss AM, Garvey WT, Gower BA. Race affects the association of obesity measures with insulin sensitivity. Diabetes 66(Suppl 1):A86, 2017. National Meetings of the American Diabetes Association, June 9-13, 2017, San Diego, California

238.`ARPITA BASU, IONUT BEBU, ALICIA JENKINS, JULIE STONER, YING ZHANG, RICHARD L.

KLEIN, MARIA F. LOPES-VIRELLA, W. TIMOTHY GARVEY, MATTHEW BUDOFF, TIMOTHY LYONS, DCCT/EDIC RESEARCH GROUP. Serum Apolipoprotein C-III and Cardiovascular Events in Type 1 Diabetes. 78th National Meetings of the American Diabetes Association, June 22-26, 2018, Orlando FL

239. ARPITA BASU, BARBARA BRAFFETT, ALICIA JENKINS, IONUT BEBU, RICHARD L. KLEIN, MARIA F. LOPES-VIRELLA, SAMUEL DAGOGO-JACK, TREVOR J. ORCHARD, AMISHA WALLIA, JOHN LACHIN, W. TIMOTHY GARVEY, TIMOTHY LYONS, DCCT/EDIC RESEARCH GROUP. Uric Acid and Cardiovascular Disease in Type 1 Diabetes. 78th National Meetings of the American Diabetes Association, June 22-26, 2018, Orlando FL

56

240. XIAOBING LIU, MINSUNG KANG, W. TIMOTHY GARVEY. The Induction of TRIB3 Causing Glucose Toxicity in Muscle Requires the O-GlcNAcylation of SP1. 78th National Meetings of the American Diabetes Association, June 22-26, 2018, Orlando FL

250. MINSUNG KANG, JESSICA P. ANTIPENKO, XIAOBING LIU, KIRK M. HABEGGER, W. TIMOTHY GARVEY. Maternal Dietary Manipulation Programs Offspring’s Metabolism. 78th National Meetings of the American Diabetes Association, June 22-26, 2018, Orlando FL

260. LUA WILKINSON, TAPAN MEHTA, W. TIMOTHY GARVEY. Cardiometabolic Disease Risk Assessment Predicts Incident Diabetes in a Large and Diverse Population. 78th National Meetings of the American Diabetes Association, June 22-26, 2018, Orlando FL

270. Lua Wilkinson, W. Timothy Garvey. Abdominal Obesity Increases Risk of Diabetes at Lower BMIs: What Does this Mean and For Whom?. Obesity Week/National Meetings of the Obsity Society, October 29-November 2, 2017, Washington DC

280. Luc Van Gaal, W. Timothy Garvey, Lawrence A. Leiter, Ujjwala Vijapurkar, James List, Robert Cuddihy, Jimmy Ren, Michael J. Davies. Effects of Canagliflozin Versus Glimepiride on Adipokines, Inflammatory Biomarkers, and Chemokines in Patients With Type 2 Diabetes Mellitus. 53RD ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD); SEPTEMBER 2017; LISBON, PORTUGAL

Not complete after 2018 NON-SCIENTIFIC PUBLICATIONS 1. Garvey T. “Zion”. Poem published in Humanitas, Medical University of South Carolina, 6:28, 2002. 2. Garvey WT. “Thoughts While Waiting in the Carpool Line”. Letter to the editor, Charleston Post &

Courier, 2002, and winner of newspaper’s the Golden Pen Award, 2002. PATENTS, DISCLOSURES, and LICENSURES 1. Application number pending, US Patent Office. “Methods for the Treatment of Insulin Resistance and

Disease States Characterized by Insulin Resistance”. March 24, 2005. 2. Intellectual property disclosure licensed to Hoffman La-Roche, “Methods for the Treatment of Insulin

Resistance and Disease States Characterized by Insulin Resistance”, June 1, 2004 3. Intellectual property disclosure licensed to Hoffman La-Roche, “Markers of Insulin Resistance”,

January, 2005. 4. Serial Number 60078972, US Patent Office. “Gene Variants for Human Uncoupling Proteins 2 & 3”,

April 27, 1998. INVITED LECTURES: 1984

57

1. Medical Grand Rounds: Loma Linda University, Loma Linda, CA. "Role of Insulin Receptors in Type II Diabetes Mellitus", 10/31/84.

2. Symposium: Twentieth Annual Staff Seminar; California Hospital Medical Center, Los Angeles, CA. "Newer Forms of Diabetes Mellitus", 11/9/84.

1985 3. Symposium: Palomar Memorial Hospital, Escondido, CA. "Current Concepts in the Etiology,

Epidemiology, and Diagnosis of Diabetes", 4/27/85. 1986 4. Symposium: 9th Annual San Diego Postgraduate Assembly in Surgery: A Multidisciplinary Approach to

Gastrointestinal Problems; USCD Continuing Medical Education Program, San Diego, CA. "Clinical Features and Diagnosis of Hyperinsulinism", 1/20/86.

5. Seminar: Endocrine-Metabolic Section, Medical College of Wisconsin, Milwaukee, WI. "Synergistic Action of Glucose and Insulin on Hexose Transporters in Adipocytes: Relevance to Type II Diabetes", 2/13/86.

6. Lecture: San Diego Chapter of the American Diabetes Association, El Centro, CA. "Current Research in Diabetes", 2/18/86.

7. Seminar: Metabolism Division, Washington University School of Medicine, Barnes Hospital, St. Louis, MO. "The Role of Glucose Transport Proteins in Insulin Resistance", 11/3/86.

1987 8. Symposium: Nobel Conference on the Pathogenesis of Non-Insulin-Dependent Diabetes Mellitus,

Karolinska Institute, Stockholm, Sweden. "Pathogenesis and Cellular Mechanisms of Insulin Resistance", 2/26/87.

9. Symposium: From Obesity to Diabetes, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. "Correlations Between In Vivo and In Vitro Actions of Insulin in Obesity and Diabetes", 9/22/87.

10. Symposium: Sulfonylureas: Cellular Mechanisms of Action. Baylor College of Medicine, Houston, TX. "Impact of Sulfonylurea and Insulin Treatment on Insulin Resistance: Implications for Cellular Glucose Transport Proteins", 10/23/87.

1988 11. Seminar: Endocrine Research and Clinical Conference. Indiana University School of Medicine,

Indianapolis, IN. "The Role of Glucose Transporters in Non-Insulin-Dependent Diabetes Mellitus", 3/22/88.

12. Symposium: Fourth International Hvidore Symposium, Insulin Resistance - Theoretical and Clinical Aspects, Copenhagen, Denmark. "The Glucose Transporter in Insulin-Resistant Diabetes Mellitus", 5/3/88.

13. Seminar: Division of Endocrinology, Baylor College of Medicine, Houston, TX. "The Role of the Glucose Transporter in Insulin-Resistant States", 5/19/88.

14. Lecture: Professional Section Meeting; Southern California Affiliate of the American Diabetes Association, Los Angeles, CA. "Glucose Transport Proteins in Clinical States of Insulin Resistance", 5/26/88.

15. Seminar: Division of Endocrinology/Metabolism, State University of New York at Stony Brook, Stony Brook, NY. "Glucose Transporters and Insulin Resistance", 6/24/88.

16. Congress: 13th International Diabetes Federation Congress, Sydney, Australia. "Interactions of Glucose and Insulin in the Regulation of Insulin Sensitivity", 11/12/88.

1989 17. Symposium: Medical Sciences Liaison, Metabolic Diseases Meeting, The Upjohn Company, San

Antonio, TX, "The Role of Glucose Transporters in Diabetes Mellitus", 2/7/89.

58

18. Lecture: Medical and Clinical Staff of Clay County Hospital, Brazil, IN. "Diabetes Mellitus Update", 7/12/89.

19. Symposium: Diabetes Mellitus - Toward a Better Understanding, Postgraduate Conference sponsored by the Diabetes Research and Training Center of Indiana University School of Medicine, Indianapolis, IN. "Retinopathy", 9/13/89.

20. Seminar: Faculty of the School of Medicine, Evansville Center for Medical Education, Evansville, IN. "Cellular and Molecular Biology of Glucose Transport Proteins", 10/13/89.

21. Medical Grand Rounds: Indiana University School of Medicine, Indianapolis, IN. "Insulin Resistance and Newer Forms of Diabetes Mellitus", 12/13/89.

1990 22. Symposium: The First International Conference on Race, Ethnicity, and Health Challenges in Diabetes

and Hypertension, Case Western Reserve University, Cleveland, Ohio. "Molecular Pathogenesis of Insulin Resistance in Non-Insulin-Dependent Diabetes Mellitus", 5/11/90.

23. Symposium: 25th International Research Symposium of the American Diabetes Association, Woods Hole, MA. "How Does Hyperglycemia Cause Insulin Resistance: Results on Animal Studies", 9/26/90.

24. Seminar: John Hopkins School of Medicine, Division of Endocrinology and Metabolism and Department of Biochemistry, Baltimore, MD. "Glucose Transport Proteins and Insulin-Resistant States", 11/15/90.

1991 25. Symposium: Diabetes and Insulin Action; UCLA Keystone Symposia on Molecular Biology and Cellular

Biology, Park City, Utah. "Glucose transporters and insulin resistance in Type II diabetes mellitus", 1/24/91.

26. Seminar: The UpJohn Company, Metabolic Diseases Research Unit, Kalamazoo, Michigan. "Role of glucose transporters in clinical states of insulin resistance", 4/11/91.

27. Symposium: Regulation of Glucose Transport in Skeletal Muscle, FASEB 75th Annual Meeting, Atlanta, Georgia. "Studies with glucose transporter antibodies and cDNA: Effects of diabetes", 4/24/91.

28. Seminar: University of Chicago School of Medicine, Division of Endocrinology and Metabolism and Howard Hughes Institute, Chicago, Illinois. "Glucose Transporters, Insulin Resistance, and Non-Insulin Dependent Diabetes Mellitus", 5/13/91.

29. Lecture: 1991 Pfizer Awards Program, Awards Ceremonies for Pfizer Pharmaceutical Fellows and Scholars, New York, NJ. "The Role of Glucose Transporter Proteins in Insulin-Resistant Disease States", 5/17/91.

30. Seminar: Medical College of Virginia and Richmond Veterans Administration Medical Center, Section of Endocrinology and Metabolism, Richmond, VA. "Glucose Transporters, Insulin Resistance, and Non-Insulin-Dependent Diabetes Mellitus", 5/30/91.

31. Symposium: Opportunities and Therapeutic Dilemmas in the Management of Patients with NIDDM; Lilly European Opinion Leaders Program, Lilly Research Laboratories, Indianapolis, IN. "Pathophysiological Issues: Glucose Disposal and Hepatic Glucose Production", 6/22/91.

32. Seminar: University of Louisville, Department of Biochemistry, Louisville, KY. "Insulin Resistance and the Cellular and Molecular Biology of Glucose Transporter Proteins", 8/4/91.

33. Lecture: Toronto city-wide Endocrine Grand Rounds (Lilly Lectureship), Division of Endocrinology and Metabolism, University of Toronto Hospital, "Clinical States of Insulin Resistance"; Seminar: Department of Cellular Biology, Toronto Hospital for Sick Children, "Insulin Resistance and Regulation of Glucose Transporter Gene Expression", 10/11/91.

1992 34. Seminar: University of Alabama at Birmingham School of Medicine, Division of Endocrinology and

Metabolism, Birmingham, AL. "Glucose Transporter Proteins in Clinical Insulin Resistance", February 20, 1992.

59

35. Symposium: Diabetes, Lipids, and Obesity: Critical Assessment of Risk Factors; University of Kentucky College of Medicine, Lexington, KY. "Intensive Management of Type I Diabetes" and "Intensive Management of Type II Diabetes", May 9 and 10, 1992.

36. Symposium: Diabetes Update 1992; national meeting of clinical fellows in Endocrinology and Metabolism sponsored by Diabetes Research and Training Center of Indiana University School of Medicine and Eli Lilly & Co., Turkey Run State Park, IN. "Type II Diabetes Mellitus". 10/1/92

1993 37. Seminar: Glaxo Research Institute, Incorporated, Research Triangle Park, North Carolina. "Mechanisms

of Insulin Resistance in Type II Diabetes Mellitus". January 22, 1993. 38. Seminar: Clinical Diabetes & Nutrition Section, NIDDK, National Institutes of Health, Phoenix, Arizona.

"Glucose Transporters and Human Insulin Resistance". February 11, 1993. 39. Seminar: University of Texas Southwestern Medical Center, Department of Biochemistry the Department

of Medicine/Division of Endocrinology and Metabolism, and the Diabetes Research Center, Dallas, Texas. "Glucose Transporters and Insulin Action". February 26, 1993.

40. Lecture: VIII Annual Meeting of the Federacao de Sociedades de Biologia Experimental. Caxambu MG, Brazil. "Glucose Transporter Proteins and Insulin Sensitivity in Humans". August 25-28, 1993.

41. Lecture: Miguel R. Covian Symposium in celebration of the 40th anniversary of the Faculdade de Medicina de Ribeirao Preto.

Ribeirao Preto SP, Brazil. "Glucose Transporters and Insulin Action", August 22-24, 1993. 1994 42. Medical Grand Rounds: University of Arkansas. "The Molecular and Genetic Pathogenesis of Non-

Insulin Dependent Diabetes Mellitus", February 3, 1994. 43. Lecture and Round Table Discussion: Rhone-Poulenc-Rorer Central Research, Collegeville,

Pennsylvania. "Diabetes and Insulin Resistance". September 12, 1994. 1995 44. Lecturer and Participant: National Center for Human Genome Research, Washington, D.C. "Genetics of

Non-Insulin Dependent Diabetes Mellitus in West Africa", May 1-2, 1995. 45. Lecturer and Participant: FASEB Summer Research Conference, Snowmass, Colorado. "Recent

Advances in Glucose Transporter Biology", July 8-13, 1995. 46. Medicine Grand Rounds: Medical University of South Carolina, Charleston, South Carolina. "New

Genetic Forms of Non-Insulin-Dependent-Diabetes Mellitus", October 17, 1995.

1996 47. Lecture: Dean's Conference ("Wednesdays at Five"), Medical University of South Carolina, Charleston,

South Carolina. "In Search of Diabetes Genes", February 21, 1996. 48. Seminar: University of Pennsylvania, Division of Endocrinology, and the Howard Hughes Medical

Institute, Philadelphia, Pennsylvania. "Glucose Transporters and Human Insulin Resistance", February 29, 1996.

49. Lecturer and Participant: 30th Research Symposium of the American Diabetes Association and the Genetics of Diabetes Mellitus, Denver, Colorado. "Genetics of NIDDM: Will Better Subphenotyping Help?", March 22-24, 1996.

50. Lecturer and Participant: Steering Committee Meeting of the Human Biological Data Interchange, Philadelphia, Pennsylvania. "Value of the DCCT Collection of DNA Samples", April 24, 1996.

51. Key-Note Address: Annual Meeting of the South Carolina Affiliate of the American Diabetes Association, Columbia, South Carolina. "Key Progress in Diabetes Research". May 4, 1996.

52. Lecture: 56th Annual Meeting and Scientific Sessions of the American Diabetes Association, Council on Exercise, San Francisco, California. "The Insulin Resistance Syndrome: What is it? A Pathophysiologist's Perspective". June 8-11, 1996.

60

53. Seminar: East Carolina University, Department of Biochemistry, Greenville, North Carolina. "Journey to the Center of Diabetes: Candidate Proteins versus Positional Cloning". September 18, 1996.

54. Lecturer and Participant: Second Annual Diabetes Symposium for Primary Health Care Professionals, Diabetes Initiative of South Carolina, Charleston, S.C. "Pathogenesis of Type II Diabetes". September 26-27, 1996.

55. Lecturer and Participant: Conference - New Developments in the Pathogenesis and Treatment of NIDDM, sponsored by the ADA and NIH, Scottsdale, Arizona. "Genetics of NIDDM". November 1-3, 1996.

1997 56. Key Note Address: South Carolina Genetics Conclave, Charleston, S.C. "Whole genome scans for

diabetes-related genes in the Pima Indians". April 18, 1997. 57. Lecturer: MUSC Department of Medicine Research Grand Rounds, Charleston, S.C. "Human research

on a metabolic ward: pathophysiology, biochemisty, and genetics of insulin resistance and obesity". May 13, 1997.

58. Seminar and Visiting Scientist: `Research Day' at the University of Washington, Seattle, WA. "The biochemical and genetic basis of human insulin resistance", May 20, 1997.

59. Seminar and Visiting Scientist: University of Virginia, Charlottesville, VA. Grand Rounds "The genetic basis of diabetes" and Research Seminar "The pathogenesis of human insulin resistance", May 26-27, 1997.

60. Symposium: In Vivo Measurement of Metabolic Processes, Prouts Neck, Maine. “Regulation of GLUT4”, October 3-6, 1997.

61. Seminar: Indiana University School of Medicine, Division of Endocrinology and Metabolism and the Department of Biochemistry and Molecular Biology, Indianapolis, IN. “Insulin Resistance and Obesity”, November 17, 1997.

1998 62. Seminar: University of Texas Health Science Center at San Antonio, Division of Diabetes, San Antonio,

TX. “Mechanisms of Human Insulin Resistance and the Role of Obesity”, January 22, 1998. 63. Symposium: Annual Research Centers in Minority Institutions (RCMI) Symposium, Howard University

College of Medicine, Washington, DC. “The Genetics of Type 2 Diabetes Mellitus with Emphasis on Patients of African Descent”, March 6, 1998.

64. Symposium: Issues in Minority Health, sponsored by the Office of Diversity, Medical University of South Carolina, Charleston, SC. “Diabetes and African Americans in South Carolina”, March 7, 1998.

65. Symposium: 13th International Interdisciplinary Conference on Hypertension in Blacks, Charleston SC. “The Genetics of Metabolic Cardiovascular Risk Factors”, July 12-15, 1998.

66. Symposium: The National Pharmaceutical Association, Charleston, SC. “Genetics of Type 2 Diabetes Mellitus: Studies in a Genetically Homogeneous Population of African-Americans”, July 27-28, 1998.

67. Medical Grand Rounds: University of South Carolina School of Medicine, Columbia, SC. “Pathogenesis of Type 2 Diabetes and the Insulin Resistance Syndrome: Implications for Therapy”. Seminar: Division of Endocrinology and Metabolism, “Genetics of Type 2 Diabetes”, September 10, 1998.

68. Symposium: 4th Annual Diabetes Fall Symposium for Primary Health Care Professionals, Charleston, SC. “New Concepts in the Pathophysiology and Natural History of Type 2 Diabetes”, October 1, 1998.

69. Symposium: San Giovanni Rotondo International Symposia on Clinical and Molecular Aspects of Endocrine and Metabolic Diseases – Inhibitors of Insulin Signaling in Human Insulin Resistance, Rome, Italy. “Inhibitors of Insulin Signaling – Protein Kinase C and Abnormalities in GLUT 4 Vesicle Trafficking”, October 16-17, 1998.

1999 70. Invited lecture: Rosiglitazone Global Advisors Meeting, Marrakech, Morocco. “Insulin resistance as a

target for therapy in Type 2 Diabetes”, February 23-25, 1999.

61

71. Seminar: Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN. Host Dr. Jose Caro. “Insulin Resistance and Obesity in Humans”, April 23, 1999.

72. Seminar: Department of Nutrition Sciences, University of Alabama, Birmingham, AL. “Obesity, Insulin Resistance, and Macronutrient Fuel Partitioning”, May 6-7, 1999.

73. Seminar: Roche Pharmaceuticals, Nutley, NJ. “Molecular and Genetic Determinants of Human Insulin Resistance and Type 2 Diabetes”, August 16, 1999.

74. Medical Grand Rounds: Rush-Presbyterian-St. Lukes Medical Center, Rush University School of Medicine, Chicago, IL. “Insulin Action and Insulin Resistance: Diseases Involving Defects in Insulin Receptors, Signal Transduction, and the Glucose Transport Effector System”, September 22, 1999.

75. Seminar: University of Colorado Health Sciences Center, Division of Endocrinology, Denver, CO. “Molecular Pathogenesis of Human Insulin Resistance”, November 2, 1999; Endocrinology Grand Rounds: “Genetic Basis of Type 2 Diabetes”, November 3, 1999.

76. Invited Lecture: North American Association for the Study of Obesity international meetings, Charleston, SC. Symposium on Fundamentals of Obesity and its Management: “Metabolic and Genetic Pathogenesis of Obesity”, November 13, 1999.

2000 77. Conference: Diabetes & Obesity International Seminar, Pennyhill Park Hotel, London, UK. Sponsored by

Bristol Myers Squibb Company. January 30 – February 1, 2000. 78. Pfizer Visiting Professor at the University of Mississippi School of Medicine, March 20-23, 2000, Jackson,

MS. Lectures include i) Medicine Grand Rounds, “Genetics of Type 2 Diabetes Mellitus: Implications for Therapy”, 3/21/00. ii) Physiology Research Seminar at the Arthur Guyton Physiology Institute, “Metabolic and Molecular Basis of Human Insulin Resistance”, 3/22/00. iii) Research Seminar with the Division of Endocrinology, “Atypical Diabetes”, 3/21/00. iv) Ambulatory Sign in Rounds with medical housestaff and medical students, “New paradigms for treatment of Type 2 Diabetes, 3/21/00. v) Morning Report with medical housestaff and medical students, “Management of the Cardiovascular Risk Factors”, 3/22/00.

79. Seminar: Washington University School of Medicine, Divisions of Endocrinology and Lipidology, St. Louis, MO. “Metabolic and Molecular Basis of Human Insulin Resistance“, April 5-6, 2000.

80. Invited Lectures: Diabetes Unit, King Edward Memorial Hospital and Research Center, Pune, India; “Human Insulin Resistance: Metabolism and Genetics”, April 15, 2000. All India Institute of Medical Sciences, Department of Medicine, New Delhi, India, “Genetics of Type 2 Diabetes and Insulin Resistance”, April 18, 2000.

81. Invited Lecture: Diabetes Update-2000. Genting Highlands, Kuala Lampur, Malaysia. “ The Role of Insulin Resistance in the Insulin Resistance Syndrome and Type 2 Diabetes Mellitus”, April 21-22, 2000.

82. Seminar: University of Arkansas for Medical Sciences and the McClellan Veterans Affairs Medical Center, Endocrinology Grand Rounds, Little Rock, AR. “Metabolic and Molecular Basis of Human Insulin Resistance and Obesity”, April 27-28, 2000.

83. Visiting Professor, Vanderbilt University Medical Student Research Training Program in Diabetes, Endocrinology, and Metabolism.. Invited lecture: “Pathophysiology and Mechanisms of Human Insulin Resistance”. Vanderbilt University, Nashville, TN, July 25-26, 2000.

84. Invited lecture: Robert Turner Memorial Symposium on Type 2 Diabetes. Bermuda. “ Mechanisms of Human Insulin Resistance and Pathophysiology of the Insulin Resistance Syndrome”, August 4-5, 2000.

85. Medical Grand Rounds: Medical College of Virginia, Richmond, VA. “Genetics of Type 2 Diabetes and Related Adventures”, and Seminar: Division of Endocrinology and Metabolism, “Pathophysiology of Human Insulin Resistance”, October 5-6, 2000.

86. Seminar: University of Alabama School of Medicine, Division of Endocrinology, Birmingham, AL. “Insulin Resistance in the Natural History of Type 2 Diabetes”, November 9, 2000.

62

87. Invited lecture: 7th Research Centers in Minority Institutions (RCMI) Symposium on Health Disparities, San Juan, Puerto Rico. “Search for Diabetes Genes in Gullah-Speaking African Americans: the Need to Measure Environment”, November 12-15, 2000.

88. Invited lecture: 7th national scientific sessions of the Consortium for Southeastern Hypertension Control (COSEHC), Savannah, GA. “The Insulin Resistance Syndrome: Pathophysiology and Role in the Management of Cardiovascular Disease”, November 29 to December 2, 2000.

2001 89. Seminar: University of Oklahoma Health Sciences Center, Department of Medicine, Oklahoma City, OK.

“Pathogenesis of Human Insulin Resistance and its Role in Type 2 Diabetes and Obesity”, February 5-6, 2001.

90. Medical Grand Rounds: Texas Tech Health Sciences Center, Department of Medicine, El Paso , TX. “Pathogenesis of Human Insulin Resistance and its Role in Type 2 Diabetes and Obesity”, March 5-6, 2001

91. Invited Site Visit. University of Washington, Division of Endocrinology and Metabolism. Critique of program project grant application in mock site visit format, PI, Dr. Alan Chait. Seattle, WA, April 4, 2001

92. Invited seminar: University of California, San Diego School of Medicine, Division of Endocrinology and Metabolism, grand rounds. San Diego, CA. “Molecular Mechanisms of Human Insulin Resistance”, April 18, 2001.

93. Invited lecture: Dealing with the Diabetes Epidemic in the 21st Century, sponsored by Indiana University for endocrinology fellows in the United States, Turkey Run State Park, Marshall, IN. “The Genetics of Type 2 Diabetes”. May14-16, 2001.

94. Medical Grand Rounds: Bristol Regional Medical Center and East Tennessee University School of Medicine, Bristol TN. “Insulin Resistance: Its Role in Type 2 Diabetes”. June 5, 2001.

95. Invited lecture: 83rd Annual Meetings of the Endocrine Society, Denver, CO. Symposium entitled “Type 2 Diabetes in Adolescence”, and lecture entitled “Insulin Resistance”. June 20-23, 2001

96. Invited seminar: University of Alabama School of Medicine, Department of Nutritional Sciences, Birmingham, AL. “Molecular Approaches to the Study of Obesity and Type 2 Diabetes in Human Patients”. August 6-7, 2001.

97. Invited seminar: University of Texas Health Sciences Center at San Antonio, Department of Medicine/Division of Diabetes, San Antonio, TX. “Human Insulin Resistance”. November 7, 2001.

2002 98. Invited lecture: 49th annual American Diabetes Association Advanced Post-Graduate Course, San

Francisco, CA. “Insulin and Weight Gain, Insulin Resistance and Obesity: Pathophysiological Interactions with Implications for Patient Management”. February 1-3, 2002.

99. Invited lecture: Annual meeting of the South Carolina Dietetics Association, Patriot’s Point, Mt. Pleasant, SC. “Metabolic Basis of Cardiovascular Disease Risk: Insulin Resistance and Obesity”. April 8, 2002.

100. Invited lectures: 9th International Congress on Obesity, Sao Paulo, Brazil; August 24-29, 2002. Lecture #1: Relationship between adipose tissue, insulin resistance, cardiovascular risk”, August 25. Lecture #2: Genetics of Obesity in Isolated Populations: The Gullah Population, August 28. 101. Invited seminar: University of Sao Paulo, Instituto Ciencisas Biomedicas, Depart. Fisiologia e

Biofisica, Sao Paulo, Brazil. “Role of Uncoupling Proteins in Human Metabolism”, August 29, 2002.

102. Invited lecture: 8th Annual Diabetes Fall Symposium for Primary Healthcare Professionals, Charleston, SC. “The Insulin Resistance Syndrome”, September 26, 2002.

103. Invited lectures: The Endocrine Society CME symposia From Diabetes to Cardiovascular Disease. “Insulin Resistance”, Phoenix, AZ, September 28, 2002, and Philadelphia, PA, November 2, 2002.

63

104. Invited lecture: Greater Issues Forum, a campus-wide series at Johnson & Wales University. “Searching for the Fat Gene: Genetics and Diet”, November 6, 2002.

105. Invited lecturer and member of organizing committee: 1st Annual Endocrine Fellowship Symposium: Managing Multiple Aspects of Diabetes Care, New Orleans, LA. “Oral Diabetic Agents and Exercise”, November 8-10, 2002.

2003 106. Invited lecture: Conference on “The Carolina Lowcountry and Caribbean Cuisines” sponsored by the

College of Charleston , Johnson & Wales University, and the Citadel. “The Fat Gene”, March 21, 2003.

107. Invited lecture: 155th Annual Meeting & Scientific Assembly of the South Carolina Medical Association, Charleston, SC. “Diabetic Treatment”, April 24, 2003.

108. Invited seminar: Wake Forest University School of Medicine, Center for Human Genomics, Winston Salem, NC. “Gullah-Speaking African Americans: Metabolic and Genetic Studies of Insulin Resistance and Obesity”. May 21, 2003.

109. Medical Grand Rounds: Department of Medicine, University of Alabama at Birmingham. “Insulin Resistance Syndrome: Pathophysiology and Diagnosis”, September 17, 2003.

110. Invited lecture: National Cooperative Growth Study (NCGS)/National Cooperative Somatotropin Surveillance (NCSS) 2003 Annual Investigator Meeting, Baltimore, MD. “The Insulin Resistance Syndrome: Evolving an Understanding of Pathogenesis and Diagnosis”, September 19-20. 2003. Symposium interrupted by Hurricane Isabel.

111. Invited lectures: 6th Annual Diabetes Update 2003-Decoding the Metabolic Syndrome: Management Implications, University of Oklahoma Department of Medicine/Division of Endocrinology, Oklahoma City, OK. “Metabolic and Genetic Basis of Type 2 Diabetes” and “Diagnosis and Treatment of the Insulin Resistance Syndrome”, October 4, 2003.

112. Invited lecture: 25 Years of the DRTC: A Scientific Symposium, Indiana University School of Medicine, Indianapolis, IN. “The Insulin Resistance Syndrome: Pathophysiological Insights and Diagnostic Uncertainties”, November 1, 2003.

113. Invited lecturer and member of organizing committee: 2nd Annual Endocrine Fellowship Symposium: Managing Multiple Aspects of Diabetes Care, Scottsdale, AZ. “The Insulin Resistance Syndrome, Obesity, and Exercise”, November 14-16, 2003.

2004 114. Invited lectures: Korean Diabetes Association, and Glucerna SR Symposium, Seoul, South Korea.

“Advancing Nutrition in Type 2 Diabetes: Achieving Better Outcomes”, February 4-6, 2004. 115. Invited lecture: Hypertension Program Seminar, University of Alabama at Birmingham. “Insulin

Resistance and the Insulin Resistance Syndrome, April 2, 2004. 116. Invited lecture: National Cooperative Growth Study (NCGS)/National Cooperative Somatotropin

Surveillance (NCSS) 2004 Annual Investigator Meeting, Baltimore, MD. Phoenix, AZ. “The Insulin Resistance Syndrome: Evolving an Understanding of Pathogenesis and Diagnosis”, October 14-17. 2004.

117. Invited lecturer and member of organizing committee: 3nd Annual Endocrine Fellowship Symposium: Managing Multiple Aspects of Diabetes Care, Las Vegas, NV. “The Insulin Resistance Syndrome, Obesity, and Exercise”, November 19-21, 2004.

2005 118. Medical Grand Rounds: Carraway Methodist Medical Center, Birmingham AL. “The Metabolic

Syndrome”, February 1, 2005. 119. Invited lecture: 32nd Annual Medical Alumni Weekend, University of Alabama School of Medicine,

Birmingham, AL. “The Insulin Resistance Syndrome”, February 12, 2005

64

120. Invited lecture, 25th Annual Meeting of the Taiwan Diabetes Association and Endocrinology Society, Taipei, Taiwan, ROC. “Diet , The Metabolic Syndrome, and Diabetes Prevention”, March 19-20, 2005.

121. Invited seminar speaker: Cardiovascular Research Institute, Morehouse School of Medicine, Atlanta GA. “The Metabolic Syndrome: Pathogenesis and Diagnosis”, March 29, 2005.

122. Invited speaker: Genetic Admixture Symposium, Minority Health Research Center, University of Alabama at Birmingham, Birmingham AL. “Applications of Genetic Admixture to Minority Health-the Metabolic Syndrome and Gullah-Speaking African Americans”, May 12, 2005.

123. Invited lecture, Bioethics, Genetics, & the Human Genome Project, Clemson University/VoorheesCollege EXPORT, Clemson, SC. “Project Sugar”, September 16, 2005

124. Invited lecture: Department of Genetics, Wake-Forest University Health Sciences, Winston-Salem, NC. “Microarray and Proteomics Studies in Human Skeletal Muscle: Potential Insights into the Genetics of Insulin Resistance and Type 2 Diabetes”, October 5, 2005.

125. Invited symposium speaker: Annual Meeting of the North American Society for the Study of Obesity (NAASO), Vancouver, British Columbia. “Role of UCP3 in Human Physiology”, October 15-19, 2005.

126. Invited lecture: Annual Retreat of the Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL. “The Metabolic Syndrome, Obesity, and Cancer”, October 24, 2005.

127. Invited lecturer and member of organizing committee: 4th Annual Endocrine Fellowship Symposium: Managing Multiple Aspects of Diabetes Care, Las Vegas, NV. “The Metabolic Syndrome and Pre-Diabetes: What to do before diabetes begins”, October 29-30, 2005.

2006 128. Invited lecture: Department of Physiology and Biophysics research seminar. University of Alabama at

Birmingham, Birmingham, AL. “Mechanisms of Human Insulin Resistance: Lessons Learned from cDNA Microarray and Proteomic Studies”, February 8, 2006.

129. Invited speaker: 2006 Annual Meeting of the Alabama Dietetic Association, Birmingham AL. “Evolving Strategies for the Treatment and Prevention of Type 2 Diabetes: Implications for the Dietitian”, March 15-17, 2006

130. Invited speaker: Eliminating Health Disparities: Obesity and Diabetes from Discovery to Delivery. Sponsored by NIH/NIDDK and the Minority Health Research Center at the University of Alabama at Birmingham, Birmingham, AL. “The Metabolic Syndrome: One Size Does Not Fit All”, March 22-23, 2006.

131. Invited Speaker: 5th Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases, Jeju, South Korea. “New Concepts Related to Diagnosis, Pathophysiology, and Treatment of the Metabolic Syndrome”, April 12-15, 2006.

132. CME speaker: The Endocrine Society CMES program: “The Endocannabinoid System”; Salt Lake City, UT, May, 18, 2006, and St. Louis, MO, June 7, 2006.

133. Invited seminar: Madras Diabetes Research Foundation/Diabetes Specialties Centre, Chennai, India – telecast. “Metabolic Syndrome and Diabetes: Diagnostic Dilemmas and Pathogenesis”, June 2, 2006.

134. Invited CME lecture: Diabetes nurse educators, nurse practitioners, dietitians, and CDEs at the Mayo Clinic, Rochester MN. “Pharmacotherapy of Diabetes and Incretin Physiology”, October 12, 2006.

135. Invited research seminar: Division of Endocrinology and Metabolism, University of Minnesota, Minneapolis, MN. “Pathophysiology of Human Insulin Resistance: Lessons from Microarray and Proteomic Studies”, October 12, 2006.

136. Invited lecturer and member of organizing committee: 5th Annual Endocrine Fellowship Symposium: Managing Multiple Aspects of Diabetes Care, Las Vegas, NV. “The Metabolic Syndrome and Pre-Diabetes: What to do before diabetes begins”, November, 2006. 2007

65

137. Invited medical education lectures: Merck Speakers Program, “The Incretin Axis and Applications for Therapy in Type 2 Diabetes”. (i) primary care physicians, Weston FL, January 25, 2007. (ii) primary care physicians, New Orleans, LA, February 7, 2007. (iii) primary care physicians, Mobile AL, February 22, 2007. (iv) primary care physicians, Montgomery AL and Maxwell Air Force Base, March 9, 2007. (v) primary care physicians, Jackson MS, March 29, 2007 (vi) primary care physicians, Pensacola FL, August 22, 2007. (vii) primary care physicians, Mobile AL, August 22, 2007. (viii) physicians, house staff, health care providers, Pittsburgh PA, December 6, 2007.

138. Invited CME lectures, The Endocrine Society CMES program: “The Endocannabinoid System”; The Philadelphia Endocrine Society, Philadelphia, PA, February 28, 2007; The Chicago Endocrine Society, Chicago IL, March 5, 2007.

139. Invited research seminar: Division of Endocrinology Grand Rounds and the Obesity Center, Columbia University/St. Luke’s Roosevelt Hospital, New York City, NY. “Determinants of the Metabolic Syndrome Trait Cluster: Impact of Race and Adiponectin”, March 14, 2007

140. Invited research seminar: Division of Preventative Medicine and Nutrition and the Irving Center for Clinical Research, Vascular and SCOR Conference, Columbia University/Columbia Presbyterian Hospital, New York City, NY. “Determinants of the Metabolic Syndrome Trait Cluster: Adiponectin and Dyslipidemia”, March 14, 2007

141. Invited research seminar: Endocrine Grand Rounds, Naomi Berrie Diabetes Center, Columbia University, New York City, NY. “Mechanisms of Human Insulin Resistance: New Clues form Muscle Microarray Studies”, March 15, 2007

142. Invited research seminar: Department of Physiology and Biophysics and the Center for Excellence in Cardiovascular-Renal Research, University of Mississippi Medical Center, Jackson, MS. “Determinants of the Metabolic Syndrome Trait Cluster: Impact of Race and Adiponectin”, March 29, 2007

143. Invited research seminar: Hypertension Grand Rounds, Division of Cardiology, Section of Hypertension, University of Alabama at Birmingham. “Determinants of the Metabolic Syndrome Trait Cluster: Impact of Race and Adiponectin”, March 30, 2007

144. Invited lecture: 22nd Annual Meeting of the American Society of Hypertension, Chicago, IL. “Insulin Resistance and Determinants of the Metabolic Syndrome Trait Cluster”, May 19-22, 2007.

145. Invited research seminar: Department of Pathology, Molecular and Cellular Pathology Seminar Series, University of Alabama at Birmingham. “The NR4A Family of Orphan Nuclear Receptors: New Modulators of Insulin Sensitivity”, September 6, 2007

146. Invited Research Seminar: Merck & Co,. Inc., Clinical Research Units in Obesity and Diabetes, Rahway, NJ. “New Drug Targets for Insulin Resistance, the Metabolic Syndrome, and Diabetes”, September 10, 2007

147. Invited lecture: National Advisory Research Resources Council (NARRC) meeting, NIH National Center for Research Resources (NCRR), Bethesda, MD. “Obesity, Diabetes, and the Metabolic Syndrome in Gullah-Speaking African Americans”, September 11, 2007.

148. Invited lecture: Investigator meeting for Daiichi-Sankyo WEL-411 clinical trial, Phoenix, AZ. “Metabolic Syndrome, Pre-Diabetes, and Type 2 Diabetes: Diagnoses and Pathogenesis”, October 13, 2007

149. Invited research seminar: Endocrinology Grand Rounds, University of Arkansas for Medical Sciences, Little Rock, AR. “New Drug Targets for Insulin Resistance, the Metabolic Syndrome, and Diabetes”, October 26, 2007

150. Invited lecturer and member of organizing committee: 6th Annual Endocrine Fellowship Symposium: Managing Multiple Aspects of Diabetes Care, Las Vegas, NV. “The Metabolic Syndrome and Pre-Diabetes: What to do before diabetes begins”, November 9-11, 2007

151. Invited lecture and seminar: (i) research seminar at the Endocrine Research Conference, Division of Endocrinology, University of Pittsburgh – “Identification of Novel Molecules Involved in Human Insulin Resistance”. (ii) Endocrine University-Wide Conference grand rounds, University of Pittsburgh – “Role of Adiponectin in the Metabolic Syndrome Trait Complex”. Pittsburgh PA, Dec 6-7, 2007.

66

2008 152. Invited seminar: Department of Genetics, University of Alabama at Birmingham, Birmingham AL.

“Genetics of Type 2 Diabetes: Studies in Gullah-Speaking African Americans”, January 11, 2008 153. Invited medical education lectures: Merck Speakers Program, “The Incretin Axis and Applications for

Therapy in Type 2 Diabetes”. (i) primary care physicians, Atlanta GA, February 21, 2008. (ii) primary care physicians and endocrinologists, Charleston SC, September 16, 2008

154. Invited colloquium speaker: Center for Study of Gene Structure and Function of Hunter College CUNY and the Clinical and Translational Science Center (CTSA) at Weill Cornell Medical College, New York City NY. “Translational Research in Diabetes: From Genomic Scans to Community Partnerships, Project Sugar—Studies in Gullah-Speaking African Americans”, February 27, 2008

155. Invited member of writing group, American College of Endocrinologists Consensus Conference. “Diagnosis and Management of Pre-Diabetes”, Washington DC, July 21-23, 2008

156. Invited seminars: Emory University School of Medicine, Atlanta GA. Nutrition Group: “Role of Adiponectin in the Pathophysiology of the Metabolic Syndrome: Racial Differences”. Division of Endocrinology Grand Rounds: “Paradigm for a Translational Research Program: Discovery of New Mechanisms and Drug Targets for Treatment of Insulin Resistance”. September 22, 2008

157. Invited medical education lecture, Merck Speaker’s Program, “Peer Discussions on Initiating Treatment in Type 2 Diabetes”. (i) Endocrinologists in the Presbyterian Hospital Health Care System, Charlotte NC, September 29, 2008

158. Invited medical education lecture, Abbott Nutrition “Glycemic Control through Advanced Nutrition”. National teleconference and internet slide presentation on (i) October 8, 2008; (ii) October 16, 2008; (iii) November 6, 2008

159. Invited lecturer and member of organizing committee: 7th Annual Endocrine Fellowship Symposium: Managing Multiple Aspects of Diabetes Care, Scottsdale, AZ. “The Metabolic Syndrome and Pre-Diabetes: What to do before diabetes begins”, November 14-16, 2008

160. Invited symposium speaker: 11th Research Centers in Minority Institutions (RCMI) International Symposium on Health Disparities-2008, hosted by the University of Hawaii at Manoa, Honolulu, HI. “Obesity and the Metabolic Syndrome”, December 3, 2008

161. Invited symposium speaker: 5th Huaxia Congress of Endocrinology, The Endocrine Society of the Republic of China and the Diabetes Association of the Republic of China. Taipei, Taiwan. “Nutritional Intervention in Diabetes Management”, December 6, 2008

162. Invited lecture: The Chinese Federation of Dietitian’s Association. Taipei, Taiwan. “Latest Nutritional Developments in Diabetes Management”, December 6, 2008

163. Invited medical education lectures: Hong Kong, China. “The Latest Advancements in Diabetes Management: Importance of Nutrition and Integrated Care Program”. (i) Medical staff of Ruttonjee Hospital, December 8, 2008; (ii) Hong Kong area endocrinologists, primary care physicians, diabetes nurse educators, dietitians, and pharmacists, December 8, 2008; (iii) Medical staff of Tung Wah Eastern Hospital, December 9, 2008

2009 164. Invited lecture: Asian KOL Scientific Summit. Singapore. “Latest Information on Diabetes

Management”, January 9, 2009. 165. Invited medical education lectures and SE Asian tour: “Latest Advances in Diabetes Management and

Medical Nutrition Therapy”. (i) Singapore Dietetics Association, Singapore, January 7, 2009; (ii) Singapore area endocrinologists, Singapore, January 8, 2009; (iii) Singapore area primary care physicians, diabetes nurse educators, and pharmacists, Singapore, January 10, 2009; (iv) Shanghai area endocrinologists and the Chinese Diabetes Association, Shanghai, China, January 11, 2009; (v) Guangzhou area endocrinologists, Guangzhou, China, January 12, 2009; (vi) Filipino key opinion leaders in diabetes, Manila, Philippines, January 14, 2009; (vii) national consortium of Filipino endocrinologists, diabetologists, and dietitians, Manila, Philippines, January 15, 2009; (viii)

67

endocrinologists, cardiologists, and internists, and nutritionists from southern provinces, Ho Chi Minh City, Viet Nam, January 17, 2009.

166. Invited lectures: American Society for Parenteral and Enteral Nutrition (ASPEN) national meetings, New Orleans LA. (i) Abbott Nutrition Night-New Paradigms in Medical Nutrition Therapy, “Advancing Nutrition in Diabetes Management”, February 1, 2009; (ii) Clinical Nutrition Week Breakfast CE Symposium, “Nutrition, Glycemic Control, and Improved Outcomes for Inpatients with Diabetes”, February 2, 2009

167. Invited Research Seminars: (i) Endocrine Grant Rounds, Division of Endocrinology. “Role of Adiponectin in the Pathogenesis of the Metabolic Syndrome Trait Cluster”. (ii) Stedman center for Nutrition and Metabolism, “New Molecules and Mechanisms Involved in Human Insulin Resistance”. Duke University School of Medicine, Durham NC, March 2-3, 2009

168. Invited Research Seminar: Endocrine Grand Rounds, Division of Endocrinology, University of Vermont School of Medicine. “Role of Adiponectin in the Pathogenesis of the Metabolic Syndrome Trait Cluster”. Burlington VT, April 16-17 , 2009

169. Invited Panelist: Health Disparities Research Symposium 2009, Birmingham AL. Debate entitled “Universal Health Coverage: Can it Decrease Health Disparities?” sponsored by UAB Minority Health Research Center, April 29, 2009

170. Invited Research Seminar: Endocrine Grand Rounds, Division of Endocrinology, Albert Einstein University of School of Medicine. “New Molecules and Mechanisms Involved in Human Insulin Resistance”. New York, NY, May 1, 2009

171. Invited Research Seminar: Endocrine Grand Rounds, Division of Endocrinology, Temple University School of Medicine. “Role of Adiponectin in the Pathogenesis of the Metabolic Syndrome Trait Cluster”. Philadelphia PA, June 2, 2009

172. Invited research presentation: NHLBI Proteomics Technology Innovation Centers Capstone Meeting, Natcher Conference Center, NIH Campus. “Insulin Resistance Syndrome Proteomics”. Bethesda MD, September 16, 2009

173. Invited lecture: Southeast Lipid Association Research Conference. “Role of adiponectin in the metabolic syndrome trait complex”. Callaway Gardens, Pine Mountain, Georgia, September 25-27, 2009

174. Medical Grand Rounds, University of Alabama at Birmingham, Birmingham AL. “Clinical Trials in Diabetes: the Role of Hippocrates and Evidenced Based Medicine in the Post-Modern Era”, September 23, 2009

175. Invited Lecture: 19th International Congress of Nutrition, Bangkok, “Care of the Hospitalized Patient with Diabetes”. Bangkok, Thailand, October 8, 2009

176. Invited lecture: Annual Meeting of the Thailand Society for Parenteral and Enteral Nutrition (SPENT), “Hyperglycemia in Hospitalized Patients: Role of Nutrition and Glycemic Variability”, Bangkok, Thailand, October 9, 2009

177. Invited medical education lectures: Departments of Critical Care and Endocrinology at Vachira Hospital, Bumrungrad Hospital, and Siriraj Hospital, “Hyperglycemia in Hospitalized Patients: Role of Nutrition and Glycemic Variability”, Bangkok, Thailand, October 8 and 9, 2009

178. Invited lecture, Endocrine Grand Rounds, Division of Endocrinology, University of Alabama at Birmingham. “PreDiabetes: Diagnosis and Treatment of a Disease”, Birmingham AL, October 29, 2009

179. Invited lecturer and member of organizing committee: 7th Annual Endocrine Fellowship Symposium: Managing Multiple Aspects of Diabetes Care, Scottsdale, AZ. “The Metabolic Syndrome and Pre-Diabetes: What to do before diabetes begins”, November 13-15, 2008

180. Invited medical education lectures: Merck Speakers Program, “Influence of Aging on Diabetes”, primary care physicians, Louisville, KY, December 1, 2009.

181. Invited Research Seminar, Endocrine Grand Rounds, Division of Endocrinology, University of Louisville. “Role of Adiponectin in the Pathogenesis of the Metabolic Syndrome”, Louisville KY, December 2, 2009

68

182. Invited Research Seminar, Division of Endocrinology and Graduate Center for Nutritional Sciences, Kentucky University of Kentucky School of Medicine. Role of Adiponectin in Cardiometabolic Disease”, Lexington KY, December 8-9, 2009

2010 183. Annual David and Natica Bahar Memorial Lecture, Medical Grand Rounds, University of Alabama

School of Medicine in Tuscaloosa. “ Metabolic Syndrome and Prediabetes”. Tuscaloosa AL, January 15, 2010

184. Ray A. Kroc Visiting Professor and Lecture, Division of Endocrinology and the Diabetes and Endocrinology Research Center, Baylor University School of Medicine. Adiponectin and Mechanisms Mediating the Cardiometabolic Disease Trait Cluster”, Houston TX, March 25, 2010

185. Invited lecture, Third International Course of Endocrinology, Diabetes, and Metabolism, Asociacion Columbiana de Endocrinologia. “Gene-Environment Interactions in Obesity: Therapeutic Implications”, Bogota, Columbia April 15-18, 2010

186. Invited symposium speaker, national meetings of the American College of Physicians, Internal Medicine 2010. “The Obesity Impact: Importance of Weight Loss in the Comprehensive Management of Metabolic Disease”. Toronto, Canada, April 21, 2010

187. Invited lecture, UAB Diabetes Center Day, University of Alabama at Birmingham,“The Trouble with Tribbles”. Birmingham AL, May 4, 2010

188. Invited medical education lecture: endocrinologists, internists, intensivists, surgeons, oncologisyts, and dietitians. “Role of Nutrition in Diabetes: Care of Inpatients and Outpatients”. Sponsored by Abbott Nutrition, Ankara, Turkey, May 10, 2010, and Izmir, Turkey, May 11, 2010

189. Invited Symposium Speaker, Congreso 2010 Spanish Enteral and Parenteral Nutrition Society. “Diabetes and Nutrition: Update”, Badajoz, Spain, May 12, 2010

190. Robert M. Hearin Distinguished Lecture Series, invited lecture, Office of Research and the Department of Medicine, University of Mississippi Medical Center. “Role of Adiponectin in Cardiometabolic Disease”, Jackson, MI, May 25, 2010

191. Invited faculty and lecturer, Dannon Institute Mid-Career Leadership Conference, “Things you should know about being a chair of a nutrition department”, Huntington Inn, Geneva IL, June 8, 2010

192. Invited Satellite Conference Speaker, Type 2 Diabetes: Combination Therapy for Comprehensive Risk Reduction, 70th Scientific Sessions of the American Diabetes Association, “Hyperglycemia: the Role of Combination Therapy”. Orlando FL, June 27, 2010

193. Invited Speaker: Grand Rounds of the Division of Endocrinology, Mayo Clinic, Rochester MN. “ Pathogenic Role of Addiponectin in Cardiometabolic Disease”, September 7, 2010

194. Invited medical education lectures: Merck Speakers Program: (i) “Patient by Patient: Individualizing our Approach to Type 2 Diabetes”, residents, internists, cardiologists, endocrinologists, and family physicians, Wilmington NC, September 16, 2010

195. Invited Symposium Speaker: Cardiometabolic Health Congress, Boston MA. “Weight Loss--The Clinical Evidence on Glycemic Control and Cardiometabolic Risk Reduction”, October 20-23, 2010

196. Speaker at CME symposia: title of presentation “Current and Emergent Treatment Strategies for Obesity and Implications for Practice”: (i) National Meetings of the American Academy of Family Physicians (AAFP), AAFP CME Symposium plus taping for Medscape, Denver CO, September 30, 2010; (ii) Obesity 2010, 28th Annual Scientific Meeting of the Obesity Society, San Diego CA, October 8-12, 2010; (iii) Primary Care Network (PCN) meeting, Dearborn MI, October 5, 2010; (iv) Pri-Med Update Meeting, Baltimore MD, October 30, 2010

197. Invited speaker: Diabetes and Endocrinology Research Center (DERC) and the Division of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania, Philadelphia PA. “Mechanistic Role of Adiponectin in the Pathogenesis of Cardiometabolic Disease”, November 9, 2010

198. Invited speaker: Grand Rounds of the Division of Geriatrics and Nutritional Science, Washington University, St. Louis MO. “Mechanistic Role of Adiponectin in the Pathogenesis of Cardiometabolic Disease”, November 11, 2010

69

199. Invited lecturer and member of organizing committee: 9th Annual Endocrine Fellowship Symposium: on Advanced Diabetes Management, Miami, FL. “The Metabolic Syndrome and Pre-Diabetes: What to do before diabetes begins”, November 12-14, 2010

200. Invited symposium speaker: Menarini Symposium on Type 2 Diabetes and Inflammation, title “Adipose Tissue and Inflammation”, Lido di Camaiaore (Lucca), Italy, December 3-4, 2010

2011 201. Invited research seminar: Division of Endocrinology, San Francisco VA Medical Center and the

University of California, San Francisco School of Medicine, title “Adiponectin and the Pathogenesis of Cardiometabolic Disease”. San Francisco, CA, February 10, 2011

202. Invited research seminar: Division of Endocrinology, University of California, Davis School of Medicine, title “Adiponectin and the Pathogenesis of Cardiometabolic Disease”. Sacramento, CA, February 11, 2011

203. Invited named lectureship: The James O. Davis Graduate Student Distinguished Lectureship, designated national speaker by vote of all graduate students in the Pharmacology and Physiology Program at the University of Missouri School of Medicine, title “Role of the Adiponectin-Macrophage Axis in Cardiometabolic Disease”, Columbia MO, February 22, 2011

204. Invited research seminar: Division of Endocrinology, DERC, and NORC, University of Washington, title “Role of the Adiponectin-Macrophage Axis in Cardiometabolic Disease”. Seattle WA, March 23-24, 2011

205. Invited lecture: Vascular Biology &Hypertension Seminar Series, Division of Cardiovascular Disease, University of Alabama at Birmingham, title “The Carcino-Metabolic Syndrome: Hypothesis Generating Discussion”. Birmingham AL, March 29, 2011

206. Invited lecture: CME symposium held in concert with the national meetings of the American Diabetes Association entitled “Issues in the Management of Hyperglycemia in Patients with Concurrent Kidney Disease”. Title of lecture: “The Challenge of Hypoglycemia in the CKD patient with Diabetes: Setting Goals, Modifying Treatment”. San Diego CA, June 26, 2011

207. Invited lecture: Symposium held in concert with the national meetings of The Obesity Society entitled “Obesity and Diabetes: the Twin Epidemics”. Title of lecture: “The prevalence of Obesity and Diabetes in Different Populations”. Orlando FL, October 2, 2011

208. Faculty member in CME program sponsored by Pri-Med entitled “Diabetes and Cardiometabolic Disease: Overcoming a Southern Epidemic”. Tile of lecture: Taking a Comprehensive Approach to the Patient with Diabetes: Managing the Cardiovascular Components: Hypertension and Dyslipidemia”. Atlanta GA October 14; Jacksonville FL November 10; Nashville TN November 17, 2011

209. Invited Research Seminar: Division of Endocrinology and Department of Medicine, Wake Forest School of Medicine. Title: Role of adiponectin in the pathogenesis of cardiometabolic disease. Winston-Salem NC, Oct 17, 2011

210. Invited lecture: 9th Annual World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease. Title of lecture: The Carcino-Cardio-Metabolic Syndrome. Hollywood CA, November 3-5, 2011

211. Invited lecturer and member of organizing committee: 10th Annual Endocrine Fellowship Symposium: on Advanced Diabetes Management, Los Angeles, CA. “The Metabolic Syndrome and Pre-Diabetes: What to do before Diabetes Begins”, November 11-13, 2011

212. Invited Research Seminar: Department of Physiology, University of Calcutta. Title: “Pathogenesis of the Metabolic Syndrome. Kolkata, India, December 12, 2011

213. Invited lecture: 17th annual Diabetes and Endocrinology Conference sponsored by the Bangladesh Endocrine Society and the Diabetic Association of Bangladesh. Title: Metabolic Syndrome: Rational Strategies for the Prevention of Diabetes and Cardiovascular Disease. Bangladesh Institute of Health Sciences, Dhaka, Bangladesh, December 14, 2011.

2012

70

214. Invited lecture and workshop participant: American Association of Clinical Endocrinologists (AACE), Expert Workshop on the Clinical Presentation of Lipodystrophy. “Type 2 Diabetes with Partial Lipodystrophy of the Limbs”, Santa Monica, CA, January 29, 2012

215. Invited medical education lectures: Merck Speakers Program, “Challenging clinical inertia: earlier initiation of combination therapy in Type 2 Diabetes”. (i) primary care physicians, Tyndall Air Force Base FL, May 3, 2012; (i) primary care physicians and endocrinologists, Panama City, FL, May 3, 2012.

216. Invited lecturer and ‘Special Session’ organizer: Treatment of Obesity, the Disease: the Endocrinologists Perspective. Title of lecture: “The Role of Obesity in Cardiometabolic Disease”. 21st Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists, Philadelphia, PA, May 23, 2012

217. Invited lecturer at a satellite symposium: Renal impairment in patients with Type 2 Diabetes. Title of lecture: “Use of available glucose-lowering agents in patients with different levels of renal impairment”. 21st Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists, Philadelphia, PA, May 24, 2012

218. Invited medical education series: Merck Speakers’ Program, “Additional Insights into the Pathophysiology of Diabetes”. (i) Faculty and fellows, University of Louisville School of Medicine, Louisville KY September 12, 2012

219. Faculty member in CME program sponsored by Pri-Med entitled “Diabetes and Cardiometabolic Disease: Overcoming a Southern Epidemic”. Title of lecture: Taking a Comprehensive Approach to the Patient with Diabetes: Managing the Cardiovascular Components: Hypertension and Dyslipidemia”. (i) Primary care physicians, New Orleans LA, September 14, 2012. (ii) Primary care physicians, Raleigh NC, November 29, 2012. (iii) Primary care physicians, Memphis TN, December 5, 2012.

220. Faculty member in CME program sponsored by CME-INCITE entitled “Looking past the scale: Strategies to promote weight loss and reduce co-morbidities in your obese patients”. (i) Primary care physicians, Chicago IL, September 19, 2012. (ii) Primary care physicians, San Francisco CA, October 10, 2012. (ii) Primary care physicians, Dearborn MI, November 3, 2012. (iii) Primary care physicians, Baltimore MD, December 8, 2012.

221. Invited Faculty Presenter, Qsymia Product Theater, “A New Once Daily Treatment for Obesity”, 30th Annual Scientific Meetings of the Obesity Society, San Antonio TX, September 22, 2012

222. Invited Research Seminar, Division of Endocrinology and Metabolism, Tulane School of Medicine. Title: “Treatment of Prediabetes: the Disease”. New Orleans LA, October 8, 2012

223. Invited Symposium Speaker: 2012 Cardiometabolic Congress, program on Advances in Weight Loss Management: Examining the Clinical Impact of Novel Therapies on Obesity, Diabetes, & Cardiometabolic Risk. Title: “The Obesity-Diabetes Link and Its Impact on Cardiometabolic Risk: Clinical Implications” Boston MA, October 12, 2012

224. Invited Research Seminar, Division of Endocrinology and Metabolism and the Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center. Title: “NR4A3 Orphan Nuclear Receptors and Insulin Resistance: from bedside to bench to bedside”. Oklahoma City OK, November 6-7, 2012

225. Invited Research Seminar, Division of Endocrinology and Metabolism and the Diabetes Research and Training Center, University of Chicago. Title: “NR4A3 Orphan Nuclear Receptors and Insulin Resistance: from bedside to bench to bedside”. Chicago IL, November 13-14, 2012

226. Invited lecturer and member of organizing committee: 11th Annual Endocrine Fellowship Symposium: on Advanced Diabetes Management, Los Angeles, CA. “What to do before Diabetes Begins: Treatment of Obesity and Prediabetic States”, November 16-18, 2012

227. Faculty member in CME program sponsored by MediKinetics entitled “Evaluating clinical use of long-acting GLP-1 therapy in Type 2 Diabetes treatment regimens”. (i) Primary care physicians, Coral Gables FL, December 15, 2012.

2013

71

228. Faculty member in CME program sponsored by Pri-Med entitled Diabetes and Cardiometabolic Disease: Overcoming a Southern Epidemic. Title of lecture: “Taking a Comprehensive Approach to the Patient with Diabetes: Managing the Cardiovascular Components: Hypertension and Dyslipidemia”. (i) primary care physicians, Tallahassee FL, January 23, 2013

229. Invited symposium speaker: Tackling the Obesity Epidemic: New Weapons to Optimize Outcomes, a dinner symposium at the American College of Physicians (ACP) Internal Medicine annual meetings. Talk title—“A fresh look at new therapeutics for obesity: targeting physiological signaling systems”. San Francisco, CA, April 10, 2013

230. Invited speaker: Valley Diabetes Symposium. “New options for the medical management of obesity: role in prevention and treatment in Diabetes”. Midland, Michigan, April 25, 2013

231. Invited medical education series: Merck Speakers’ Program, “Challenging clinical inertia: earlier initiation of combination therapy in Type 2 Diabetes”. (i) primary care physicians, Atlanta GA, March 12, 2013; (ii) primary care physicians and providers, Maxwell Air Force Base, Montgomery AL, February 8, 2013

232. Symposium organizer and speaker: 22nd Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists, Phoenix, AZ. Symposium title--The Medical Model for the Treatment of Obesity. Talk title—“A Complications-Centric Model for the Medical care of the Obesity Patient”. Phoenix AZ, May 1, 2013

233. Plenary Lecturer: 22nd Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists. “New and Emerging Drugs for Management of Obesity”. Phoenix AZ, May 5, 2013

234. Faculty member in CME program sponsored by Pri-Med and CME Incite entitled Obesity Primary Care Update. Title of lecture: “Weighing the Consequences: The Time is Now for Tackling the Obesity Epidemic”. (i) Washington DC, May 21, 2013; (ii) New York City NY, June 24, 2013; (iii) Denver CO, September 9, 2013; (iv) Chicago IL, October 16, 2013; (v) Baltimore MD, December 5, 2013

235. Invited lecturer for CME program sponsored by the American Association of Clinical Endocrinologists (AACE) entitled “Approaches to Obesity Treatment in Diabetes: The Roles of Lifestyle Modification and Pharmacotherapy”. Presented to the Lower New York Chapter of AACE and the Metropolitan Diabetes Society combined meeting (LNY-AACE/MDS). New York City, NY, May 22, 2013

236. Faculty member in CME program sponsored by Vindico Medical Education entitled “Obesity Forum 2013”. Lecture Title: “Evaluation and Staging of Obesity Complications and a Complications-Centric Model for Obesity Management”. (i) New York City NY, June 1, 2013; (ii) Chicago IL, June 29, 2013; (iii) Dallas TX, September 28, 2013; (iv) Los Angeles CA, October 11, 2013; (v) New Orleans LA, October 26, 2013

237. Faculty member in CME program sponsored by MediKinetics entitled “Evaluating clinical use of long-acting GLP-1 therapy in Type 2 Diabetes treatment regimens”. (i) Primary care physicians, St. Louis, MO, June 3; (ii) Memphis TN, June 19, 2013

238. Invited lecturer: 95th Annual Meeting and Expo of the Endocrine Society. Title: “Obesity Pharmacotherapy:Past, Present, and Future”. San Francisco CA, June 15, 2013

239. Meet the Professor session at the 95th Annual Meeting and Expo of the Endocrine Society. Title: New Pharmacological Therapies for Obesity Management”. San Francisco CA, June 15, 2013

240. Invited lecturer: 73rd Scientific Sessions of the American Diabetes Association. Symposium title is Pharmacologic Management of Obesity and lecture title is “Past Efforts at Pharmacological Intervention: the Good, the Bad, and the Ugly”. Chicago IL, June 22, 2013

241. Invited symposium lecturer: 24th Annual Vascular Biology and Hypertension Symposium. Title: Weight Loss as a Strategy for Cardiometabolic Disease Risk Reduction. Carraway-Davie House, Birmingham AL, September 24, 2013

242. Invited lecturer for CME program sponsored by the American Association of Clinical Endocrinologists (AACE) entitled “New Strategies in Obesity Management: Risk Stratification and Long-term Weight Control. Half-Day program presented to clinical endocrinologists and primary care practitioners. (i) Houston TX September 21, 2014. (ii) Phoenix AZ, October 19, 2013; (iii) Orlando FL, November 9. 2013; (iv) New Orleans LA, December 14, 2013

72

243. Invited lecturer at CME program entitled , “Controversial Issues and Challenging Cases in the New Frontier of Obesity: You be the Judge”. Presented as a satellite program at the Annual Meeting of the American Academy of Family Practice, San Diego CA, September 26, 2013

244. Invited lecturer at the 2013 Cardiometabolic Health Congress, program on “The next generation of weight-loss medications: expert recommendations for managing obesity, diabetes, and cardiometabolic risk”. Lecture title: “Novel pharmacologic strategies for weight loss: examining the evidence”. Boston MA, October 3, 2013

245. Faculty member in CME program sponsored by Pri-Med and Global Directions in Medicine entitled “Breakthroughs in new treatment options for obese patients with comorbidities”. (i) Tampa FL, October 8, 2013; (ii) Los Angeles CA, December 10, 2013

246. Faculty member in CME program sponsored by Pri-Med and CME Incite entitled “Southern Diabetes Initiative”. Title of lecture: “Setting up patients for long term success: enhanced patient treatment and counselling for obesity and T2DM”. (i) primary care physicians, Augusta GA, October 22, 2013; (ii) Richmond VA, October 30, 2013

247. Invited lecturer at the 5th Annual Orange County Symposium on Cardiovascular Disease Prevention. Title: “AACE Complications-Centric Model for Care of the Overweight/Obesity Patient”. Anaheim CA, November 2, 2013

248. Invited lecturer at the 11th Annual World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease. Title: “Rationale for a Complications-Centric Medical Model for Obesity”. Los Angeles CA, November 8, 2013

249. Invited CME lecture presented as a satellite symposium at Obesity Week (national meetings of the Obesity Society), programs entitled “Personalized medicine in obesity treatment: an in-depth look at how to use today’s obesity medications in patients who need to lose weight”. Lecture title: “Efficacy and tolerability of the new therapeutics for obesity”. Atlanta GA, November 11, 2013

250. Invited lecturer at the AACE Symposium on the Endocrine Aspects of Obesity, presented at Obesity Week (national meetings of the Obesity Society). Lecture titles: “Complications-Centric Risk Stratification Paradigm”, “Obesity as a Prediabetes Condition”, and “The AACE Obesity Algorithm”. Atlanta GA, November 12, 2013

251. Invited lecturer at the AACE Obesity Algorithm Symposium, presented at Obesity Week (national meetings of the Obesity Society). Lecture titles: “Obesity Risk Stratification” and “Weight Loss Pharmacotherapy”. Atlanta GA, November 14, 2013

252. Invited lecturer and member of organizing committee: 12th Annual Endocrine Fellowship Symposium: on Advanced Diabetes Management, Dallas TX. “What to do before Diabetes Begins: Treatment of Obesity and Prediabetic States”, November 15-17, 2013

253. Medical Grand Rounds Speaker, Michigan State University School of Medicine and Sparrow Hospital. Title: “New strategies for weight loss management: risk stratification and long-term weight control”. East Lansing MI, December 17, 2013

2014 254. Invited lecturer at the annual meeting of the Puerto Rican Society of Endocrinology and Diabetes.

Lecture titles: “Weight Loss Therapy for Diabetes and Prediabetes: Role of the Endocrinologist” and “Novel Medical Therapeutic Options in Obesity”. San Juan, Puerto Rico, February 1 and 2, 2014

255. Invited lecturer at the 2014 Annual Meeting of the Alabama Dietetic Association. Lecture title: “Medical Nutrition Therapy of Diabetes – Where are we now and where are we going?”. BJCC, Birmingham AL, March 13, 2014

256. Conference Chair and lecturer, AACE/ACE Consensus Conference on Obesity. Lecture titles: “Conference Overview” and “AACE Perspective - Obesity as a Disease”. Washington DC, March 23-25, 2014

List not complete 2015

73

Invited Meet-the-Professor, “Treatment of Obesity in Diabetes”, 97th Annual Meeting of the Endocrine Society, San Diego, CA, March 5-8, 2015 List not complete 2016 257. Invited lecturer and chair of the session on Obesity, Endocrine University (week-long course for second

year Endocrinology fellows). Lecture title: “Treatment Option for the Disease of Obesity”. Mayo Clinic, Rochester, MN, March 8, 2016

258. Invited faculty, Obesity Summit for Residents and Fellows (Medical education program in obesity for residents and fellows in Endocrinology, Internal Medicine, and OB/GYN programs. Topics of lectures: Defining Biology beyond Obesity”; “Hot Topics in Obesity”; Obesity Co-Morbidities”; Intensifying Obesity Management”; “Challenging Cases”; “Wheel of Knowledge”. Orlando FL March 11-13, 2016

259. Invited lecture, Cardiometabolic Risk Summit (Spring 2016, CME). Lecture title: “How Success Should Be Defined in Treating Obesity: Managing Patient Expectations”. New Orleans, LA, March 19, 2016

260. Invited lecture, Annual Symposium: Novel Therapeutics for the Treatment of Diabetes and Obesity. Lecture Title: “Current State of Therapies for Obesity”. University of Washington, Seattle, WA, May 5, 2016

261. Invited lecturer at the American Association of Clinical Endocrinologists 25th Annual Scientific and Clinical Congress. Lecture title at pre-congress special session: “Guidelines for the Management of Obesity as an Endocrine Disease”. Lecture title at evening CME event: “Individualizing Pharmacotherapy for Patients with Obesity”. Lecture title at In-Depth Symposium presenting the AACE Clinical Practice Guidelines for Obesity: “Putting it together: an Evidence-Based Algorithm for Obesity Management”. Orlando FL, May 25-29, 2016

262. Invited lecturer at CME satellite event at the American Diabetes Association 76th Scientific Sessions. Lecture title:”Considering the Options: Current Recommendations and Interventions for the Management of Adult Obesity”. New Orleans LA, June 12, 2016

263. Invited faculty at Annual Diabetes Symposia (CME). 5th Annual Arizona Diabetes Symposium, Title: “Managing Obesity as a Disease and Impact on T2DM”, Scottsdale AZ, September 10, 2016. 3rd Annual New Mexico Regional Diabetes Symposium, Title: “Evidence-Base Guidelines for Managing Patients with Obesity”, El Paso TX, September 24, 2016. 5th Annual Arizona Diabetes Symposium, Title: ““Managing Obesity as a Disease and Impact on T2DM, Tucson AZ, October 1,2016. 3th Annual New Mexico Regional Diabetes Symposium, Title: “Evidence-Base Guidelines for Managing Patients with Obesity”, Albuquerque NM, October 29, 2016

265. Invited lecturer, 3rd annual National Obesity Collaborative Care Summit. Title: “Building Consensus for Best Practices in the Medical Care of Patients with Obesity”. Chicago IL, September 16-17, 2016

254. Faculty member in CME program sponsored by Pri-Med entitled “Southern Diabetes Initiative”. Title of lecture: “Practical Clinical Strategies to Manage the Obese Patient”. Audience of primary care physicians, Charleston WV, November 7, 2016

Note: Invited lectures 2014-present not complete Updated 8/10/2018